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In daily dermatologic care, the growing geriatric population frequently presents with clinical 
challenges regarding the risk of both under- or overtreatment. This highly heterogeneous and 
growing group of patients regularly presents with comorbidities, polypharmacy, functional 
impairment and often with the clinical syndrome frailty. In this thesis, the impact of patient- and 
frailty-associated characteristics on treatment decisions is evaluated in two common disease 
entities; the inflammatory disease psoriasis, and non-melanoma skin cancer, with the focus on 
basal cell carcinoma.
1.1 Population ageing
Due to ageing of the world population, geriatric care has a profound impact on the healthcare 
system for several years to come. It is estimated that the world’s oldest population (≥80 years 
of age) will increase threefold in the coming decades.1 Moreover, it is estimated that in 2050, 
one in four European inhabitants are aged 65 years or over. The process of getting older, 
ageing, is a consequence of the interaction between environmental and genetic factors. 
Ageing is related to several changes in the body (Figure 1), including immunosenescence, 
alterations in endocrine system function, organ impairment (e.g. renal impairment and 
physiological changes in the brain), pharmacokinetics and -dynamics (e.g. changes in volume 
of distribution, drug metabolism and hepatic drug clearance).2-4 These changes are thought 
to be a consequence of molecular and cellular damage, accumulated over a lifetime. 
However, the population of older adults is highly heterogeneous in terms of the effects 
of ageing. For instance, the healthiest quartile of 80-year old patients has a remaining life 
span of 11 years, whereas the sickest quartile of 80-year old individuals will live for 3 years 
only.5 It has therefore been suggested to move beyond chronological age and incorporate 
frailty evaluation in medical decision-making, as this more accurately reflects functional status 
and life expectancy.6
1.1.1 Frailty
Frailty is a dynamic clinical syndrome in which reduced functional reserve leads to organ 
function deterioration, dependency, and the reduction of psychosocial abilities.7 As a 
consequence, frail patients have a disproportional low tolerability of stressors (Figure 2). 
Therefore, both disease-related symptoms as well as treatment-related experiences 
can lead to extensive patient burden in this vulnerable population. Frailty has been 
associated with increased complication rates, mortality, disability, falls and hospitalization 
in several medical fields.2,7,8 Although comorbidity, age, and functional status all contribute to 
frailty, it is important to emphasize these aspects are not synonymous. For instance, a 
robust 80-year old patient who walks 5km per day, lives independently and prepares food 
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1independently might be less frail than a 50-year old patient suffering from malnutrition, social 
isolation and cancer. In other words, although the incidence of frailty does rise with increasing 
age, not all older adults are necessarily frail.7  







































Figure 1. An illustration of the physiological changes occurring in several organ systems as 
a consequence of ageing, adapted from Soto-Perez-de-Celis et al4. 
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    Adequate recognition of frailty can identify patients in need of more extensive assess-
ment, or patients in need for extra precautions during or in preparation of certain medical 
interventions (e.g. surgical procedures or in case of systemic therapies). Frailty can be 
identified by a comprehensive geriatric assessment (CGA), in which functional, somatic, 
and psychosocial aspects are systematically evaluated.8 This is, however, a time-consuming 
process, frequently performed by a geriatrician. Moreover, no consensus exists on which 
specific components should be included in a full geriatric assessment. Frequent components 
of a CGA are: dependency regarding activities of daily living (ADL; bathing, dressing, 
transferring, toileting, continence and eating),9 instrumental activities of daily living (iADL; 
telephone use, grocery shopping, preparing meals, housekeeping, laundering, using 
transportation, taking medication, and managing finances),10 mobility/falls, comorbidity, 
cognitive function, mood/depression, polypharmacy (the chronic use of five or more 
medications), and nutritional status.8 Some aspects can already be observed when a 
patient enters the examination room, for instance the time to get up from a chair, the use of 
walking aids, balance and gait speed. Other aspects can be identified during the consultation, for 
instance exhaustion at the end of the consultation, social support or cognitive dysfunction. 
Many of these aspects, for instance (i)ADL dependency, comorbidities, nutritional status 
and social isolation, have been associated with mortality and/or cognitive decline.4,7,8
Figure 2. Frail patients show a disproportional low tolerability of stressors.2
Vulnerability of frail elderly people to a sudden change in health status after a minor illness 
The green line represents a fit elderly individual who, after a minor stressor event such as an infection, has a small 
deterioration in function and then returns to homoeostasis. The red line represents a frail elderly individual who, 
after a similar stressor event, undergoes a larger deterioration, which may manifest as functional dependency, 

















Items Possible responses (score)
Has food intake declined over the past 3 
months due to loss of appetite, digestive 
problems, chewing, or swallowing difficulties?
0 = severe decrease in food intake
1 = moderate decrease in food intake
2 = no decrease in food intake
Weight loss during the last 3 months? 0 = weight loss >3 kg
1 = does not know
2 = weight loss between 1 and 3 kg
3 = no weight loss
Mobility? 0 = bed or chair bound
1 = able to get out of bed/chair but does not go out
2 = goes out
Neuropsychological problems? 0 = severe dementia or depression
1 = mild dementia
2 = no psychological problems
BMI? (weight in kg)/(height in m2) 0 = BMI <19
1 = BMI 19 to <21
2 = BMI 21 to <23
3 = BMI ≥23




In comparison with other people of the same 
age, how does the patient consider his/her 
health status?
0.0 = not as good
0.5 = does not know






Figure 3. An example of a frailty screening tool, the Geriatric-843
BMI, body mass index.
     A wide variety of short screening instruments have been developed to detect potential 
frailty in 5-15 minutes7 and identify those patients in need for more extensive evaluation by a 
geriatrician (Figure 3). However, data on the use of frailty screening tools in dermatology is 
currently sparse. Moreover, the articles reporting on their use have included 
heterogenous populations, mostly with both patients with skin problems as well as other 
medical diseases, but rarely focus on specific dermatology populations. To provide more 
guidance in individualized care for the growing population of older adults, more research is 
needed in this field.
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1.2 Skin diseases in older adults
As older adults constitute a large and rapidly growing part of the world population, 
dermatologists are frequently confronted with older adults with skin diseases. Several 
studies show that health-related quality of life (QoL) in older adults with skin diseases might 
be severely impaired.11,12 Due to overall frailty, comorbidities, concomitant medication, physical 
and psychosocial impairments and ageing-related pharmacokinetic changes, it can be a 
challenge to determine the optimal risk-to-benefit ratio when treating older adults with 
skin diseases. The most common skin disease seen in older adults are skin tumors, skin 
infections, dermatitis, ulcers, pruritus, urticaria and psoriasis.5,13,14 In this thesis, two common skin 
diseases are studied in the geriatric population; the inflammatory disease psoriasis and the 
most frequent type of skin cancer: basal cell carcinoma. 
1.2.1 Psoriasis
Clinical features of psoriasis
Psoriasis is chronic, relapsing immune-mediated inflammatory disease. Psoriasis is estimated 
to affect 1-3% of the Caucasion population,15 with a bimodal peak of onset around 30-39 
years and 50-59 years.16 The clinical presentation of psoriasis can vary widely, according to the 
different phenotypes. The most common type of psoriasis is psoriasis vulgaris, characterized 
by sharply demarcated erythematosquamous plaques, classically localized on the knees and 
elbows (Figure 4). Other types include guttate psoriasis, psoriasis inversa, psoriasis capitis, 
palmoplantar psoriasis, genital psoriasis, erythroderma and pustular psoriasis. The 
clinical course of psoriasis is frequently fluctuating, characterized by remissions and 
exacerbations. Exacerbations of psoriasis can be triggered by several factors, for instance 
seasonal differences, trauma (Koebner phenomenon), medications (e.g. betablockers, 
chloroquine, non-steroidal anti-inflammatory agents and interferons), stress and 
streptococcal infection.17 Most of these factors are more frequently seen in older 
adults (e.g. medication use and skin trauma) than in younger patients. The sparse available 
studies on geriatric psoriasis have shown that disease severity is frequently similar in older 
adults and younger adults, although types of psoriasis might differ.18,19 However, much is still 
unknown regarding psoriasis in older adults. 
Pathogenesis of psoriasis
The pathogenesis of psoriasis is multifactorial, both genetic and environmental factors con-
tribute. Several chromosomal loci have been identified associated with psoriasis susceptibility. 
Moreover, adaptive genes related to both innate and adaptive immunity have been identi-
fied, leading to inappropriate T-cell and dendritic cell activation and subsequent release of 
cytokines as Interleukin-12 (IL-12), IL-23 and tumor necrosis factor (TNF)-alpha.17 




the clinical signs of scaling and redness of the clinical plaques. Available studies comparing 
age groups showed no difference in gene expression regarding geriatric psoriasis specifically.20
Comorbidities associated with psoriasis
Psoriatic arthritis (PsA) is the most commonly known comorbidity associated with psoriasis. 
It is characterized by inflammation of the joints and, if not adequately treated, PsA can cause 
permanent joint destruction.17 Several studies have shown associations between psoriasis 
and other comorbidities, even when corrected for confounders.21 The risk of cardiovascular 
disease has been shown to increase with increasing psoriasis severity, and specific therapies 
(e.g. tumor necrosis alpha inhibitors) have been identified to reduce the cardiovascular risks 
associated with psoriasis.21 Other comorbidities associated with psoriasis are metabolic 




syndrome (including hypertension, hyperlipidemia, diabetes mellitus, and obesity), 
inflammatory bowel disease, malignancies, renal disease, hepatic disease, and depression.21,22-24 
Several of these (e.g. cutaneous malignancies, renal disease and hepatic disease) 
or not only related to psoriasis independently, but also to the use of anti-psoriatic 
therapies as well. Multiple studies have shown increased incidence of psoriasis- 
related comorbidities in older adults,25,26 further emphasizing the need for personalized 
treatment in this population. 
Quality of life
Psoriasis can have a significant impact on QoL, due to aspects as itching, scaling, visibility, 
but also stigmatization of society and the burden of (topical) treatment. Although 
studies on QoL as perceived by this population are scarce, it seems that psoriasis has 
quite an impact of QoL in older adults.26 QoL can be measured by using several QoL-indices, 
of which the Dermatology Life Quality Index (DLQI) is the most frequently used.27 The DLQI 
is a short self-administered questionnaire consisting of 10 questions on possible domains 
affected by skin diseases. The impact of the skin disease on each item is scored using 
a 4-point Likert-scale, with 8 items offering a not relevant response (NRR) option. 
Recently, the DLQI has been criticized, as it might underestimate the true QoL-impact in 
specific patient-groups, including older adults.28-30 Some authors have suggested 
to use a different scoring system for the DLQI, to account for the NRRs selected by older 
patients.28  
Treatment
Treatment options for psoriasis include topical treatment (mono- or combination therapy), 
UV therapy, conventional systemic therapies and modern systemic therapies (biologics 
and small-molecule inhibitors). Traditional systemic therapies (methotrexate, cyclosporin, 
acitretin and dimethyl fumaric acid) have been used for several decades in psoriasis care, 
and many studies on long-term effects and safety have been carried out. In addition, 
modern systemic therapies, including biologics and the small-molecule inhibitor 
apremilast, have significantly improved psoriasis management during the past years, 
since they appear more effective and require less hospital visits than traditional 
systemic therapies.31-33 The first biologics approved for psoriasis treatment were the 
TNF-alpha inhibitors etanercept, infliximab, and adalimumab (2004, 2005 and 2007). In 
2009, the therapeutic array expanded with IL-12 and IL-23 antagonist ustekinumab. More 
recently, IL-17 inhibitors secukinumab, ixekizumab, and brodalumab were introduced, 
followed  by guselkumab, risankizumab and tildrakizumab (IL-23 inhibitors) and certolizumab 
pegol (a PEGylated TNF-alpha inhibitor).
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1Although many studies on systemic psoriasis therapies have been carried out, little is 
known on the effects of these therapies specifically in older adults. Psoriasis 
management in older adults can be complicated due to the higher prevalence of 
comorbidities, concomitant medication, functional deterioration, and frailty. 
Moreover, physical impairments can complicate applying topical therapies and in 
ultraviolet therapy, whereas altered pharmacokinetics and -dynamics in older adults can 
complicate using systemic medications. As research in the field of geriatric psoriasis is 
limited, it is currently debatable whether or not additional risks are associated with the use 
of systemic antipsoriatic therapies in older psoriasis patients and whether or not they 
are treated optimally.
1.2.2 Basal cell carcinoma
Clinical features and quality of life
The most common type of skin cancer in older adults is keratinocyte cancer, in particular basal 
cell carcinoma (BCC).34,35 The last two decades, the incidence of BCCs rises rapidly, especially in 
older adults.36 Due to the high incidence and the associated morbidity, BCC treatment causes a 
considerable worldwide burden on healthcare systems. Risk factors for BCCs include ultraviolet 
exposure, previous radiation therapy, advanced age, male gender, a fair skin type (Fitzpatrick 
skin type I and II) and genetic predisposition (e.g. Gorlin syndrome).36,37 Histopathological 
subtypes include nodular, superficial, infiltrative and micronodular BCCs (Figure 5), although 
frequently a mix of subtypes is seen. Nodular BCCs frequently present as asymptomatic 
skin-colored noduli with a raised border in the head-and-neck area with or without bleeding, 
central ulceration or crustae. Superficial BCCs more frequently present on the trunk and 
Figure 5. Examples of the basal cell carcinoma and the clinical aspects of different BCC 
subtypes 
A. A nodular basal cell carcinoma      B. A superficial basal cell carcinoma     C. An infiltrative basal cell carcinoma 
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resemble eczema-like erythematosquamous plaques. Infiltrative and micronodular BCCs 
might resemble pearly scar-like plaques and can frequently be hard to recognize and 
delineate. Dermoscopy might aid in diagnosis by the presence of typical characteristics like 
arborizing vessels or ovoid nests.37 However, to confirm the diagnosis and determine the 
histopathological subtype, punch biopsies are typically taken at first suspicion.37
  
    Although BCCs are usually slowly growing tumors which rarely metastasize, advanced 
BCCs can cause significant morbidity due to local tissue invasion and functional impairment 
(Figure 6).38 For instance, a BCC on an eyelid could lead to ectropion and ingrowth in vital 
structures, frequently causing infections, pain, bleeding, crustae and/or purulent discharge. 
The currently known prognostic factors include aggressive histopathological subtype 
(infiltrative and/or micronodular subtype), tumor size (larger than 2 cm), tumor location (head-
and-neck area), perineural growth, and recurrent tumors.37,38 It should be noted that these 
factors are prognostic for the recurrence risk after therapy; prospective research on the natural 
tumor growth, tumor invasion and the development of symptoms is currently extremely sparse.
Figure 6. Advanced basal cell carcinoma can cause substantial morbidity
Pathogenesis of basal cell carcinoma
The pathogenesis of BCCs has been associated with a dysregulation of the sonic hedgehog 
signaling pathway, including the tumor suppressing PTCH1 receptor.39 Mutations in the PTCH1 
gene can be caused by UV radiation exposure or germ line mutations (e.g. in case of Gorlin 
syndrome). Subsequent truncation of the PTCH1 receptor leads to a reduced suppression of the 
G-protein-coupled SMO receptor, leading to activation of the hedgehog pathway.36 
Treatment
Although a broad array of BCC treatment options exist, surgery is considered the golden 
practice.38 Most frequently used surgical therapies are Mohs micrographic surgery (MMS) and 
conventional excision (CE). In MMS, complete tumor removal is histologically confirmed by 
studying all resection sides during surgery, corresponding with low recurrence rates (5-year 




Figure 7. Histological examination of conventional excision vs. Mohs micrographic surgery, 
adapted from Dundee University School of Medicine, illustrated by A. Campbell.
via bread-slicing technique (Figure 7). Typically, as this cannot be completed at the same day, 
the duration of surgery is mostly shorter than MMS. Radiotherapy can be an alternative in case 
surgery is not possible or suitable. Radiotherapy is frequently carried out in 10-20 visits with 
radiation in the form of electron beams, brachytherapy or orthovolt. Other therapeutic options 
may include topical treatments (5-fluorouracil cream and imiquimod cream), photodynamic 
therapy and locally destructive therapies (electrodessication and curettage and, cryotherapy). 
Locally advanced basal cell carcinomas not suited for surgical excision or radiotherapy and me- 
tastatic BCCs can be treated with registered systemic hedgehog pathway inhibitors (vismode-
gib and sonidegib) and the more recently registered immune checkpoint inhibitor cemiplimab.
1. Eliptical excision
margin.
2. The tumor, and a mar-
gin of healthy appearing 
skin surrounding the tu-
mor, is removed. Exten-
sion of tumor (circled) is 
illustrated beyond surgi-
cal margin.
3. Breadloaf sectioning 
is carried out for micro-
scopic examination.
4. Histologic slides show 
no remaining tumor cells 
in peripheral and deep 
edges, as extension of the 
tumor is not represent-
ed in histology sections 
(A-F).
B. Mohs micrographic surgery
1. Mohs surgical 
margin layer 1.      
2. The tumor, and a small 
margin of healthy appear-
ing skin surrounding the 
tumor, is removed and 
divided into sections. In 
this example, extension 
of tumor (circled) is repre-
sented in Mohs histologi-
cal sections.
3. The undersurface and 
peripheral edges of the 
sections are microscop-
ically examined for the 
presence of remaining 
malignant cells. If tumor 
cells are identified micro-
scopically, a second layer 
of skin is removed in that 
section.
4. This process is repeated 
until microscopically all 
edges show the absence 
of tumor cells. In this pos-
terior view of the deep 
and peripheral margins, 
extension of the tumor is 





    As BCCs in older adults are more frequently larger and located in the head-and-neck 
area,41 it can be quite challenging to appropriately balance under- and overtreatment in older 
adults. Moreover, it is frequently presumed that extensive surgery (e.g. MMS) is too 
burdensome for older adults.42 However, if those patients live longer than expected, advanced 
BCCs can cause diminished QoL and the need for even more extensive and burdensome 
therapies. In the geriatric population, it is highly relevant to determine whether or not patients 
will live long enough to benefit from treatment (time-to-benefit), or whether the time to ever 
develop bothersome BCC-related symptoms exceeds their remaining lifespan. If the latter is 
the case, treatment-associated risks (e.g. complications and treatment burden) should be 
avoided if possible. Therefore, more research on tumor burden and natural growth is needed, 
as well as the experienced treatment burden and factors influencing life expectancy of this 
patient group.
1.3 Aims and outline of this thesis
This thesis describes studies on common skin diseases in older adults (psoriasis and skin 
cancer) to provide insight into what is currently known and unknown regarding patient 
preferences, disease burden and treatment-related risks and benefits. The aim of this thesis was 
to provide more guidance in patient-centered geriatric dermatology care and to improve shared 
decision-making in this rapidly growing patient group, whilst striving for optimal risk-to-benefit 
ratio and improvement of overall quality of life.
To improve patient-centered care in older psoriasis patients, it is essential to acquire insight 
into what is known and what is unknown in this particular patient population. As many systemic 
agents are primarily studied in randomized controlled trials (RCTs) and guidelines frequently 
rely on data retrieved from RCTs, we performed a systematic review assessing whether or 
not older adults are appropriately represented in these studies in chapter 2.1. Since RCTs 
frequently maintain strict in- and exclusion criteria, we studied whether upper age limits were 
used and whether older adults were indirectly excluded from randomized controlled trials on 
psoriasis by disproportionally excluding patients with certain comorbidities.
       In chapter 2.2 we conducted a systematic review to evaluate the effectiveness and safety 
of systemic antipsoriatic therapies in older adults in both RCTs, retrospective and prospective 
cohort studies. We studied whether or not evidence exists for differences in outcomes when 
older adults were compared with younger patients.
    In chapter 2.3 we aimed to expand the available data on older psoriasis patients by 
evaluating disease, treatment- and patient- characteristics of older adults with psoriasis in a na-
tionwide self-administered survey. Next to disease severity, subtypes and therapies used in the 
past and the present, we discussed comorbidities and concomitant medication use in both age 
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1groups, adverse events to treatment and evaluated whether or not patients needed help from 
care takers or relatives in psoriasis treatment (e.g. applying topical treatment).
      The second part of this survey is described in chapter 2.4, in which we aimed to evaluate 
whether or not older adults experience differences compared with younger patients regarding 
disease burden, patient preferences and treatment goals. Moreover, we studied the impact of 
psoriasis on the QoL and evaluated whether QoL-impairment is adequately represented by the 
most commonly used QoL-assessing tool, the DLQI.
To improve patient-centered care in older adults with skin cancer, more guidance is needed to 
determine the time-to-benefit and identifying those patients benefitting from early treatment 
and those who might not benefit from treatment. 
    To estimate whether or not a patient will benefit from treatment, estimation of the 
treatment-related burden and the remaining life expectancy is essential, as well as identifying 
associated predictive factors. Therefore, we studied the treatment burden and mortality in 
patients treated with Mohs micrographic surgery or conventional excision for BCC in a 
prospective multicenter cohort study, described in chapter 3.1. Moreover, we aimed to 
identify frailty-related characteristics associated with the experienced treatment burden and 
overall survival.
    Currently, little patient- and frailty-related factors are discussed in clinical guidelines, 
although in other medical fields, is has been shown that frailty-related characteristics are 
associated with postoperative complications and mortality. Incorporating these assess-
ments in daily dermatology care could help clinicians distinguishing those patients who most 
likely benefit from treatment from those who might not develop tumor-related 
symptoms in their remaining lifespan. Therefore, we aimed to study the requirements for 
frailty screening in dermato-oncology in a two-round modified Delphi study, described 
in chapter 3.2. Moreover, we incorporated a systematic literature search to select an existing 
frailty screening tool which met these requirements.
     We studied the incorporation of frailty screening and the consequences for treatment 
choices in frail older adults with basal cell carcinoma in a prospective cohort study, 
demonstrated in chapter 3.3. Moreover, we evaluated treatment goals and subsequent 
treatment choices after a careful shared decision-making process aiming to achieve 
personalized medical decision-making in the heterogeneous geriatric population.
      To further aid in personalized decision-making, it is essential to obtain more knowledge 
on when to refrain from BCC treatment. Therefore, we studied reasons for refraining from 
treatment and the natural course of disease without treatment in an observational cohort study, 
presented in chapter 3.4.
The results of these studies, as well as possible implications for clinical care and future research, 




1.   United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population 
Ageing 2017 - Highlights (ST/ESA/SER.A/397). Available from: https://www.un.org/en/development/desa/
population/publications/pdf/ageing/WPA2017_Highlights.pdf 
2     Clegg A, Young J, Iliffe S et al. Frailty in elderly people. Lancet 2013; 381: 752–762.
3 Endo JO, Wong JW, Norman RA et al. Geriatric dermatology: Part I. Geriatric pharmacology for the 
dermatologist. Journal of the American Academy of Dermatology 2013; 68: 521 e1-10.
4 Soto-Perez-de-Celis E, Li D, Yuan Y et al. Functional versus chronological age: geriatric assessments to guide 
decision making in older patients with cancer. Lancet. Oncology 2018; 19: e305-e16.
5 Linos E, Chren MM, Covinsky K. Geriatric Dermatology-A Framework for Caring for Older Patients With Skin 
Disease. JAMA Dermatology 2018; 154: 757-8.
6 Garcovich S, Colloca G, Sollena P et al. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric 
Oncology. Aging and Disease 2017; 8: 643-61.
7 Faller JW, Pereira DDN, de Souza S et al. Instruments for the detection of frailty syndrome in older adults: 
A systematic review. PloS One 2019; 14: e0216166.
8 Hamaker ME, Vos AG, Smorenburg CH et al. The value of geriatric assessments in predicting treatment 
tolerance and all-cause mortality in older patients with cancer. Oncologist 2012; 17: 1439-49.
9 Katz S, Ford AB, Moskowitz RW et al. Studies of Illness in the Aged: The Index of ADL: A Standardized Measure 
of Biological and Psychosocial Function. JAMA 1963; 185: 914-9.
10 Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. 
Gerontologist 1969; 9: 179-86.
11 Kim EK, Kim HO, Park YM et al. Prevalence and risk factors of depression in geriatric patients with dermato-
logical diseases. Ann Dermatol 2013; 25: 278-84.
12 Shah M, Coates M. An assessment of the quality of life in older patients with skin disease. British Journal of 
Dermatology 2006; 154: 150-3.
13 Makrantonaki E, Steinhagen-Thiessen E, Nieczaj R et al. Prevalence of skin diseases in hospitalized 
geriatric patients : Association with gender, duration of hospitalization and geriatric assessment. Zeitschrift 
fur Gerontologie und Geriatrie 2017; 50: 524-31.
14 Wong JW, Koo JYM. Dermatogeriatrics: A case for developing a new dermatology subspecialty. Journal of 
Dermatological Treatment 2013; 24: 324-6.
15 Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. Journal of the 
European Academy of Dermatology and Venereology 2017; 31: 205-12.
16 Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and 
prevalence. Journal of Investigative Dermatology 2013; 133: 377-85.
17 Nestle FO, Kaplan DH, Barker J. Psoriasis. The New England Journal of Medicine 2009; 361: 496-509.
18 Medina C, Carretero G, Ferrandiz C et al. Safety of classic and biologic systemic therapies for the treatment 
of psoriasis in elderly: An observational study from national BIOBADADERM registry. Journal of the European 
Academy of Dermatology and Venereology 2015; 29: 858-64.
19 Trettel A, Spehr C, Korber A et al. The impact of age on psoriasis health care in Germany. Journal of the 
European Academy of Dermatology and Venereology 2017; 31: 870-5.
20 Napolitano M, Balato N, Ayala F et al. Psoriasis in elderly and non-elderly population: Clinical and molecular 
features. Giornale Italiano di Dermatologia e Venereologia 2016; 151: 587-95.
21 Elmets CA, Leonardi CL, Davis DMR et al. Joint AAD-NPF guidelines of care for the management and 
treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of 
Dermatology 2019; 80: 1073-113.
22 Grozdev IS, Van Voorhees AS, Gottlieb AB et al. Psoriasis in the elderly: From the Medical Board of the 
National Psoriasis Foundation. Journal of the American Academy of Dermatology 2011; 65: 537-45.
23 Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: Epidemiology. Journal of the 
American Academy of Dermatology 2017; 76: 377-90.
24 Rodriguez-Zuniga MJM, Garcia-Perdomo HA. Systematic review and meta-analysis of the association 
between psoriasis and metabolic syndrome. Journal of the American Academy of Dermatology 2017; 77: 657-
66.e8.
25 Phan C, Sigal ML, Esteve E et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation 
of patients with very late onset psoriasis. Journal of the European Academy of Dermatology and Venereology 
2016; 30: 78-82.
26 Lopez-Estebaranz JL, Sanchez-Carazo JL, Sulleiro S. Effect of a family history of psoriasis and age on 
comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA 
study. Journal of Dermatology 2016; 43: 395-401.
General introduction 
23
127 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. 
Clin Exp Dermatol 1994; 19: 210-6.
28 Rencz F, Gulacsi L, Pentek M et al. Proposal of a new scoring formula for the Dermatology Life Quality Index 
in psoriasis. British Journal of Dermatology 2018; 179: 1102-8.
29 Nijsten T. Dermatology life quality index: time to move forward. Journal of Investigative Dermatology 2012; 
132: 11-3.
30 Rencz F, Poor AK, Pentek M et al. A detailed analysis of "not relevant" responses on the DLQI in psoriasis: 
potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology 
2018; 32: 783-90.
31 Esposito M, Giunta A, Mazzotta A et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha 
agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An obser-
vational long-term study. Dermatology 2012; 225: 312-9.
32 Momose M, Asahina A, Hayashi M et al. Biologic treatments for elderly patients with psoriasis. Journal of 
Dermatology 2017; 25: 25.
33 Navarro R, Vilarrasa E, Herranz P et al. Safety and effectiveness of ustekinumab and antitumour necrosis 
factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study 
in a clinical setting. British Journal of Dermatology 2013; 168: 609-16.
34 Leus AJG, Frie M, Haisma MS, Terra JB, Plaat BEC, Steenbakkers R, et al. Treatment of keratinocyte carcinoma 
in elderly patients - a review of the current literature. Journal of the European Academy of Dermatology and 
Venereology. 2020;34(9):1932-43.
 35 Kim JYS, Kozlow JH, Mittal B et al. Guidelines of care for the management of basal cell carcinoma. Journal of 
the American Academy of Dermatology 2018; 78: 540-59.
36 Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010; 375: 673-85.
37 Kelleners-Smeets NW, Karsch SAT, Kuin RA et al. Evidence based guideline for basal cell carcinoma [in Dutch]. 
Dutch Society for Dermatology and Venereology. 2015.
38 Thomson J, Hogan S, Leonardi-Bee J et al. Interventions for basal cell carcinoma: abridged Cochrane 
systematic review and grade assessments. British Journal of Dermatology 2021.
39 de Zwaan SE, Haass NK. Genetics of basal cell carcinoma. Australasian Journal of Dermatology 2010; 51: 81-92; 
quiz 3-4.
40 Cameron MC, Lee E, Hibler BP et al. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, 
and prevention. Journal of the American Academy of Dermatology 2019; 80: 321-39.
41 Lubeek SFK, Michielsens CAJ, Borgonjen RJ et al. Impact of High Age and Comorbidity on Management 
Decisions and Adherence to Guidelines, adherence in nonmelanoma skin cancer. Acta Dermato- 
Venereologica 2017; 97: 825-9.
42 Linos E, Parvataneni R, Stuart SE et al. Treatment of nonfatal conditions at the end of life: nonmelanoma skin 
cancer. JAMA Internal Medicine 2013; 173: 1006-12.
43 Bellera CA, Rainfray M, Mathoulin-Pelissier S et al. Screening older cancer patients: first evaluation of the G-8 
geriatric screening tool. Annals of Oncology 2012; 23: 2166-72.

CHAPTER 2
Psoriasis management in older adults

CHAPTER 2.1
Representation of older adults 
in randomized controlled trials 
on systemic treatment in plaque psoriasis: 
a systematic review
M.J. Schaap, M.E.C. van Winden, M.M.B. Seyger, 
E.M.G.J. de Jong and S.F.K. Lubeek






Psoriasis is frequently seen in older patients, and systemic treatment is often indicated. 
Randomized controlled trials (RCTs) generally maintain strict inclusion and exclusion criteria, 
which might lead to a disproportionally high exclusion rate of older adults.
Objective 
To determine the representation of older adults (≥65 years) in RCTs studying systemic 
treatment in plaque psoriasis.
Methods 
A systematic literature search was performed in PubMed/MEDLINE, Embase, and CENTRAL, 
including RCTs concerning systemic treatments in plaque psoriasis in the past 15 years. Direct 
exclusion (based on age limits) and indirect exclusion (other exclusion criteria) were assessed. 
Study selection and data extraction were performed by 2 independent reviewers.
Results 
Of 162 trials reviewed in full, 54 (33.3%) maintained an upper age limit (55-85 years). 
Of the remaining 108 trials, 106 reported exclusion criteria and did not use an upper age 
limit. However, 96 (90.6%) of these trials used exclusion criteria that might unequally 
affect older adults. The exclusion criteria serious concurrent infection (n=104, 66.7%) and 
malignancy (n=100, 64.1%) were most commonly mentioned in the included RCTs.
Limitations 
Only published RCTs were included.
Conclusion 
Older adults might be poorly represented in RCTs studying systemic treatment in plaque 
psoriasis because of a high rate of direct and indirect exclusion. 




Psoriasis is a chronic inflammatory skin disease frequently seen in older patients that 
can have a significant impact on quality of life.1-3 The prevalence of psoriasis in older 
adults (≥65 years) is estimated at 0.51% to 1.13%.4 In moderate to severe psoriasis, 
systemic therapy is frequently indicated.5 Treating older adults with systemic therapy can be 
challenging because of factors such as frailty, comorbidity, and possible drug interactions.5,6 
Frailty is a common syndrome in older adults, defined as severely reduced functional 
reserve, increasing the risk of poor health outcomes and reducing stress tolerance.7 
Moreover, the literature shows that the prevalence of most comorbidities increases 
with age.8-11 
Over the past 15 years, there have been many developments regarding systemic 
treatment options for patients with psoriasis.12 Biologic therapies, which neutralize 
cytokines or cytokine receptors, have especially revolutionized the treatment of psoriasis. 
In addition, small-molecule inhibitors have emerged that block intracellular targets such 
as enzymes.13 Nonetheless, conventional systemic drugs such as methotrexate and 
dimethyl fumarate have been used in practice for decades and currently remain major 
players in the systemic treatment of psoriasis. Drugs are primarily studied in randomized 
controlled trials (RCTs), which usually define strict inclusion and exclusion criteria. 
These strict criteria might result in a suboptimal representation of patients seen in actual daily 
clinical practice.
In several medical fields, it has been shown that RCTs often exclude or underrepresent 
older adults, possibly leading to clinical risks when treating this ineligible population.14-16 
Both direct exclusion (based on age limits) as indirect exclusion (by other exclusion criteria 
disproportionally excluding older adults) might lead to an underrepresentation of older 
adults in RCTs. Several studies mention the extent of ineligibility of real-world patients 
with psoriasis for RCTs, but information about the representation of older adults in 
RCTs is currently lacking in the field of psoriasis.16,17
Our aim was to perform a systematic review to assess the representation of older adults 
in RCTs studying systemic treatments in plaque psoriasis, including the extent of both 





This systematic review was conducted according to the Cochrane Handbook for Systematic 
Reviews of Interventions18 and Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) guidelines.19
Search strategy and study selection
In July 2018, a systematic literature search was performed with the aid of a medical 
librarian using PubMed/MEDLINE, Embase, and CENTRAL (Cochrane Central Register 
of Controlled Trials). The term psoriasis was combined with different terms and 
synonyms for systemic agents used in psoriasis based on the literature.20 To identify RCTs, 
the sensitivity- and precision-maximizing Cochrane Randomized Controlled Trail filter (2008 
revision) was used in PubMed/MEDLINE and Embase. A detailed overview of the search 
strategy is provided in the Supplementary Materials. Results of the search strategy were 
merged into Endnote X8.0.1 (Clarivate Analytics, Philadelphia, PA) and duplicates were removed. 
Articles were screened and assessed for eligibility by 2 independent reviewers (MJS and SFKL). 
All inconsistencies were resolved by consensus meetings. When full-text articles were not 
available, the corresponding author was approached at least 2 times to request a copy of the 
full-text article.
Inclusion and exclusion criteria
All phase 2 and phase 3 RCTs concerning systemic therapy in plaque psoriasis, published 
within the past 15 years (July 1, 2003, through July 1, 2018), were included. Herbals and nutri-
tion were not considered to be systemic treatments of interest. Studies that were not RCTs 
were excluded. Additional exclusion criteria were specified as studies that focused on diseases 
other than plaque psoriasis, conference abstracts, study protocols, studies targeting only a 
nonrelevant subpopulation (such as children or young adults), interim- or follow-up studies 
of a research cohort that had already been included in our systematic review, and studies not 
written in English, French, Spanish, German, or Dutch.
Data extraction
Data extraction was performed separately for each RCT by 2 independent reviewers (MJS 
and SFKL) using a predefined form. Extracted information included inclusion and exclusion 
criteria, in particular whether or not an upper age limit was set; population of interest; 
population characteristics (distribution of age, sex, psoriasis severity, and comorbidities 
reported); sample size; medication of interest; type of control intervention; and year of 
publication. Polypharmacy was defined as the use of 5 or more medications daily.21 
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Figure 1. Study selection process
 1737 Articles identified in PubMed/MEDLINE
2847 Articles identified in EMBASE
 2191 Articles identified in CENTRAL
3392 Excluded based on title or abstract
  Reasons for exclusion:
 1326 conference abstract
  990 no RCT
  328 no systemic treatment
   170 no plaque psoriasis as main interest
   114 pooled-, integrated- or sub study
    61 not reported in English, German, French,
  Spanish or Dutch
  403 other reason of exclusion or irrelevant
     86 Excluded based on full text
 Reasons for exclusion:
     35 cohort that was already included in the
   systematic review
     18 no phase II or III RCT
     18 no RCT
      7 no full text articles available
      2 irrelevant subpopulation
      6 other reason of exclusion
3144 Duplicates removed
3631 Articles identified through systematic search
239 Articles reviewed in full
153 Articles included in analysis
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a Number and percentage of 162 trials, unless specified otherwise. 
b Total number (n=215) exceeds the number of trials (n=162) because 53 trials had more than 1 systemic agent of 
 interest. Percentages are presented out of the total of 215 trials. 
c Examples of other medications: atorvastatin, liraglutide, pimecrolimus.
d Defined as a trial studying the effect of different dosages or dosing regimens of 1 systemic agent.
e As defined in the population of interest of the randomized controlled trial.
f Usually defined as Physician Global Assessment score of 3 or higher, Body Surface Area ≥10% or ≥12%, and 
 Psoriasis Area Severity Index score ≥10 or ≥12.
g In a total of 116 trials reporting a mean age and standard deviation. Both values weighted by sample size. 
 Total sample size of 45550 patients.
SD, Standard deviation.
Table 1. Trial and population characteristics (n=162)
Characteristics Valuea
Trial
   Sex eligibility, n (%)
     Both male and female participants included 162 (100)
   Year of publication, n (%)
     2003-2007 33 (20.4)
     2008-2012 48 (29.6)
     ≥2013 81 (50.0)
   Medication of interest, n (%)b
     Biologics (including biosimilars) 120 (55.8)
     Conventional systemic treatment 50 (23.3)
     Small-molecule inhibitors 23 (10.7)
     Other medicationc 22 (10.2)
   Placebo-controlled studies, n (%) 110 (67.9)
   Dose-finding studies, n (%)d 89 (54.9)
Trial population
   Psoriasis severity, n (%)e
     Mild 1 (0.6)
     Moderate to severef 145 (89.5)
     Severe 7 (4.3)
     Not reported 9 (5.6)
   Total sample size, n 60447 patients
     Median (range) 202 (9-2546) patients
Age in years, mean ± SDg 44.9 ± 12.9
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A risk of bias assessment with the Cochrane Risk of Bias Tool was either retrieved 
or performed for all included articles. Additional trial information was obtained 
from supplementary files on journal websites or trial registries. If not described, 
at least 2 attempts were made to reach the corresponding author with a request for trial 
characteristics.
Data analysis
A descriptive analysis of the data was performed in IBM SPSS statistics, version 23.0 
(IBM, Armonk, NY). The number and proportion of trials that excluded older adults 
by an upper age limit or other exclusion criteria that might disproportionately exclude 
older adults was calculated. Exclusion criteria that could disproportionately exclude older 
adults were determined based on real-world data, reporting prevalences of comorbidities in 
different age groups in populations with psoriasis.8-11 The pooled mean and standard 
deviation of the reported mean ages in RCTs were calculated, weighted by sample size.
Results
Study selection and trial characteristics
The search strategy for RCTs yielded 3631 titles (Figure 1). A total of 153 articles met our 
eligibility criteria and were included in the final analysis.22-174 Eight articles reported results 
of more than 1 RCT.22-29 Altogether, the 153 included articles reported results of 162 RCTs. 
A risk of bias assessment of all included studies can be found in the Supplementary 
Materials. Most RCTs were placebo controlled (67.9%), and biological agents were mostly 
studied (55.8%). Full trial characteristics can be found in Table 1.
Direct exclusion of older adults
Of the 162 studies included, a total of 54 (33.3%) RCTs excluded individuals by an upper 
age limit. Upper age limits varied from 55 to 85 years, with an upper age limit of 
75 years (n=20) most commonly applied. One trial did not report enough information to 
determine whether an upper age limit was used.141 Focusing on the period of publication, the 
proportion of articles maintaining an upper age limit decreased over time from 42.4% 
(n=14) in the period from 2003 through 2007, to 37.5% (n=18) and 27.2% (n=22) in 
the periods from 2008 through 2012 and 2013 through 2018, respectively.
Indirect exclusion of older adults
Of the 108 trials not handling an upper age limit, 2 trials did not report any exclusion 
criteria.30,141 Of the remaining 106 trials, 96 (90.6%) used exclusion criteria that could 
disproportionally exclude older adults. Exclusion criteria most frequently mentioned in the 
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malignancy (n=100, 64.1%), hematologic disease (n= 92, 59.0%), immunodeficiency (n=85, 54.5%), 
and hepatic or renal impairment (n=84, 53.8%). The frequencies of other exclusion criteria 
extracted are shown in Table 2. No RCTs excluded patients based on limited life expectancy. 
Although some trials prohibited the use of certain drugs, no trials excluded patients based on 
the number of drugs. As shown in Table 3, only a very small number of the RCTs included in this 
systematic review reported the presence of comorbidities in the study population.
Studies on comorbidities in real-world populations with psoriasis support the idea that the 
majority of exclusion criteria reported in this systematic review could potentially affect older 
patients with psoriasis unequally.8-11,175 An exclusion criterion frequently used was history of 
malignancy (n=100, 64.1%). Kimball et al10 state in the large real-world evidence registry 
PSOLAR that 12.0% of patients with psoriasis older than 65 years had a history of cancer 
(other than nonmelanoma skin cancer) compared with 0.6% in younger patients. 
Cardiovascular disease is reported to be present in up to 67.8% of patients older than 60 to 65 
years, but 45.5% (n=71) of the trials included in our systematic review excluded patients based 
a  Number and percentage of studies that reported the mentioned comorbidity in baseline population characte- 
 ristics out of a total of 159 studies. Three studies40,121,169  did not report any baseline characteristics.
b Includes history of hospitalization, anemia, history of allergy,thyroid disorders, and gastric disturbances. Each  




   Hypertension or blood pressure 13 (8.2)
   Hyperlipidemia 6 (3.8)
   Total cholesterol or hypercholesterolemia 5 (3.1)
   Any history of CVD 5 (3.1)
   Triglycerides or hypertriglyceridemia 3 (1.9)
   Myocardial infarction or ischemic heart disease 2 (1.3)
   Peripheral vascular disease 1 (0.6)
   Transient ischemic attack 1 (0.6)
Other
   Diabetes mellitus 9 (5.7)
   Latent tuberculosis 2 (1.3)
   Other comorbiditiesb 5 (3.1)




Basis for exclusion  % exclusion in RCTs 18-50 years ≥65 years
Serious (concurrent) infection 66.7 - -
History of or active malignancy 64.1 0.6-1.5%10 12.0%10
Hematologic disease 59.0  0.4%11,b,c 1.1%11,b,c
Immunodeficiency 54.5  1.2%11,b,d 0%11,b,d
Hepatic impairment 53.8  1.6%-3.4%10,e 5.7%10,e
Renal impairment 53.8  0.9%11,b,f 6.3%11,f
Tuberculosis (active or latent) 51.3  5.2%-14.5%9,g 14.5%9,h
Cardiovascular disease 45.5  0.9%-29.3%9,10 17.4%-67.8%9,10
Hepatitis 34.0  0.2%-5.6%10,11,b,i 1.5%-7.5%10,11,i
Cerebral or neurologic disease 28.8  0%-0.5%9,g,j 0%9,h,j
0.1%-0.6%10,k 4.4%10,k
Psychiatric disease 28.8  7.8%-9.1%9,l,g 9.8%9,l,h
12.9%-15.8%9,m,g 17.9%9,m,h
Pulmonary disease 24.4 10.6%-12.9%10,11,n 19.2%10,11,n
Diabetes mellitus 23.7 2.6%-9.1%9-11,b*o 22.8%-36.6%9-11,o
Uncontrolled hypertension 19.9  0.9%-21.6%9-11 48.0%-63.4%9-11
Gastrointestinal disease 18.6  1.6%-1.9%10,p 3.1%10,p
Cognitive impairment  1.9  1.30175,q 1.08175,r
a  Prevalence numbers unless stated otherwise. Dash indicates no prevalence numbers by age in the population 
   with psoriasis found in the literature.
b  Age ˂65 years.
c  Patients with lymphoma.
d  Patients with HIV.
e  Patients with hepatic disease (including hepatitis, cirrhosis, and drug-induced disease).
f   Patients with renal failure.
g  Age range, ˂31-60 years.
h  Age ˃60 years.
i   Patients with hepatitis B and C combined.
j   Patients with multiple sclerosis.
k  Patients with transient ischemic attack/stroke.
l   Patients with depression.
m Patients with anxiety disorder. 
n  Including asthma, sleep apnea, and chronic obstructive pulmonary disease.
o  Including diabetes mellitus types 1 and 2.
p  Patients with inflammatory bowel disease (including Crohn’s disease, ulcerative colitis, and indeterminate colitis).
q  Hazard ratio of developing Alzheimer disease in patients with psoriasis aged 40-65 years.
r   Hazard ratio of developing Alzheimer disease in patients with psoriasis ≥65 years.  
Table 4. Epidemiology of comorbidities identified as common RCT exclusion criteria in the 
population with psoriasis
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on this factor.8-10 In younger patients with psoriasis, cardiovascular disease is reported in 0.9% 
to 29.3%.9,10 Other comorbidities that increase in prevalence with age in patients with psoriasis 
include but are not limited to diabetes, hepatic disease, renal impairment, hypertension, and 
pulmonary disease.8-11 An overview of prevalence numbers by age of comorbidities used as 
exclusion criteria in RCTs in patients with psoriasis can be found in Table 4. 
Age of trial participants 
The number of patients aged 65 years and older included in RCTs was reported in only 
3 (1.9%) of the 162 included trials.104,151,163 These articles reported that 1.9% to 9.0% of the 
patients in their research cohorts were aged 65 years or older. None of the included 
studies focused on an older subpopulation or reported specific outcome data for older adults. 
In total, 60447 participants were included in the 162 RCTs assessed, with a median sample 
size of 202 (range, 9-2546 patients) (Table 1). The mean age of the trial participants was 
reported in 143 (88.3%) of the 162 trials. Because only 116 trials reported a standard deviation, 
not all 143 trials that reported a mean could be included in the analysis shown in Table 1. 
Of the 162 RCTs included, 56 (34.6%) reported an age range (full or interquartile), and 23 (14.2%) 
trials reported a median age. Three RCTs did not report any baseline characteris-
tics.40,121,169 Three RCTs that excluded patients by an upper age limit reported an age 
range in their baseline population characteristics extending this upper age limit.38,53,103 
No clarification was received for this finding after contacting the authors.
Discussion
This systematic review on the representation of older adults in RCTs studying systemic 
agents in psoriasis showed that 54 (33.3%) of the 162 RCTs excluded older individuals 
through the use of an upper age limit, ranging from 55 to 85 years. Of the included trials 
that did not use an upper age limit, 90.6% (n=96) maintained exclusion criteria that might 
disproportionally exclude older patients. Exclusion criteria most frequently reported were 
serious concurrent infection (n=104, 66.7%), active or history of malignancy (n=100, 64.1%), 
hematologic disease (n=92, 59.0%), immunodeficiency (n=85, 54.5%) and hepatic or renal 
impairment (n=84, 53.8%). Besides the potential disproportional exclusion of older 
adults, the number of patients older than 65 years participating in the RCTs was rarely 
mentioned (n=3, 1.9%). None of the RCTs reported specific efficacy or safety data 
for older patients with psoriasis. An underrepresentation of older adults in RCTs results 
in less RCT-based guidance for treating the growing population of older patients with 
psoriasis with systemic therapy. In the absence of RCT-based guidance, some guidance 
regarding the safety and efficacy of systemic treatment in older patients with psoriasis based 
on observational study designs is available. Although observational studies provide valuable 
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information, data from RCTs would improve evidence on safety and efficacy of systemic 
treatments in older adults. 
Several real-world studies showed that a large proportion of patients with psoriasis 
are not eligible for RCTs.16,17 An observational study by Malatestinic et al17 mentioned that 
28.7% of 16284 patients with moderate to severe psoriasis would not have been medically 
eligible to participate in RCTs. Garcia-Doval et al16 showed that 29.8% of 1042 patients in a 
real-world population with psoriasis receiving systemic therapy would not have been eligible 
for RCTs. In this study, the second most frequent factor leading to ineligibility was advanced 
age: 77 patients (7.4%) were aged 70 years or older and would have been excluded 
by the upper age limit.16 Both studies showed that advanced age increases the chance 
of ineligibility for RCTs. Ineligible patients were on average 7 years older and had 
more comorbidities than patients who were eligible for RCTs.17 Treating patients with 
psoriasis who are ineligible for RCTs with systemic agents may be associated with clinical 
risks, such as higher occurrence of serious adverse events.11,16 Notably, the benefit-risk ratio 
of systemic agents in an older population might differ from results presented in the RCTs 
included in our review.
Previous studies have indicated that the prevalence of most comorbidities increases 
with age in patients with psoriasis. These studies support the idea that the majority 
of exclusion criteria reported in this systematic review probably unequally affect older 
patients with psoriasis.8-11 Most of the RCTs included in our review excluded patients 
based on comorbidities that could unequally affect the representation of older adults. 
However, the most frequently reported exclusion criterion was serious concurrent infection 
(n=104, 66.7%). Given the heterogeneity of the definitions, symptoms, and etiology 
of serious infection, identification of exact prevalence data from the literature is limited. 
Therefore, it is challenging to determine the possible impact of this exclusion criterion 
on the potential disproportional exclusion of older adults. However, infection by 
tuberculosis is reported in 5.2% of young adults (<31 years) compared with 14.5% 
in older patients with psoriasis (>60 years).9 Furthermore, the prevalence of psychiatric 
diseases and alcohol consumption is generally comparable across age groups.9,10 
Only a very small number of the RCTs included in this systematic review reported 
comorbidities in the study population, which limits the interpretation of study 
generalizability in patients with psoriasis who have comorbidities. Exclusion 
based on comorbidities cannot always be avoided because certain comorbidities 
might be contraindication for the treatment studied. However, there is no evidence 
available that justifies excluding patients based solely on age. Therefore, to promote 
the representation of older adults in RCTs, we discourage the use of an upper age limit 
in RCTs. More RCT-based evidence in older adults would benefit clinical decision 
making in older patients with psoriasis.
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Some potential limitations in this systematic review should be addressed. First, the 
possibility of publication bias could not be ruled out because we included only 
published RCTs. Furthermore, some articles did not provide online supplementary 
information or additional information in trial registries regarding exclusion criteria 
or baseline characteristics, limiting the assessment of older adult representation. 
However, when additional information was available, it resulted in an increase 
of exclusion criteria that might disproportionally exclude older adults from participating 
in the trial in a majority of cases (75%). Therefore, the results shown in this report 
might be an underrepresentation of the degree of disproportional exclusion of older adult 
patients.
Conclusion
This systematic review implies that many RCTs on systemic treatment in psoriasis might 
not be generalizable to an older population. Given the increasingly aging world population, 
the need for guidance in treating older adults with psoriasis is likely to increase over time. 
To be able to make better and more thoughtful management choices for older adults in 
the future, more clinical research is needed regarding the efficacy and safety of systemic 
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1 psoriasis vulgaris/ 8453
2 psoriasis.ab,kw,ti. 53126
3 1 or 2 54274
4 crossover procedure/ or double-blind procedure/ or randomized
controlled trial/ or single-blind procedure/
573133
5 (random* or factorial* or crossover* or (cross adj1 over*) or placebo* or (doubl* 
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6 4 or 5 2039836




11 fumaric acid dimethyl ester/ 2722
12 fumaric acid derivative/ or diroximel fumarate/ or tepilamide fumarate/ 1963
13 (Methotrexate OR Amethopterin OR Mexate OR Cyclosporin OR Cyclospo-
rine OR Ciclosporin OR Neoral OR CyA-NOF OR Sandimmun OR Acitretin OR 
Etritinate OR Etretin OR Isoacitretin OR Isoetretin OR Neotigason OR Soriatane 
OR Fumarate OR Dimethylfumarate OR FAG 201 OR Fumaderm OR fumaric acid 
monoethyl ester OR ethylhydrogenfumarate OR ethyl fumarate OR Monoeth-
yl fumarate OR Dapsone OR acedapsone OR DADPS OR Sulfonyldianiline OR 
Diaminodiphenylsulfone OR Diaphenylsulfone OR Sulfona OR Disulone).ti,ab,kw.
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18 (Apremilast OR Tofacitinib OR Ponesimod OR tasocitinib OR Xeljanz 
OR CP-690550 OR Otezla OR CC 10004 OR ACT 128800).ti,ab,kw.
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29 interleukin 1 receptor blocking agent/ 12139
30 guselkumab/ 224




35 (Adalimumab or Etanercept or Infliximab or Ustekinumab or Secukinumab or 
Gevokizumab or Canakinumab or Ixekizumab or Brodalumab or Anakinra or 
Guselkumab or Certolizumab or Tildrakizumab or Itolizumab or Alefacept or 
D2E7 Antibody or Humira or Enbrel or Monoclonal Antibody cA2 or MAb cA2 
or Remicade or Stelara or CNTO 1275 or Cosentyx or AIN 457 or "XOMA 052" or 
Ilaris or ACZ885 or Taltz or LY2439821 or Siliq or AMG-827 or IL1 Febrile Inhibitor 
or IL-1Ra or Urine-Derived IL1 Inhibitor or Antril or Kineret or Cimzia or CDP 870 
or MK-3222 or LFA-3 IgG1 fusion protein or Amevive).ti,ab,kw.
47855
36 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 
or 34 or 35
82704
37 14 or 19 or 36 344869
38 7 or 37 346018
39 3 and 6 and 38 3137
40 limit 39 to yr=2003 -Current 2872
41 After manually excluding 25 articles with a publication date before 1st of July 
2003
2847
Search d.d. 24-07-2018 Results CENTRAL
#1 MeSH descriptor: [Psoriasis] this term only 2717
#2 "psoriasis":ti,ab,kw (Word variations have been searched) 5691
#3 #1 or #2 5691
#4 MeSH descriptor: [Psoriasis] this term only and with qualifier(s): [Drug 
therapy - DT]
1684
#5 MeSH descriptor: [Acitretin] explode all trees 78
#6 MeSH descriptor: [Dimethyl Fumarate] explode all trees 65
#7 MeSH descriptor: [Methotrexate] explode all trees 3606
#8 MeSH descriptor: [Cyclosporine] explode all trees 2687
#9 MeSH descriptor: [Fumarates] explode all trees 295
Table S3. Cochrane Central Register of Controlled Trials (CENTRAL) search
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Christophers 2003 + ? + + ? ?
Gordon (efalizumab) 2003 + + + + + ?
Gordon (alefacept) 2003 - ? + + ? ?
Gottlieb 20031 + ? + + - ?
Heydendael 20031 + + - ? + ?
Krueger 20031 ? ? + + + ?
Lebwohl 2003 + ? + + + ?
Leonardi 20031 + + + + + ?
Ortonne 2003 ? ? + ? ? ?
Skov 2003 ? ? ? ? ? +
Gottlieb 20041 ? ? + + + ?
Gottlieb 2005 + + + ? ? ?
Gribetz 2005 ? ? + ? ? ?
Leonardi 2005 + + + ? + ?
Menter 2005 + + ? + + +
Reich 20051 + + + + + ?
Shafiq 2005 ? ? ? ? ? ?
Vena 2005 ? ? ? ? ? ?
Bissonnette 2006 ? ? ? ? ? ?
Dubertret 2006 + + + + + ?
Gordon 20061 + ? + + + ?
Netto 2006 ? ? ? ? + ?
Papp 2006 ? ? ? ? ? +
Tyring 20061 + ? + + + +
Chaidemenos 2007 - - - - ? ?
De Groot 2007 + + + + + -
Ellis (study A) 2007 + + + - - ?
Ellis (study B) 2007 + + + - - ?
Ezquerra 2007 ? ? - ? + ?
Krueger 20071 ? ? + + + +
Menter 2007 1 + + + + + +
Moore 2007 + ? - - + ?
Yoon 2007 ? ? ? ? ? ?
Flytstrom 20081 + + ? - ? ?
Gisondi 20081 + ? - - ? ?
Kimball 2008 ? ? ? ? + -

















































































Menter 20081 + + + + + ?
Papp (ISA247) 2008 ? + + + ? +
Papp (PHOENIX 2) 20081 + + + + + +
Saurat 20081 + + + + + +
van de Kerkhof 20081 + ? + + + ?
Williams 2008 ? ? ? ? ? +
Zachariae 2008 + + - - + ?
Ali 2009 ? ? ? ? ? ?
Beissert 2009 + - ? + + +
Bissonnette 2009 ? ? + + + +
Caproni 20091 ? ? - - ? ?
Mittal 2009 + + ? ? + +
Akhyani 20102 + - - - ? +
Asahina 20101 ? ? + + + ?
Bhuiyan 2010 + ? ? ? ? ?
Colombo 2010 + + ? ? - +
Griffiths 20101 ? ? - ? ? +
Malik 2010 ? ? ? ? ? ?
Naseri 2010 ? ? ? ++ ? ?
Saxena 2010 ? ? ? ? ? ?
Torii 20101 ? ? + + + ?
Barker 20111 + + - - + +
El-Mofty 2011 ? + - - ? ?
Faghihi 2011 + ? + ? + ?
Fallah Arani 20111 + ? - ? - ?
Gottlieb 20111 ? ? + + + +
Radmanesh 2011 ? ? - ? - ?
Reich 20112 ? + + + + +
Shintani 2011 ? ? - ? + ?
Strober 20111 ? ? + + + +
Tsai 20111 + + + ? + ?
David 2012 ? ? ? ? + ?
Dogra 20121 + + + + - ?
Gordon 2012 + + + ? - +
Gottlieb 20121 ? ? + + + +
Igarashi 20121 ? ? + + + ?
Leonardi 20121 + + + + + +




















































































Papp (brodalumab) 20121 + + + + + +
Papp (tofacitinib) 20121 + + + + + +
Reich 20121 + + + + + +
Yang 2012¹ ? ? + + ? ?
Dogra 2013¹ + + ? ? - ?
Papp (apremilast) 2013¹ + + + + - +
Papp (secukinumab) 2013¹ ? + + + - -
Rich 2013¹ + + + + + +
Strohal 2013¹ ? ? + + + +
Akcali 2014 + ? - - ? ?
El-Darouti 2014 + + - + + ?
Krupashankar 2014¹ ? ? + + + ?
Langley (ERASURE) 2014¹ + + + + + +
Langley (FIXTURE) 2014¹ + + + + + +
Paul 2014 + + - - ? +
Roberti 2014 + + + + ? ?
Vaclavkova 2014¹ + + + + + +
Bachelez 2015¹ + + + + + +
Blauvelt 2015¹ + + + + + +
Drateln 2015 + + + ? + ?
Faurschou 2015 ? + + ? - ?
Goldminz 2015² + - - + + +
Gordon 2015¹ ? ? - + + +
Hafez 2015 + + + + + ?
Krueger 2015 ? ? - ? - ?
Lajevardi 2015² + - - + ? +
Lebwohl (IMAGINE 2) 2015¹ + + + + + -
Lebwohl (IMAGINE 3) 2015¹ + + + + + -
Micali 2015 ? ? + ? - +
Mrowietz 2015¹ ? ? + + + +
Papp (ASP015K) 2015 + + + + + +
Papp (ESTEEM 1) 2015¹ + ? + + + ?
Papp (tildrakizumab) 2015¹ ? + ? ? + +
Papp (REFINE) 2015 ? ? - ? + ?
Papp (OPT Pivotal 1) 2015¹ + + + + - +
Papp (OPT Pivotal 2) 2015¹ + ? + + - +
Paul (ESTEEM 2) 2015¹ ? + + + + +


















































































Reich 2015¹ + + + + + +
Singh 2015 ? ? - - - ?
Thaci 2015¹ + + + + + +
Wu 2015 ? ? - ? ? ?
Asahina 2016¹ + + + + + +
Bissonnette 2016 ? ? + + + +
David 2016 ? ? ? ? + ?
Gordon (UNCOVER 1) 2016¹ + + + + + +
Gordon (UNCOVER 2) 2016¹ + + + + + +
Gordon (UNCOVER 3) 2016¹ + + + + + +
Krueger 20161 + + + + ? +
Lee 2016 ? ? - - ? ?
Ludbrook 2016 + + + + - +
Nakagawa 20161 ? ? ? ? ? -
Papp (baricitinib) 2016 + + + + + ?
Papp (IMAGINE 1) 20161 ? + + + + +
Van Bezooijen 20161 + + - + + ?
Balak 2017 + + + + + +
Blauvelt (PSTELLAR) 2017 ? ? ? ? + +
Blauvelt (VOYAGE 1) 20171 + + + + + +
Cai 20171 + + + + + +
Choi 2017 ? ? - - ? ?
Chua 2017 + + + ? - ?
De Vries 20171 + + - ? + ?
Griffiths 2017 + + + + + +
Jin 2017 ? ? ? ? ? ?
Mrowietz 2017¹ + + + + - -
Noor 2017 + ? ? ? + ?
Ohtsuki 2017 + + ? ? + ?
Papp (adalimumab) 2017 + + + + + ?
Papp (risankizumab) 2017 ? ? ? + + +
Reich (VOYAGE 2) 20171 + + + + + +
Reich (LIBERATE) 20171 + + + + + -
Reich (reSURFACE 1) 2017 + + + + + +
Reich (reSURFACE 2) 2017 + + + + + +
Reich (IXORA-S) 2017 + + + + + ?
Sticherling 2017 + + + + + +
Warren 20171 + + + + + +
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Reich 2015¹ + + + + + +
Singh 2015 ? ? - - - ?
Thaci 2015¹ + + + + + +
Wu 2015 ? ? - ? ? ?
Asahina 2016¹ + + + + + +
Bissonnette 2016 ? ? + + + +
David 2016 ? ? ? ? + ?
Gordon (UNCOVER 1) 2016¹ + + + + + +
Gordon (UNCOVER 2) 2016¹ + + + + + +
Gordon (UNCOVER 3) 2016¹ + + + + + +
Krueger 20161 + + + + ? +
Lee 2016 ? ? - - ? ?
Ludbrook 2016 + + + + - +
Nakagawa 20161 ? ? ? ? ? -
Papp (baricitinib) 2016 + + + + + ?
Papp (IMAGINE 1) 20161 ? + + + + +
Van Bezooijen 20161 + + - + + ?
Balak 2017 + + + + + +
Blauvelt (PSTELLAR) 2017 ? ? ? ? + +
Blauvelt (VOYAGE 1) 20171 + + + + + +
Cai 20171 + + + + + +
Choi 2017 ? ? - - ? ?
Chua 2017 + + + ? - ?
De Vries 20171 + + - ? + ?
Griffiths 2017 + + + + + +
Jin 2017 ? ? ? ? ? ?
Mrowietz 2017¹ + + + + - -
Noor 2017 + ? ? ? + ?
Ohtsuki 2017 + + ? ? + ?
Papp (adalimumab) 2017 + + + + + ?
Papp (risankizumab) 2017 ? ? ? + + +
Reich (VOYAGE 2) 20171 + + + + + +
Reich (LIBERATE) 20171 + + + + + -
Reich (reSURFACE 1) 2017 + + + + + +
Reich (reSURFACE 2) 2017 + + + + + +
Reich (IXORA-S) 2017 + + + + + ?
Sticherling 2017 + + + + + +















































































Zhang 2017 + + + + + ?
Anil Kumar 2018 + + + + + ?
Blauvelt 2018 ? + + + ? +
Gottlieb (CIMPASI-1) 2018 + + + ? ? +
Gottlieb (CIMPASI-2) 2018 + + + ? ? +
Khattri 2018 ? ? - - + +
Langley (IXORA-P) 2018 + + ? + ? ?
Langley (NAVIGATE) 2018 + + ? ? - +
Lebwohl 2018 + + + + ? +
Ohtsuki 2018 + + + + + +
If no reference was mentioned as a source, the risk of bias assessment was performed by either MJS or MECvW.
Table S4 (continued)
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Effectiveness and safety of systemic therapy  
for psoriasis in older adults
a systematic review
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Treating older adults with psoriasis can be challenging owing to comorbidities, concomitant 
medication use, and consequent safety risks. Although many studies focus on the effectiveness 
and safety of systemic antipsoriatic therapies in the general population, their effectiveness in 
older adults with psoriasis has not been systematically assessed.
Objective 
To evaluate the effectiveness and safety of systemic antipsoriatic therapies in patients 65 years 
or older.
Evidence Review
A systematic literature search was conducted in Embase, MEDLINE, and the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) on November 11, 2019. No date limit was used. 
Randomized clinical trials, cohort studies, large case series, and meta-analyses assessing 
efficacy (or effectiveness) and/or safety of systemic antipsoriatic therapies in patients 65 years 
or older were included.
Findings 
The initial search yielded 11096 results, of which 31 unique articles with 39561 patients were 
included in analysis. Overall, limited data were available per systemic agent, and overall quality 
of the included studies on conventional systemic therapies was low. At the end of the induction 
phase (12-16 weeks after start of treatment), a reduction of 75% in Psoriasis Area and Severity 
Index was achieved in 49% of 74 methotrexate sodium users 65 years or older, 46% to 52.6% 
of 178 older cyclosporin users, 27% to 47.8% of 108 older acitretin users, 15.6% to 64% of 256 
etanercept users 65 years or older, 66.7% to 93% of 43 infliximab users 65 years or older, 
60.7% to 65% of 100 adalimumab users 65 years or older, 56.5% of 46 ustekinumab users 65 
years or older, and 86.4% of 67 secukinumab users 65 years or older. Effectiveness of acitretin, 
etanercept, adalimumab, and secukinumab appeared not to be associated with age; 
studies regarding other systemic antipsoriatic therapies did not provide age group 
comparisons. Older age was significantly associated with renal function deterioration in 
cyclosporin users and with lymphopenia in fumaric acid esters users (hazard ratio, 2.42; 95% 
CI, 1.65-3.55; p˂.001). Infections were the most frequently reported adverse event in patients 65 
years or older using biologics, but no significant association with age was found.
Conclusions and relevance
On the basis of limited available evidence, age alone should not be a limiting factor in psoriasis 
management. Awareness of comorbidities and concomitant medication use is very important, 
as well as appropriate dosing and frequent laboratory and clinical monitoring. More real-world 
evidence and (sub)analyses of prospective cohort studies on the effectiveness and safety of 
systemic therapies in older adults are critical to optimize personalized, effective, and safe 
antipsoriatic management in this growing patient group.
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Introduction
Psoriasis is an immune-mediated inflammatory disease associated with significant 
morbidity. Owing to the chronic course of psoriasis and aging of the world population, 
older patients with psoriasis constitute a large and growing population.1,2 Psoriasis 
management in older adults can be challenging, with the aim of achieving an optimal 
benefit-to-risk ratio while considering comorbidities, comedication, organ impairment, and 
functional deterioration.3
Although many studies have been conducted on the efficacy and safety of systemic 
antipsoriatic therapies, older adults are frequently excluded from clinical trials.4 
Therefore, many dermatologists seem to maintain a cautious approach when treating this 
population, possibly leading to undertreatment.5 The aim of this systematic review was to 
systematically evaluate available evidence concerning efficacy or effectiveness and 
safety of systemic antipsoriatic therapies in patients 65 years or older.
Methods
Search Strategy
This systematic review was conducted and reported according to the Cochrane 
Handbook for Systematic Reviews and the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) reporting guideline.6,7 On November 11, 2019, a systematic 
literature search was conducted in Embase, MEDLINE, and the Cochrane Central Register 
of Controlled Trials (CENTRAL). With the support of a medical librarian, all relevant 
synonyms of the terms psoriasis and older adults were combined with all currently available 
conventional and modern systemic antipsoriatic therapies (Table S1 in the Supplementary 
Materials). No date limit was used. Reference lists of included articles were screened for addi-
tional relevant studies.
Study
Eligibility assessment, data extraction, quality assessment, and risk of bias assessment were 
performed independently by 2 reviewers (M.E.C.vW. and L.S.vdS. or M.vdLI.A.). In case 
of discrepancies, a third reviewer (J.M.P.A.vdR. or S.F.K.L.) was consulted. Randomized 
clinical trials (RCTs), cohort studies, large case series (>10 patients), and meta-analyses 
assessing efficacy, effectiveness, and/or safety in patients with psoriasis 65 years or older were 
included. To provide a complete overview, additional studies could be included 
in case both reviewers agreed on the relevance of the article, for example, in case a 
different age cutoff value was used, or for studies in which a relatively old population was 
included. Studies in languages other than English, Spanish, German, French, and Dutch were 
excluded, as well as case reports, small case series (<10 patients), conference abstracts, 
oral communications, and expert opinions. At least 2 attempts were made to contact 




a Additional studies were included when both reviewers agreed on the relevance of the article, for instance in  
   case of a relatively old population or in case a different age cutoff was maintained.
Figure 1. Flow Diagram of the Literature Search
11096 Records identified
 4214 MEDLINE (OVID)
 6645 Embase (OVID)
   237 CENTRAL
8632 Records after deduplication
7846 Records excluded after title and
         abstract assessment
786 Full-text articles assessed for   
       eligibility
755 Full-text articles excluded, because
       no separate analysis on patients
       65 y or older, <10 study participants,
       language, no full text available
17 Articles included on
    efficacy/effectiveness
    and/or safety in patients
    65 y or older
14 Additional articles
     includeda
31 Articles included for data
    extraction
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Outcome Measures
The primary outcome measure was the efficacy or effectiveness (for readability, hereinafter 
both are denoted as effectiveness), evaluated by the percentage of older adults achieving 
a reduction of 75% in the Psoriasis Area and Severity Index (PASI75) at weeks 12 to 16. 
Secondary outcome measures were PASI50, PASI90, and PASI100 at weeks 12 to 16 and long-
term effectiveness, as well as treatmentrelated safety and tolerability profiles.
Data Extraction and Quality Assessment
Data were extracted using a predesigned form. Percentages were calculated by the reviewers 
wherever possible, if not stated in the articles. Study quality was graded according to 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
reporting guideline for observational studies8 and the Consolidated Standards of Reporting 
Trials (CONSORT) reporting guideline for RCTs.9 Risk of bias was assessed using the 
Newcastle-Ottawa Scale for cohort and case-control studies10 and the Cochrane Risk of Bias 
Tool for RCTs.6 p<.05 indicated significance.
Results
Study Characteristics
The literature search yielded a combined total of 8632 unique articles, of which 17 reported 
on effectiveness and safety of systemic antipsoriatic therapies in a cumulative 5352 treatment 
episodes in patients 65 years or older (Figure 1).11,18-33 Fourteen additional articles did not 
describe (sub)analyses of patients 65 years or older but were considered relevant by 
both reviewers and subsequently included (Table 1 and Tables S2-8 in the Supplementary 
Materials).12-17,34-41 A total of 39561 patients were included in the analysis. Baseline 
comorbidities were mentioned in 18 (58%) of the included articles,11,16-18,21-29,31,33,34,36,37 and 4 (22%) 
of these17,22,33,37 included comorbidities as independent variables or predictors in analyses. Twelve 
studies (39%)12,13,18,24,26,34,35,37-41 showed a high risk of selection bias, and overall quality of 
the studies on modern systemic therapies was higher than that of studies on conventional 
therapies (Table 2 and Tables S2-10 in the Supplementary Materials). No studies were available 
assessing the effectiveness and/or safety of ixekizumab, brodalumab, guselkumab, 
certolizumab pegol, tildrakizumab, and risankizumab in patients 65 years or older. 
A comparison of efficacy measures between treatment modalities in patients 65 years or older 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Three articles11-13 assessed methotrexate effectiveness in older adults, and 4 studies11,26,28,31 
assessed methotrexate safety and tolerability in patients 65 years or older. At week 12, 
49% of 74 patients 65 years or older achieved PASI75 (Table 2).11 Two studies11,12  concluded 
that the mean effective dose of methotrexate was significantly lower for patients older than 
70 years compared with younger patients. No data were available regarding long-term 
effectiveness. The most frequently reported adverse events in older methotrexate users 
were nausea (24%-80%) and elevated liver enzyme levels (18.2%-56%).13,34,35,38,39,41 
Two studies26,41 reported on the association of methotrexate safety and age; no significant 
associations were found (Table S2 in the Supplementary Materials).
Cyclosporin
Three studies11,14,15 assessed cyclosporin effectiveness in a cumulative number of 178 
older adults, and 3 studies11,31,32 assessed cyclosporin safety and tolerability in patients 65 
years or older. At week 12, 46% to 52.6% of the included patients reached PASI75. No data 
were available regarding long-term effectiveness. The most frequently reported 
adverse events were hypertension and renal insufficiency,11,32 the latter being 
significantly more prevalent in patients 65 years or older (4 of 12 patients [33%]) 
compared with patients younger than 65 years (10 of 110 patients [9%]; p=.03).32 
Other frequently reported adverse events in older cyclosporin users were 
hypercholesterolemia, hypertriglyceridemia, and infections (Table S2 in the Supplementary 
Materials).32,40 Cyclosporin use in patients 65 years or older was associated with a significantly 
higher overall rate of adverse events (1.4 per patient-year) compared with methotrexate (0.12 
per patient-year; p<.001).11
Retinoids
Two studies11,16 assessed acitretin effectiveness in a cumulative number of 108 older 
adults, and 4 studies11,16,28,31 assessed acitretin safety and tolerability in older adults. 
None of the studies described a combination of acitretin and UV phototherapy in 
older adults. At weeks 12 to 16, 27% to 47.8% of the included patients achieved PASI75,11,16 
and no significant association between age and treatment failure or response rate was seen.16 
The effectiveness of acitretin (PASI75 achieved by 27%) was significantly lower 
compared with the effectiveness of other systemic therapies (49% [p=.01] for methotrexate, 
64% [p<.001] for etanercept, 65% [p<.01] for adalimumab, and 93% [p<.05] 
for infliximab).11 No data were available regarding long-term effectiveness. 
The most common adverse effects were alopecia, xerophthalmia, cheilitis, 
and fatigue (Table S2 in the Supplementary Materials). One study16 reported on the 
association between acitretin safety and age; no correlation was found between the 
incidence of adverse effects and age (p=.62, not otherwise specified).
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Methotrexate
Piaserico et al,11 2014
Cyclosporin
Piaserico et al,11 2014
Acitretin
Piaserico et al,11 2014
Etanercept
Esposito et al,18 2012 (50 mg TW)
Gordon et al,20 2006 (50 mg OW)
Gordon et al,20 2006 (50 mg TW)
Piaserico et al,11 2014
Infliximab
Chiricozzi et al,21 2016 
Piaserico et al,11 2014
Adalimumab
Esposito et al,18 2012 
Menter et al,22 2010 
Piaserico et al,11 2014
Ustekinumab
Hayashi et al,23 2014
Secukinumab
Körber et al,25 2018
0 20 40 60 80 100
PASI75 achievement, %
Figure 2. Efficacy or Effectiveness in Patients 65 Years or Older at Induction Phase (Weeks 
12-16)
Each bar indicates the percentage of patients 65 years or older achieving a 75% reduction in Psoriasis Area and 
Severity Index (PASI75) per antipsoriatic agent. Studies describing patient groups with different age cutoffs were 
not included in this Figure. Data were too heterogeneous to perform appropriate meta-analyses. No data on 
effectiveness at the induction phase were available for fumaric acid esters, apremilast, ixekizumab, brodalumab, 
guselkumab, certolizumab pegol, tildrakizumab, and risankizumab. 
OW indicates once weekly; TW, twice weekly.
Fumaric Acid Esters
No studies were identified examining effectiveness of fumaric acid esters in patients 
65 years or older. However, 1 study17 reported similar PASI75 responses in 88 patients 
older than 55 years compared with 221 patients 55 years or younger (51 [58.0%] 
vs. 111 [50.2%]; p=.22). In this study, PASI75 was achieved at different time points, 
which limits comparison with other studies. Older age was significantly associated 
with the development of T-cell lymphopenia (hazard ratio, 2.42; 95% CI, 1.65-3.55; 




Four studies11,18-20 assessed etanercept effectiveness in a cumulative number of 256 patients 65 
years or older, and 6 studies11,18,28-31 assessed safety and tolerability in etanercept users 65 years 
or older. PASI75 was attained by 15.6% to 64% of patients 65 years or older at week 1211,18,20 
and by 83.6% to 86.9% after 1 to 3 years (Figure 3).18 Response rates varied between 
etanercept doses (Table 2). Two studies19,20 comparing patients 65 years or older with 
patients younger than 65 years found no difference in effectiveness between age groups. 
As is shown in Table S3 in the Supplementary Materials, the most frequently reported 
adverse events were mild infections (e.g, flulike symptoms).11,18,29 No significant difference was 
seen in incidence of serious infections in etanercept users 65 years or older compared with 
methotrexate users 65 years or older.28 One article36 with participants with a high overall mean 
age reported an increased risk for malignant neoplasms for tumor necrosis factor inhibitors, 
although a separate analysis including only etanercept did not reach significance (odds 
ratio [OR], 1.37; 95% CI, 0.94-2.01; p=.10). One study30 reported on the association between 
etanercept safety and age; serious adverse events were more frequently seen in patients 
65 years or older compared with patients younger than 65 years, although according to 
the authors none of these were associated with etanercept use (not further specified).
Each bar indicates the percentage of patients 65 years or older achieving 75% reduction in Psoriasis Area 
and Severity Index (PASI75) per antipsoriatic agent. Data were too heterogeneous to perform appropriate 
meta-analyses. No data on long-term effectiveness were available for cyclosporin, methotrexate, retinoids, 
fumaric acid esters, apremilast, infliximab, ixekizumab, brodalumab, guselkumab, certolizumab pegol, 
tildrakizumab, and risankizumab.
a
 The study used intention-to-treat analysis with the last observation carried forward. Results should be 
 interpreted with caution; a high risk of selection bias was present in this study.
b The study used intention-to-treat analysis with nonresponder imputation.
Etanercept
Esposito et al,18 2012a
Adalimumab
Esposito et al,18 2012a
Ustekinumab
Hayashi et al,23 2014 
Megna et al,24 2016
Secukinumab
Körber et al,25 2018b
0 20 40 60 80 100
PASI75 achievement, %
Figure 3. Long-term (Week 52) Efficacy or Effectiveness in Patients 65 Years or Older
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Two retrospective studies11,21 assessed infliximab effectiveness with a cumulative inclusion 
of 43 patients 65 years or older, and 5 studies11,21,28,29,33 assessed safety and tolerability in 
infliximab users 65 years or older. PASI75 response at week 12 ranged from 66.7% to 93%,11,21 
including 6 patients using combination therapy with methotrexate, 7.5 to 15.0 mg/wk.21 
No data were available regarding long-term effectiveness. As is shown in Table S4 in the 
Supplementary Materials, the most frequently reported adverse events were mild 
infections.21,29,33 Two studies described a trend of an increased infection rate with rising age, 
although the differences found were not statistically significant (11 of 117 [9.4%] patients aged 
≥65 years vs. 28 of 647 [4.3%] patients aged <65 years; p=.06)33 or not reported (4 of 6 
[66.7%] patients aged ≥76 years vs. 2 of 22 [9.1%] patients aged 75 years; p-value not 
reported).29 Comorbidities were associated with an increased incidence of infections, especially 
respiratory disease.33 Fiorentino et al36 reported an increased risk for malignant neoplasms 
in older patients using tumor necrosis factor inhibitors, although a separate analysis 
including only infliximab did not reach significance (OR, 1.01; 95% CI, 0.59-1.74; p=.96). 
Adalimumab
Three studies11,18,22 assessed adalimumab effectiveness in a cumulative number of 100 
patients 65 years or older, and 5 studies11,18,27,28,31 assessed safety in adalimumab users 
65 years or older. At weeks 12 to 16, PASI75 was achieved in 60.7% to 65% of patients 
65 years or older11,18,22 and in the longer term (1-3 years) in 67.9% to 71.4%.18 No statistically 
significant association was seen between PASI75 response and age.22 One study27 
reported on the association between adalimumab safety and age; a similar frequency 
of adverse events was seen in patients older than 65 years (2 of 16 [12.5%]) compared 
with patients 65 years or younger (13 of 101 [12.9%]; p-value not reported), most commonly 
infections (Table S5 in the Supplementary Materials). No statistically significant difference 
was seen in incidence of infections in adalimumab users 65 years or older compared with 
methotrexate users 65 years or older.28 An increased risk for malignant neoplasms in older 
patients using tumor necrosis factor inhibitors was reported by Fiorentino et al,36 although 




Two retrospective studies23,24 assessed ustekinumab effectiveness in a cumulative 46 
patients 65 years or older, and 3 articles23,24,28 assessed safety and tolerability in 
ustekinumab users 65 years or older. At week 16, PASI75 was achieved in 56.5% of 
patients 65 years or older,23 and in the long term (52-100 weeks) by 60.0% to 90.9%.23,24 
As is shown in Table S6 in the Supplementary Materials, no significant difference was 
seen in incidence of infections in ustekinumab users 65 years or older compared with 
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methotrexate users 65 years or older.28 Moreover, a large prospective cohort study reported 
that no increased risk for malignant neoplasms was seen in older ustekinumab users compared 
with older patients not using ustekinumab.36 None of the studies compared outcomes with 
those of patients younger than 65 years.
Secukinumab
One study assessed secukinumab effectiveness and safety in 67 patients 65 years or 
older.25  PASI75 was achieved by 86.4% of patients 65 years or older at week 16 compared 
with 89.0% of patients younger than 65 years (p-value not reported). Long-term effectiveness 
(52 weeks) was achieved by 81.8% of patients 65 years or older and 79.4% of patients 
younger than 65 years (p-value not reported). As is shown in Table S7 in the 
Supplementary Materials, the most frequently reported adverse events were infections, 
which were seen in 36 of 67 patients (53.7%) 65 years or older vs. 527 of 839 (62.8%) 
younger than 65 years (p>.05, not otherwise specified).25 Cardiac disorders 
were seen in 8 of 67 patients (11.9%) 65 years or older vs. 24 of 839 (2.9%) 
younger than 65 years (p-value not reported), although patients 65 years or older also had 
significantly more pre-existent cardiovascular comorbidities at baseline (e.g, hypertension 
in 71.8% of patients aged >65 years vs. 20.8% of patients aged <65 years [p<.001]; 
myocardial infarction in 7.7% of patients aged >65 years vs. 1.9% of patients 
aged <65 years [p=.02]; coronary artery disease in 10.3% of patients aged >65 years 
vs. 1.7% of patients aged <65 years [p<.001]). Treatment-related serious adverse 
events were seen in 4.5% of patients 65 years or older and in 1.8% of patients younger than 65 
years (p-values not reported, not otherwise specified).25
Apremilast
No studies were identified studying the effectiveness of apremilast in patients 65 years 
or older. Dommasch et al28 found no significant increase in risk of serious infections 
in apremilast users 65 years or older compared with methotrexate users 65 years 
or older (propensity score–adjusted hazard ratio, 0.51; 95% CI, 0.05-5.60; p=.58). 
No other studies were identified assessing apremilast safety and tolerability in older adults 




Disease management in older adults (aged ≥65 years) with psoriasis can be challenging 
owing to patient-related factors and the lack of scientific guidance owing to disproportional 
exclusion of older adults in clinical trials.4,42 This systematic review was conducted to provide 
an overview of the literature on effectiveness and safety of systemic antipsoriatic therapies in 
older adults. 
At the end of the induction phase (weeks 12-16), PASI75 was achieved in 15.6% to 64% of 
etanercept users 65 years or older,11,18,20 66.7% to 93% of infliximab users 65 years or older,11,21 
60.7% to 65% of adalimumab users 65 years or older,11,18,22 56.5% of ustekinumab users 
65 years or older,23 and 86.4% of secukinumab users 65 years or older.25 Conventional 
therapies were studied less frequently; PASI75 after the induction phase was achieved by 49% of 
methotrexate users 65 years or older,11 46% to 52.6% of older cyclosporin users,11,14,15 
and 27% to 47.8% of older acitretin users.11,16 The included studies were heterogeneous 
regarding the age cutoff, treatment regimens, and methodological approaches. 
Moreover, overall quality of the studies on conventional therapies was low. 
Interestingly, 2 studies11,12 reported that the mean effective methotrexate dose was 
lower in patients older than 70 years compared with patients 70 years or younger, 
possibly owing to impaired renal function associated with aging.42-44 No data were 
available regarding drug level monitoring in older patients with psoriasis, although this 
could be an interesting consideration for further research. Long-term effectiveness was not 
studied in older adults using conventional systemic treatment, whereas 4 studies18,23-25 
reported on long-term (week 52) effectiveness of etanercept (PASI75 in 83.6%), 
adalimumab (PASI75 in 67.9%), ustekinumab (PASI75 in 60.0%-86.4%), and 
secukinumab (PASI75 in 81.8%). Overall, effectiveness in patients 65 years or 
older appears to be in line with effectiveness in patients younger than 65 
years,16,19,20,22,25,45-49 although several studies were subject to selection bias leading 
to overestimation of the outcomes. No data on effectiveness in patients 65 years or 
older were available for fumaric acid esters, apremilast, ixekizumab, brodalumab, 
guselkumab, certolizumab pegol, tildrakizumab, and risankizumab.
   For conventional systemic treatment, the most important adverse events in patients 
65 years or older included liver dysfunction in methotrexate users,26,34,35,38,39 hypertension 
and renal function deterioration in cyclosporin users,11,32,40 and lymphopenia 
infumaric acid ester users.17 Literature is inconsistent on methotrexate-related 
hepatotoxicity and the association with age. Whereas some studies have 
identified age as a risk factor for hepatotoxicity,50,51 more recent studies found no 
such association.26,52,53 Cyclosporin should be prescribed in patients 65 years or older 
with absolute caution, because it appears to be associated with the highest 
adverse events rate of all antipsoriatic systemic therapies,11 and an association of 
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adverse events with increasing age was identified.32,37 However, most adverse events 
associated with conventional systemic therapies were reversible after dose adjustment or 
discontinuation or were successfully treated (e.g. hypertension, laboratory changes).16,32,39,40
     Infections were the most frequently reported adverse events in patients 65 years or older 
using biologics. In this systematic review, no evidence was found of differences in infection 
risk by age category.25,28,33 Other previous studies are inconsistent regarding the association 
between age and infection risk; Kalb et al54 found a higher risk of serious infections with 
increasing age in 11466 patients with psoriasis (mean [SD] age, 48.5 [13.8] years), in 
contrast to a meta-analysis55 with a cumulative number of 17739 patients (mean [SD] age, 
49.1 [14.6] years). In rheumatoid arthritis and inflammatory bowel disease, an increased 
infection risk was seen in patients 65 years or older using biologics.56 However, multiple 
studies have suggested that adverse events in patients with psoriasis might differ from those 
seen in patients with other immune-mediated inflammatory diseases owing to differences 
in the underlying immunologic changes.56-58 Moreover, combination therapy with other 
immunomodulators is maintained far more frequently (15%-79%) than in dermatological 
daily practice.56 In line with previous research, no increased risk of malignant neoplasms 
(excluding nonmelanoma skin cancer) was seen in methotrexate and ustekinumab users 
(mean [SD] age, 59.9 [10.9] years).36,59 Although tumor necrosis factor inhibitors (etanercept, 
adalimumab, and infliximab) were associated with a higher risk for malignant neoplasms 
after at least 12 months, analysis per agent did not show significant associations, possibly owing 
to a lack of statistical power.36 No data were available for patients 65 years or older specifically. 
Therefore, results of real-world studies are needed to identify rare long-term adverse 
events of antipsoriatic therapies and the association with older age (≥65 years).
     Some studies have reported a higher incidence of serious adverse events in patients 65 
years or older, irrespective of whether or not an association with antipsoriatic treatment was 
suspected.60 However, the definition of serious adverse events in RCTs entails 
hospitalization and emergency department visits, regardless of association with the treatment. 
Patients 65 years or older frequently have more comorbidities and a higher a priori chance of 
hospitalization than younger patients. It is therefore questionable whether the results on 
serious adverse events in these studies, frequently lacking a control group with patients of the 
same age, can be attributed to antipsoriatic treatment. Considering the risk-to-benefit ratio 
remains important in every individual patient. Because coronavirus disease 2019 (COVID-19) 
is at present a global threat to older adults, many dermatologists might hesitate to prescribe 
or continue immunomodulatory therapies. Clinical guidelines advise not to cease systemic 
antipsoriatic therapies unless COVID-19 symptoms arise.61 The scarce available data do not 
imply a more severe course of the disease in patients using antipsoriatic therapies, some of 
which possibly even ameliorate the organ damage associated with severe COVID-19.62-66 




     The results of this systematic review on psoriasis management in older adults indicate 
that age should not be a limiting factor in its own right. Obviously, awareness of 
comorbidities and concomitant medication use is very important when selecting 
antipsoriatic treatment. However, disproportional age-based reluctance to optimally treat 
older patients with psoriasis could be a pitfall.
 
Limitations
Thirteen of the included studies12-15,19,20,30,32,35,38-41 did not report baseline comorbidities, which 
limits interpretation of the results in the heterogeneous population older adults comprise. 
Moreover, data were too scarce and heterogeneous to perform appropriate meta-analyses, 
which limits generalizability of the results. Outcomes varied among studies owing to 
dosing differences, inclusion of biologic-naive patients or those previously exposed to biologics, 
concomitant medication, and differences in sample sizes, study design, and methodological 
approach. Head-to-head comparisons between systemic agents with age-matched control 
participants and comparisons with younger patient groups are needed to provide more 
guidance in treating older psoriasis patients.
Conclusions
Age alone should not be a limiting factor in psoriasis management. The available studies 
have demonstrated that response to several systemic therapies is not influenced by age. 
Results on safety are scarce but appear to be limited to a higher chance of laboratory 
abnormalities and (mild) infections. Appropriate monitoring of physical and laboratory 
changes is essential in this patient group, as well as dose adjustments when indicated. 
More data on efficacy, effectiveness, and safety of systemic therapies in patients 65 years 
or older, from RCTs and real-world studies, are critical to optimize personalized, effective, 
and safe psoriasis management in this growing patient group.
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Table S1. Search Strategy
Search d.d. 11-11-2019
         Results
         Medline
#1 psoriasis/ OR psorias*.tw,kf 46865
#2 *Drug Therapy/ OR adalimumab/ OR certolizumab pegol/ OR Cyclosporine/ OR Dimethyl 
Fumarate/ OR etanercept/ OR infliximab/ OR Methotrexate/ OR dt.fs. OR retinoids/ or 
acitretin/ or etretinate/ OR ustekinumab/ 
OR 
(Acitretin OR adalimumab OR AIN?457 OR am#evita OR Amethopterin OR apremilast 
OR avakine OR benepali OR brodalumab OR CC?10004 OR certolizumab OR Ciclosporin* 
OR cimzia OR cnto?1275 OR cosentyx OR CyA-NOF OR Cyclosporin* OR D2E7 OR 
Dimethylfumarate OR e#brel OR erelzi OR etanercept OR ethylhydrogenfumarate OR 
Etretin* OR Etrinoate OR FAG 201 OR flixabi OR Fumaderm OR Fumarate OR Fumaric OR 
guselkumab OR humira OR ilumetri OR immunosuppressive OR inflectra OR infliximab 
OR Isoacitretin OR Isoetretin OR ixekizumab OR kyntheum OR Liarozole OR LY?2439821 
OR Methotrexate OR Mexate OR Neoral OR Neotigason OR otezla OR Psorinovo OR 
Rambazole OR remicade OR remsima OR Retinoids OR revellex OR risankizumab OR 
Sandimmun OR secukinumab OR siliq OR Skyrizi OR Soriatane OR stelara OR Systemic 
calcineurin inhibitor* OR SYSTEMIC MONOTHERAPIES OR SYSTEMIC MONOTHERAPY 
OR Systemic pharmacolog* OR SYSTEMIC THERAPIES OR SYSTEMIC THERAPY OR 
Talarozole OR taltz OR Tigason OR Tigazon OR tildrakizumab OR TN#R?Fc OR TNF-
FC OR TNR?001 OR tremfya OR trudexa OR ustekinumab OR (anti-IL* adj2 agent*) OR 
(anti-IL* adj2 drug*) OR (anti-IL* adj2 therap*) OR (anti-IL* adj2 treatment*) OR (anti-
interleukin* adj2 agent*) OR (anti-interleukin* adj2 drug*) OR (anti-interleukin* adj2 
therap*) OR (anti-interleukin* adj2 treatment*) OR (anti-TNF* adj2 agent*) OR (anti-
TNF* adj2 drug*) OR (anti-TNF* adj2 therap*) OR (anti-TNF* adj2 treatment*) OR (anti-
tumo?r adj2 necrosis adj2 factor* adj2 agent*) OR (anti-tumo?r adj2 necrosis adj2 factor* 
adj2 drug*) OR (anti-tumo?r adj2 necrosis adj2 factor* adj2 therap*) OR (anti-tumo?r 
adj2 necrosis adj2 factor* adj2 treatment*) OR (IL* adj2 blocker*) OR (IL* adj2 blocking 
adj2 agent*) OR (IL* adj2 inhibitor*) OR (interleukin* adj2 blocker*) OR (interleukin* 
adj2 blocking adj2 agent*) OR (interleukin* adj2 inhibitor*) OR (MAb adj2 cA2) OR 
(monoclonal adj2 antibody adj2 cA2) OR (TN# adj2 receptor adj2 fusion adj2 protein) 
OR (TNF* adj2 blocker*) OR (TNF* adj2 blocking agent*) OR (TNF* adj2 inhibitor*) OR 
(tumo?r adj2 necrosis adj2 factor* adj2 blocker*) OR (tumo?r adj2 necrosis adj2 factor* 
adj2 blocking adj2 agent*) OR (tumo?r adj2 necrosis adj2 factor* adj2 inhibitor*)).tw,kf
2326241
#3 exp aged/ OR exp geriatrics/ OR exp nursing homes/ OR Geriatric assessment/ OR Exp 
aging/
OR 
((old adj2 adult*) OR (old adj2 age*) OR (old adj2 females) OR (old adj2 males) OR (old 
adj2 men) OR (old adj2 patient*) OR (old adj2 population) OR (old adj2 subject*) OR (old 
adj2 women) OR (older adj2 adult*) OR (older adj2 age*) OR (older adj2
females) OR (older adj2 males) OR (older adj2 patient*) OR (older adj2 population) OR 
(older adj2 subject*) OR (older adj2 women) OR (oldest?old) OR (senior* adj2 patient*) 
OR (senior* adj2 population) OR (very adj2 old) OR Ageing OR aging OR centarian* OR 
centenarian* OR community-dwelling OR elder* OR eldest OR frail* OR geriatri* OR 
nonagenarian* OR oct#genarian* OR old people OR older OR oldest OR Psycho 
geriatrics OR septuagenarian* OR sexagenarian OR supercentenarian*).tw,kf
3613 081
#4 #1 AND #2 AND #3 4214
 
The search strategy for Medline was shown, a similar search was developed for the other databases.
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Table S9. Risk of Bias Assessment of Included Studies According to the Newcastle- 
Ottawa Scale10
Abe et al, 2007 NA * NA * * NA * - -
Almeyda et al, 1972** NA - * * - - * * -
Bauer et al, 2017** NA - NA * * NA * - -
Birnie et al, 1985** NA - - * - - * * -
Borghi et al, 2015 NA * NA * * NA * * *
Chiricozzi et al, 2016 NA * NA * * NA * * -
Chiricozzi et al, 2017 NA * NA * * NA * * -
Dommasch et al, 2019 NA * NA * * NA * * -
Dickel et al, 2019 NA * NA * * NA * * -
Duhra et al, 1993** NA - NA - * NA * * -
Esposito et al, 2012** NA - NA * * NA * * -
Fairris et al, 1989** NA - NA * * NA * - -
Fiorentino et al, 2017 * * * * NA * * * NA
Giunta et al, 2014 NA * NA * * NA * * -
Grossman et al, 1996** NA - NA * * NA * * -
Hayashi et al, 2014 NA * NA * * NA * * -
Kaur et al, 1995** NA - NA * * NA * * -
Megna et al, 2016** NA - NA * * NA * * -
Migliore et al, 2009 NA * NA * * NA * - -
Napolitano et al, 2016 NA * NA * * NA * * -
Nyfors et al, 1970** NA - NA * * NA * * -
Nyfors, 1978** NA - NA * * NA * * -
Piaserico et al, 2014 NA * NA * * NA * * -
Timonen et al, 1990 NA * NA * * NA * - -
Torii et al, 2016 NA * NA * * NA * * *
Veller Fornasa et al, 2003** NA - NA * * NA * * -
NA, not applicable. * Criterium achieved - criterium not achieved. ** Results should be interpreted with caution; 
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  Table S10. Risk of Bias Assessment of Included Studies According to the Cochrane Risk of   















































































Ohtsuki et al, 2003 ? + ? ? - -
Gordon et al, 2006 + + + + ? ?
Körber et al, 2018 + + + + + ?
Menter et al, 2010 + + + + + ?
Militello et al, 2006 + + + + + ?
+ criterium achieved; 
?  unclear; 
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Disease and treatment characteristics 
in geriatric psoriasis: 
a patient survey comparing age groups
M.E.C. van Winden, E.L.M. ter Haar, H.M.M. Groenewoud, 






Little is known about psoriasis in geriatric patients, whereas treating this growing 
population can be challenging due to comorbidities, comedication and physical 
impairments. To compare disease and treatment characteristics of psoriasis 
patients ≥65 years old with patients <65 years old, a self-assessment survey 
was sent to all members of the Dutch Psoriasis Association (n=3310). In total, 
985 (29.7%) patients returned the survey, 414 (43.6%) respondents were ≥65 years old. 
Patients ≥65 years old had experienced erythrodermic psoriasis significantly 
more frequently than patients <65 years old, other disease characteristics were highly 
comparable. Despite a significantly higher prevalence of comorbidities and comedication 
use in patients ≥65 years old, no difference was seen between the age groups regarding 
systemic antipsoriatic treatment (38.3% in ≥65 years old vs. 42.3% in <65 years old; p=0.219). 
Remarkably, treatment-related side-effects were reported more frequently by patients 
<65 years old. In conclusion, age alone should not be a limiting factor in psoriasis 
management, and proper attention must be paid to additional patient-related factors.
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Introduction 
Psoriasis is an immune-mediated inflammatory disease which is frequently seen in older adults. 
As the ageing world population continues to expand, dermatologists will increasingly be 
confronted with patients aged 65 years and older. Although the exact prevalence of 
psoriasis in older adults is unknown, it is estimated to range from 1% to 19%.1–3 Balancing the 
possible risks of antipsoriatic therapies in older adults and optimal psoriasis treatment can be 
challenging, due to factors such as comorbidities, concomitant medication, physical 
impairments and changing pharmacokinetics and pharmacodynamics.4,5
     Little research has been conducted concerning disease and treatment characteristics in older 
psoriasis patients, or geriatric psoriasis (Figure S1). The few available studies show similar 
disease severity compared with younger patients, although prescribed therapies appear to 
differ.6,7 Moreover, data concerning the use of systemic treatment in geriatric psoriasis 
are scarce, since older adults are frequently excluded from clinical trials.8,9 Therefore, it is 
currently unclear what risks are associated with antipsoriatic treatment in this growing population 
and whether geriatric patients with psoriasis are treated optimally.
   To improve patient-centred clinical care in geriatric psoriasis, more knowledge needs to 
be acquired in this particular patient group. The objective of this study was therefore to 
provide more insight into the disease and treatment characteristics in older adults with psoriasis 
compared with younger patients.
Materials and methods
Study design and participants
A nationwide cross-sectional study was conducted to assess the clinical characteristics 
of older adult patients with psoriasis, as well as current and previous treatments. 
A self-assessing multimodality survey was sent to all members of the Dutch Psoriasis 
Association (n=3310), along with study information and a prepaid envelope. In addition to 
this paper-based version, a hyperlink to the online web-based survey (Qualtrics, Provo, 
UT, USA) was provided and printed repeatedly in the Dutch Psoriasis Association 
Magazine. Returning the survey was construed as informed consent. Approval from the 
Research Ethics Committee of Radboud University Medical Centre was obtained before 
starting the study. This study was reported in accordance with the Strengthening the 




A survey was developed based on an extensive review of the literature, patient interviews, and 
multiple meetings with a multi- disciplinary focus group consisting of physicians in dermatology 
and rheumatology, (specialized) nurses, clinical researchers, and a dermato-psychologist. 
The survey included multiple sections enquiring about sociodemographic aspects, psoriasis 
characteristics and associated therapy using multiple choice questions, Likert scales, and 
visual analogue scales. Furthermore, open-ended questions were added to each section 
to further evaluate relevant items not captured by the questions included in the survey, 
answers were categorized for further analyses. Disease severity was measured using the Self- 
Administered Psoriasis Area Severity Index (SAPASI), a validated patient-assessed instrument 
based on the frequently used Psoriasis Area Severity Index.11 The SAPASI ranges from 0 to 72 and 
can be classified into 4 categories: in remission (SAPASI=0), mild (>0≤3), moderate (>3≤15) and 
severe (>15).12 Prescribed therapies were categorized into 4 different groups: topical therapy, 
phototherapy, conventional systemic therapy, and modern systemic therapy (biologics and 
small-molecule inhibitors). Body mass index (BMI) was calculated based on reported weight 
and height. Polypharmacy was defined as the simultaneous use of 5 or more medications.13 
A pilot study was performed in 10 geriatric patients with psoriasis prior to distribution of the 
survey to improve its quality, and assess the relevance and comprehensibility of the questions, 
instructions and response options.
Data processing and analysis
Data were processed anonymously using the automatic form identification software Remark 
Office Optical Mark Recognition, version 9.5 (Gravic, Inc. Malvern, PA, USA) and Castor Electronic 
Data Capture, a web-based data management system in compliance with Good Clinical 
Practice (GCP) standards (Castor Research Inc., Hoboken, NJ, USA). To ensure correct data entry, 
10% of the data entry was checked manually by an independent researcher who was not 
involved in data entry. Statistical analyses were performed using Statistical Package for 
Social Sciences (SPPS) Statistics for Windows, version 25.0 (IBM, Armonk, NY, USA). Descriptive 
statistics were used to summarize categorical data as frequencies and percentages and 
continuous variables as mean ± standard deviation (SD) or median (range), as appropriate 
according to the distribution of the data. Missing values were excluded from analyses. 
Patients were categorized into 2 age groups; patients ≥65 years old and patients <65 years old. 
Comparisons were made using Student’s t-test or Mann–Whitney U test for continuous 
variables, and the χ2 or Fisher’s exact test for categorical variables. Subgroup analyses were 
performed comparing outcome measures of patients ≥80 years old with patients <80 years 
old, and comparing patients with early disease onset (onset of symptoms before the age 
of 40 years) and patients with late disease onset (onset of symptoms after the age of 40 
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years).14 Logistic regression was used to correct for confounding variables and to determine 
odds ratios (ORs). Age and sex distribution of the respondent population were compared 
with the target population to test for non-response bias, using available current data on the 
members of the Dutch Psoriasis Association and previous research in this population.15
Results
Study participants
Between 11 December 2018 and 4 September 2019, 3310 patients with psoriasis were 
approached for participation. In total, 985 (29.7%) surveys were returned. Due to 
missing age values, 27 respondents were excluded from analyses. Eight more respondents 
were excluded from analyses due an insufficient number of answered items 
(e.g. responses to age and sex only). The remaining 950 respondents were suitable for analysis. 
The mean ± SD age was 61.1 ± 13.7 years, range 7–95, and 414 (43.6%) of the respondents were 
≥65 years old. Of these, 58 (14.0%) respondents were ≥80 years old. A full overview of 
responder characteristics is given in Table 1. Although a significant difference in sex was seen 
between patients ≥65 years old vs. those <65 years old, results after stratification for sex 
did not differ from the main analysis (data not shown).
    Non-response bias was assessed by comparing age and sex distribution of the study 
respondents with the target population; no significant differences were found (Table S1). 
Since 95.5% (n=879) of the surveys were returned in the winter, an additional analysis on 
seasonal difference was performed; no significant impact on outcome measures was seen. 
There were no significant differences in outcome measures between paper-based and web-
based responses (data not shown).
Comorbidities and medical history
Except for depression, all reported comorbidities were significantly more common in 
patients ≥65 years old, as is illustrated in Table 1. A cardiovascular risk profile (e.g. obesity, 
hypertension, hypercholesterolaemia, diabetes mellitus, myocardial infarction, heart failure 
and cerebral vascular accident) was more prevalent in patients ≥65 years old compared with 
patients <65 years old. Moreover, patients ≥65 years old had a significantly higher BMI 
(median 26.2 (range 17.7–65.9 kg/m2) in ≥65 years old vs. 25.4 (14.3–56.1 kg/m2) in <65 years old; 
p=0.006). A (history of) malignancy was significantly more often reported by patients ≥65 years 
old compared with patients <65 years old (n=94 (23.2%) vs. 44 (8.3%) respectively; p<0.001). 
Of all patients reporting a (history of) malignancy, 71 (43.3%) reported skin cancers (35.2% 







Sex, n (%) <0.001
    Male 247 (46.2) 246 (59.6)
    Female 288 (53.8) 167 (40.4)
Age, years, median (range) 56 (7–64) 71 (65–95) NA
    Mean ± SD 52.4 ± 11.4 72.4 ± 5.9
Age at onset, n (%) NA
    Early onseta 459 (85.6) 305 (73.7)
    Late onsetb 74 (13.8) 108 (26.1)
    Unknown 2 (0.4) 0 (0.0)
Family history of psoriasis, n (%)  0.719
    Positivec 333 (62.2) 266 (64.6)
    Negative 118 (22.1)     88 (21.4) 
    Unknown 84 (15.7)     58 (14.1) 
Medical history, n (%)
    Overweight (BMI>25) 285 (53.7) 250 (62.3)   0.008
    Hypertension 108 (20.5) 197 (49.0) <0.001
    Hypercholesterolaemia 68 (12.9) 149 (37.3) <0.001
    Myocardial infarction 10 (1.9) 35 (8.8) <0.001
    Heart failure 21 (4.0) 66 (16.6) <0.001
    Cerebral vascular accident 9 (1.7) 22 (5.5)   0.002
    Diabetes mellitus 25 (4.7) 64 (15.9) <0.001
    Cancerd 44 (8.3) 94 (23.2) <0.001
    Depression 99 (18.9) 69 (17.3)   0.530
Use of comedicatione, n (%) 236 (44.7) 306 (75.6) <0.001
Table 1. Responder characteristics of geriatric psoriasis patients (≥65 years old)  
compared with patients <65 years old
Values might not add up due to missing values.
a  Defined as onset of symptoms before and 
b  after the age of 40 years.14 
c  Including all family members affected by psoriasis. Separate analyses were done only including first-degree family 
 members; 233 (43.6%) patients <65 years old reported 1 or more affected first-degree family members, compared
 with 206 (50.0%) patients ≥65 years old (p=0.142). 
d Excluding non-melanoma skin cancer (n=25). In uncertain cases (e.g. 30 patients reported “skin cancer”), patients
 were included in the analysis. 
e Other than psoriasis medication.
NA: not applicable, since the categorization of patients in separate age groups automatically leads to differences in 
age-related variables; BMI: body mass index; SD: standard deviation.
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   The use of concomitant medication was reported by 306 (75.6%) patients ≥65 years 
old, vs. 236 (44.7%) patients <65 years old (p<0.001). The most frequently used types of 
concomitant medication were cardiovascular drugs (n=211 (69.0%) ≥65 years old 
vs. n=104 (44.1%) <65 years old; p<0.001) and antidiabetic drugs (n=42 (13.7%) ≥65 years old 
vs. n=21 (8.9%) <65 years old; p=0.004). Moreover, polypharmacy was significantly more 
prevalent in patients ≥65 years old (n=103 (30.7%) ≥65 years old vs. n=47 (13.9%) <65 years old; 
p<0.001).
Disease characteristics
As shown in Table 2, plaque psoriasis and psoriasis capitis were the most frequently reported 
clinical psoriasis types currently present in both patient groups (cumulative prevalence: 67.2% 
and 70.6%, respectively). Patients ≥65 years old had experienced erythrodermic psoriasis 
significantly more frequently than patients <65 years old (n=70 (17.1%) ≥65 years old vs. 
n=31 (5.8%) <65 years old; p<0.001). Comparable rates of psoriatic arthritis were reported 
in both age groups (n=158 (38.5%) ≥65 years old vs. n=193 (36.2%) <65 years old; p=0.464). 
Guttate and genital psoriasis were significantly more frequently reported by patients <65 years 
old. In both groups, patients experienced their first symptoms of psoriasis most frequently 
before the age of 18 years (n=136 (32.9%) ≥65 years old vs. n=219 (40.9%) <65 years old). 
Of all patients ≥65 years old, 65 (15.7%) reported disease onset after the age of 50 years, 
14 (3.4%) respondents reported disease onset after the age of 65 years, as is illustrated 
in Figure S2.
     A subgroup analysis was performed to compare disease characteristics in patients ≥65 years 
old with early disease onset with those with late disease onset. Erythrodermic psoriasis was 
significantly more frequently reported by patients with early disease onset (n=63 (20.8%) vs. 
n=7 (6.5%); p=0.001), as well as psoriasis unguium (n=160 (52.8%) vs. n=42 (39.3%); p=0.016). 
Other disease characteristics did not differ between the onset groups.
   The majority of all patients had never experienced a period of total skin clearance 
(n=228 (55.6%) ≥65 years old vs. n=302 (56.7%) <65 years old; n=0.774). Only 82 (8.7%) 
patients in the total study population experienced a period of total skin clearance longer 
than 3 years in a row. Although patients ≥65 years old reported a slightly lower current 
SAPASI score compared with patients <65 years old (median 5.24 (0–20.2) in ≥65 years old vs. 
5.72 (0–35.5) in <65 years old; p=0.016), disease severity was considerably high in both groups, 
as most patients currently received antipsoriatic treatment. When comparing the age groups 
according to categorized SAPASI scores, no significant difference was seen in disease severity; 
a current moderate disease activity was reported by 266 (68.9%) patients ≥65years old, severe 
psoriasis was reported by 17 (4.4%) patients ≥65 years old, whereas 371 (71.1%) patients <65 
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Antipsoriatic treatment
As shown in Table 2, there were no significant differences in currently used therapies by 
patients ≥65 years old compared with patients <65 years old. No significant difference was 
seen between the age groups regarding the use of conventional systemic therapies 
(n=107 (26.1%) ≥65 years old vs. n=140 (26.4%) <65 years old; p=0.913), nor in the use of 
modern systemic therapies (n=63 (15.4%) ≥65 years old vs. n=100 (18.9%) <65 years 
old; p=0.160). A combination of systemic agents was used by 17 (4.1%) patients ≥65 
years old and 22 (4.2%) patients <65 years old (p=0.997). When comparing the specific 
systemic agents between the age groups, no significant differences were 
seen. As is shown in Figure S3, most frequently used systemic agents were fumaric acid, 
methotrexate and adalimumab in both age groups (cumulative respectively 34.1%, 
30.2% and 16.0%). No significant differences between the age groups were seen in previously 
used therapies.
     A separate analysis comparing patients ≥80 years old (n=58) with patients <80 years 
old showed systemic treatment usage by 22 (38.6%) patients ≥80 years old, compared with 
359 (40.7%) patients <80 years old (p=0.759). Modern systemic therapies were used in 
6 (10.5%) patients ≥80 years old, compared with 157 (17.8%) patients <80 years old (p=0.161). 
A significant higher number of patients ≥80 years old were currently treated with 
phototherapy, although the sample size was quite small (n=8 (14.0%) vs. n=38 (4.3%); 
p=0.001), as is summarized in Table S2.
    Adverse events were reported significantly more frequently by patients <65 years old 
compared with patients ≥65 years old, even after correction for type of treatment (only 
topical therapy, UV therapy with or without topical therapy, conventional systemic therapy 
with or without topical or UV therapy, modern systemic with or without topical or UV 
therapy and combined systemic therapies with or without topical therapy, (OR: 1.57; 95% CI: 
1.09–2.25; n=0.015).
         Patients ≥65 years old were significantly more often dependent on assistance with treatment 
or skin care compared with patients <65 years old (n=56 (14.9%) ≥65 years old vs. n=46 
(9.0%) <65 years old; p=0.007); 47 (83.9%) were helped by a partner or family member, and 
9 (16.1%) relied on medical caretakers or others. Of all patients ≥80 years old, 11 (20.8%) 
were dependent on others, 6 (54.5%) were assisted by a partner or family member, and 5 
(45.5%) by medical caretakers. No difference was seen among the age groups in the daily 
amount of time patients spent on their treatment or skin care. Most patients spent less than 





Managing psoriasis in older adults can be a clinical challenge, due to factors such as 
comorbidity, concomitant medication, ageing-related organ impairment and functional 
deterioration. Limited data are available to guide clinicians in treating this growing patient 
group. The aim of this study was to evaluate disease and treatment characteristics in geriatric 
psoriasis patients and to identify differences compared with a younger population.
In this large cross-sectional study, plaque psoriasis and psoriasis capitis were the most 
frequently reported types of psoriasis in both groups. Erythrodermic psoriasis was significantly 
more often reported by patients ≥65 years old, in line with previous research.6,7,21  
A possible explanation for this difference could be that patients ≥65 years old have been treated 
with less potent therapies in the past during prolonged periods of time, increasing the potential 
of developing more severe and extensive psoriasis. Furthermore, since the question was posed 
whether patients had ever experienced an episode of erythrodermic psoriasis in the past, the 
a priori chance is higher in older patients due to the higher number of cumulative disease years. 
This too explains the fact that erythrodermic psoriasis was reported more frequently by patients 
with early disease onset, as has also been stated previously.14 Other types of psoriasis have 
been studied to a lesser extent; Phan et al. reported a higher prevalence of guttate psoriasis in 
patients ≥70 years old compared with patients <70 years old.21 In other studies,6,7 including the 
current study, this difference was not seen.
     In this study, the majority of patients ≥65 years old reported a moderate current disease 
activity, although median SAPASI scores were slightly higher in patients <65 years old. Previous 
studies are in line with these results, showing comparable disease severity in both age groups.6,7 
Strikingly, the majority of the respondents in both groups reported never having achieved 
total skin clearance, while total clearance of psoriasis is frequently mentioned as one of 
the most important treatment goals to improve quality of life in patients with psoriasis.22,23 
It seems that psoriasis treatment in both age groups could be further improved, tailored to 
individualized treatment goals. Currently, little research is available assessing treatment goals 
and quality of life in geriatric psoriasis patients specifically, to evaluate whether patients 
consider themselves optimally treated.
  Patients ≥65 years old reported significantly more comorbidities and concomitant 
medication in comparison with patients <65 years old, in line with previous research.7,21 
Comorbidities and concomitant medication should be acknowledged when considering 
management options, especially with regard to contra-indications of antipsoriatic therapies. 
Despite a significant higher prevalence of (relative) contra-indications for several antipsoriatic 
systemic therapies reported by patients ≥65 years old, no significant differences were found 
between the age groups when comparing the individual systemic agents. Even in a subgroup 
analysis of patients ≥80 years old, systemic therapies did not differ significantly from in 
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younger patients, although the number of patients ≥80 years old using modern systemic 
therapies was small. This is in contrast with previous studies stating that (modern) systemic 
therapies are less often prescribed in older patients.7,21,24,25 Some studies suggest that 
prescription of systemic therapies increases over time, due to the fact that 
physicians have gained more experience with these therapies and are 
therefore more comfortable with prescribing systemic therapies, explaining the 
difference between the present study results and those found in previous studies.7,24 
Another explanation could be that the treatment goals and preferences of patients ≥65 
years old have changed over time, although available literature in this field is scarce.23 
Significantly more patients ≥65 years old required assistance with treatment or skin care, 
 it is therefore important to consider this aspect in choosing antipsoriatic treatment.
     In order to minimize the risks of potential drug interactions, as well as treatment-related 
adverse events, managing psoriasis in patients with comorbidities and concomitant 
medication requires extra attention. In this study, significantly fewer adverse events 
were reported by patients ≥65 years old, even when corrected for the type of treatment. 
It should be noted that this involves only self-reported side-effects and probably does not 
include asymptomatic treatment-related laboratory changes. Moreover, the reasons for 
ceasing previous therapies were not evaluated, which could be related to adverse events 
experienced in the past. Available research varies widely concerning the rates of adverse events 
and tolerability profiles in older adults, frequently stating adverse event rates do not differ 
between age groups.6,7,25-27 More real-life data is needed to provide clarity and guidance in this 
field.
Limitations
This study has certain limitations due to the study design. Firstly, any survey is associated with 
a risk of recall bias and misinterpretation of the questions, although this risk was minimized 
by pre-testing the survey in a pilot study. Since all participants were members of a 
patient association, a risk of selection bias exists. A higher level of education was seen in the 
study population compared with the Dutch overall population,17 which might be associated 
with membership of a patient association altogether (Table S3). Moreover, members of a 
patient association might be older16,18–20 and have more severe psoriasis than the overall 
psoriasis population.20 Since this study aimed to study a population representative of daily 
dermatological care, it was assumed that the Dutch Psoriasis Association closely resembles 
the target population. A relatively large cohort of patients ≥65 years old responded 
compared with the composition of the Dutch population. The survey was introduced 
explaining the nature of the study; to study differences in psoriasis management and 
characteristics among different patient age groups. Therefore, patients ≥65 years old may 
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have been stimulated to respond, whereas patients in middle-age felt less urge to respond 
(sampling bias). However, age and sex distribution of the respondent population were 
shown to be representative for the target population. In addition, response rates were similar 
to previous studies with comparable study designs.15,28 Moreover, the current study 
comprised one of the largest geriatric psoriasis populations described so far.
Conclusion
Treating geriatric patients with psoriasis requires extra attention to comorbidities and the 
use of concomitant medication, since these were significantly more frequently seen in 
patients ≥65 years old than in patients <65 years old. Despite these obvious differences 
in patient-related characteristics, a better tolerability profile was reported by patients ≥65 
years old. Based on the results of this study, chronological age alone should not be a 
limiting factor inchoosing antipsoriatic therapy, although patient-related characteristics 
must be considered; physical impairments, availability and necessity of help, and possible 
drug-interactions can complicate treatment decisions. In order to provide personalized 
medicine, more research on treatment goals and patient preferences in geriatric psoriasis 
patients is needed to further guide clinicians in optimally treating this growing patient group.
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Figure S1. Psoriasis in geriatric patients (≥65 years old).
Figure S2. Age of onset in geriatric patients with psoriasis (≥65 years old, n=413).
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Figure S3. Current systemic therapies used in patients aged <65 years old and patients 
≥65 years old. 
Percentages are presented in relation to the percentage systemic therapies used. In case of combined systemic 
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Table S1. Study respondent characteristics compared with the overall target population
Study respondent 
population, %
Dutch Psoriasis  
Associationa, %
Klaassen et al., 
201315 %
Age,
    <65 years 56.4 59.0 NR
    ≥65 years 43.6 41.0ns NR
Sex, male 52.0 50.7ns 48.3ns
Education level
    Primary school, high school or  
    vocational training
55.9 Unknown NR
    Higher educationb 40.7 Unknown NR
    Other/unknown 3.4 Unknown NR
Due to anonymity of the respondents, a formal non-responder analysis was not possible. Therefore, 
characteristics of respondents were compared with characteristics of the overall target population, if available. 
a Age and sex distribution of the current members of the Dutch Psoriasis Association are represented here. 
 Additional data on the overall population were provided by the Dutch Psoriasis Association upon request. 
b Defined as universities of applied sciences (Dutch: hogescholen or hoger beroepsonderwijs (HBO)) and 
 (research) universities.










   Topicalsa 584 (66.1) 37 (64.9) 0.850
   UV therapy 38 (4.3) 8 (14.0) 0.001
   Systemic 359 (40.7) 22 (38.6) 0.759
      Conventional systemicb 230 (26.0) 17 (29.8) 0.530
         Methotrexate 109 (12.3) 6 (10.5) 0.685
         Ciclosporin 2 (0.2) 2 (3.5) 0.020
         Acitretin 7 (1.4) 1 (1.8) 0.395
         Fumaric acid 122 (13.8) 8 (14.0) 0.963
      Modern systemicc 157 (17.8) 6 (10.5) 0.161
         Apremilast 6 (0.7) 0 (0.0) 1.000
         Etanercept 23 (2.6) 3 (5.3) 0.205
         Adalimumab 59 (6.7) 2 (3.5) 0.575
         Infliximab 3 (0.3) 0 (0.0) 1.000
         Ustekinumab 46 (5.2) 1 (1.8) 0.355
         Secukinumab 9 (1.0) 0 (0.0) 1.000
         Ixekizumab 3 (0.3) 0 (0.0) 1.000
         Brodalumab 4 (0.5) 0 (0.0) 1.000
         Guselkumab 2 (0.2) 0 (0.0) 1.000
         Certolizumab pegol 2 (0.2) 0 (0.0) 1.000
   No prescribed therapiesd 144 (16.3) 11 (19.3) 0.555
Requiring assistance with treatment or skin care 0.030
   Yes 91 (10.9) 11 (20.8)
   No 742 (89.1) 42 (79.2)
Table S2. Treatment characteristics of geriatric patients with psoriasis (≥80 years old) 
compared with patients <80 years old
Values might not add up due to missing values.
* Patients could select more than 1 answer option.
a Including keratolytic agents, corticosteroids, vitamin D derivatives, calcineurin inhibiting agents, coal tar, 
 combination therapies, dithranol (anthralin). 
b Including methotrexate, ciclosporin, acitretin and fumaric acid. 
c Including apremilast, etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, 
 guselkumab, certolizumab pegol. 
d Defined as no prescribed therapies and non-prescription therapies, usage of emollients only, homeopathic 
   treatment, over-the-counter products, and dietary or lifestyle adjustments.
UV: ultraviolet.
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Age, years, mean±SD 61.1±13.7 48.2±18.5* 51.1±18.6* 46.4±17.2* 41.8±NR
Sex, male 52.0% 49%ns 46.7%* 48.3%* 49.6%ns
Education level NR NR
   Primary school, high   
   school or vocational 
   training
55.9% 75.6% 68.3%
   Higher educationa 40.7% 18.1% 30.3%
   Other/unknown 3.4% 6.3%* 1.4%*
 * Statistically significant compared with the current study population.
a Defined as universities of applied sciences (Dutch: hogescholen or hoger beroepsonderwijs (HBO)) and 
 (research) universities.
SD: standard deviation; NR: not reported; ns: not significant compared with the current study population.
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To enhance personalized management in older adults with psoriasis, identifying the unmet 
needs in this rapidly growing population is of utmost importance to improve patient-centred 
care.
Objectives
To study disease burden, quality of life, treatment goals, preferences and satisfaction in geriatric 
psoriasis patients.
Methods
A self-administered survey was distributed among all members of the Dutch Psoriasis 
Association (n=3310). Patients were stratified into two age groups: respondents aged ≥65 years 
old (≥65yo) and respondents <65 years old (<65yo). 
Results 
A response rate of 29.7% (n=985) was achieved, 414 (43.6%) of the valid respondents were 
≥65yo. The most bothersome aspects of psoriasis were itch, scaling and visibility in both groups, 
which were also rated as the most relevant treatment goals. Although the median Dermatology 
Life Quality Index (DLQI)-score was significantly higher in patients <65yo, the DLQI-Relevant, 
correcting for not relevant responses (NRRs), was not significantly different between the groups. 
Significantly more NRRs were marked by patients ≥65yo vs. patients <65yo (mean 1.91±2.43 
vs. 0.79±1.77, p<0.001). Patients ≥65yo valued reduction of topical treatment, subcutaneously 
administered treatment, hospital visits and laboratory assessments as significantly more 
important than patients <65yo. 
Conclusions
To evaluate QoL impairment, the DLQI-R is more appropriate in older psoriasis patients than 
the original DLQI. Patient preferences were significantly different in older adults compared 
to younger patients; in particular the reduction of medication use and hospital visits. The 
heterogeneity of the psoriasis population requires the identification of individual patient 
preferences and treatment goals to further facilitate shared decision-making in psoriasis 
management. 
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Introduction
Psoriasis is a chronic inflammatory disease frequently seen in older adults, which can be 
associated with a significant psychosocial burden.1-3 Despite of increasingly available 
antipsoriatic therapies, evidence guiding psoriasis treatment in older adults is relatively 
limited.4,5 Furthermore, previous studies show prescribed (systemic) therapies in older adults 
frequently differ from those prescribed to younger patients, although comparable disease 
severity was seen.6-8 Next to a higher prevalence of specific contraindications (e.g. certain 
comorbidities or comedication), the reported differences are not yet fully understood and 
might be (partially) explained by differences in quality of life impairment, treatment goals, 
patient preferences and treatment satisfaction. Unfortunately, less is known regarding these 
essential topics in older adults with psoriasis. Although recognition of quality of life (QoL) 
impairment and disease burden increased over the past years, some studies suggest that currently 
available QoL assessment tools do not always appropriate reflect true QoL impairment in the 
rapidly expanding geriatric population.9 
    To understand existing treatment patterns and improve patient-centred care for older 
psoriasis patients, the purpose of this study was to gain more insight on adequate 
QoL-assessment in older adults with the use of a patient-oriented survey. Also, we aimed to 
identify patient preferences and treatment goals in older psoriasis patients and compared these 
with preferences and goals of younger patients. 
Methods
Study design and participants
A nationwide self-administered survey was distributed among all members of the Dutch 
Psoriasis Association in order to evaluate quality of life, treatment goals, preferences and 
treatment satisfaction in patients with psoriasis (n=3310). Both patients aged 65 years and 
over as well as younger patients were included, in order to compare outcomes among the 
age groups. The methodology of this study was more extensively described in a previous 
publication.10 The Research Ethics Committee of the Radboud University Medical Centre passed 
a positive judgement on the study before execution of the study had started. 
Survey
The survey was developed based on literature research, patient interviews and focus group 
meetings with a multidisciplinary team consisting of physicians, (specialized) nurses, a medical 
psychologist and researchers studying psoriasis. The survey consisted of several sections 
enquiring about burden of the disease and QoL impact, treatment satisfaction, treatment 
goals and patient preferences using multiple choice questions and 5-point Likert scales. 
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Open-ended questions were used to further evaluate which disease aspects were most 
bothersome for patients and to enquire about items not covered by the questions 
included in the survey. Answers to open questions were stratified into relevant categories for 
further analyses. The survey was pretested on 10 geriatric patients to assess the relevance and 
comprehensibility of the questions.
    The impact on health-related QoL was measured primarily using the Dermatology Life 
Quality Index (DLQI), a validated and frequently used questionnaire consisting of 10 items 
concerning domains possibly influenced by skin diseases.11 Each item is scored with a 4-point 
Likert scale, and 8 items provide a not relevant response (NRR) option. A total score was 
calculated for each patient, yielding sum scores ranging from 0 to 30; a higher DLQI score 
representing a more severely impaired QoL. In addition, the DLQI-Relevant (DLQI-R) score 
was calculated, a scoring formula adjusting for the effects of NRRs.12 A maximum of 3 NRRs 
per patient was maintained according to the suggestion of previous research.12
Data processing and analysis
Survey responses were processed anonymously with the aid of the automatic form identification
software Remark Office Optical Mark Recognition, version 9.5 (Gravic, Inc. Malvern, PA, 
U.S.A.) and CASTOR Electronic Data Capture, a web-based data management system in 
compliance with Good Clinical Practice (GCP) standards (Castor Research Inc., Hoboken, NJ, 
U.S.A.). Ten percent of the data was checked by an independent researcher to ensure 
proper data processing. Statistical analyses were performed using Statistical Package for Social 
Sciences (SPPS) Statistics for Windows, version 25.0 (IBM, Armonk, NY, U.S.A.). Patients were 
categorised into two groups: those aged 65 years and over (≥65yo) and those younger than 65 
years of age (<65yo). To improve comprehensibility of the outcomes, all continuous variables 
were expressed as means (±SD), and categorical variables were presented as frequencies and 
percentages. A Mann-Whitney U-test was used to compare continuous variables in both age 
groups and a Kruskal-Wallis Test to compare continuous variables in more than two groups. 
Chi-square or Fisher’s exact test were used for categorical variables. Missing values were not 




The patients demographics, as well as disease and treatment characteristics are presented 
in the previous publication of Van Winden et al.10 A total of 3310 psoriasis patients were 
approached for participation, 985 (29.7%) returned the survey thereby consenting for 
participation. Data was collected between December 11, 2018 to September 4, 2019. Data of 
950 respondents was included in the analysis; 27 respondents were excluded from analyses 
due to missing values in age, eight more respondents were excluded due to missing data on 
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too many other relevant questions (e.g. responses to age and gender only). The mean age of 
the 414 (43.6%) patients ≥65yo was 72.4±5.9 years (median 71, range 65-95), compared with 
52.4±11.4 years in patients <65yo (median 56, range 7-64). Comparable disease severity was 
seen in both age groups, and no significant differences were found in currently used therapies 
(e.g. systemic medication usage in n=157 [38.3%] ≥65yo, vs. n=224 [42.3%] <65yo; p=0.219).10  
Disease burden and quality of life
Disease burden
Both patients ≥65yo and patients <65yo reported pruritus as the most bothersome aspect of 
their psoriasis (n=127 [35.0%] ≥65yo vs. n=200 [39.8%] <65yo, p=0.146), followed by flaking 
(n=72 [19.8%] ≥65yo vs. n=122 [24.3%] <65yo, p=0.120) and visibility (n=58 [16.0%] ≥65yo vs. 
n=107 [21.3%] <65yo, p=0.049). Social factors were significantly less often reported by patients 
≥65yo, whereas these were regularly mentioned by patients <65yo: psychological problems 
due to psoriasis were mentioned by 13 (3.6%) patients ≥65yo compared with 35 (7.0%) patients 
<65yo (p=0.032), and stigmatization by 5 (1.4%) patients ≥65yo and 20 (4.0%) patients <65yo 
(p=0.024). A summary of the most frequently reported bothersome aspects is shown in Figure 1. 
Dermatology Life Quality Index (DLQI)
The overall DLQI was significantly lower in patients ≥65yo compared with patients <65yo (mean 
2.98±3.5 vs. 3.89±4.55 respectively, p=0.006). A current DLQI >5 was seen in 63 (16.1%) ≥65yo vs. 
122 (23.7%) <65yo (p=0.005). As illustrated by Figure 2, significantly more NRRs were reported 
by patients ≥65yo in comparison with patients <65yo (mean 1.91±2.43 vs. 0.79±1.77, p<0.001). At 
least one NRR was reported by 238 (60.7%) patients ≥65yo, compared with 161 (31.3%) patients 
<65yo (p<0.001). The least applicable items according to patients ≥65yo were item 7 (work; 
n=191 [49.2%]) and item 6 (sports; n=117 [30.3%]). The distribution of the DLQI outcomes and 
NRRs per DLQI item in both age groups is illustrated in Figure 3. 
Dermatology Life Quality Index-Relevant (DLQI-R)
The mean DLQI-R was 3.42±4.00 in patients ≥65yo, vs. 4.13±4.76 in patients <65yo (p=0.076). In 
patients ≥65yo, the mean increase between the DLQI and the DLQI-R score was 0.44±0.84 vs. 
0.24±0.62 in patients <65yo (p<0.001). Significantly less patients ≥65yo reported that the DLQI 
lacked assessment of important QoL-related aspects (n=90 [24.4%] ≥65yo vs. n=160 [32.9%] 
<65yo, p=0.009). Most frequently mentioned items were the lack of specific attention for joint 
pain (overall n=35 [14.0%]), followed by lifestyle adjustments such as dietary alterations (n=17 
[6.8%]), e.g. alcohol consumption.  
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Figure 1. Self-reported most bothersome aspects of psoriasis in patients ≥65 years old 
compared with patients <65 years old.
* indicating a significant difference between patients ≥65yo and patients <65yo was found.




Recurrent nature of disease







   n=127; 35.0%
               n=200; 39.8%
   n=72; 19.8%
               n=122; 24.3%
   n=58; 16.0%        
                 n=107; 21.3%
      n=39; 10.7%  
   n=47; 9.4%  
       n=23; 6.3% 
   n=23; 4.6%
   n=17; 4.7% 
       n=31; 6.2% 
     n=17; 4.7% 
      n=26; 5.2%
   n=21; 5.8% 
            n=47; 9.4% 
   n=15; 4.1%  
          n=35; 7.0% 
   n=13; 3.6% 
            n=35; 7.0% 
   n=5; 1.4% 




0                      10                      20                     30                      40
Percentage of patients
<65yo       ≥65yo
135
Quality of life, treatment goals, preferences and satisfaction in geriatric psoriasis
2.4
Figure 2. The frequency of not relevant responses (NRRs) Dermatology Quality of Life In-



























yo, years old. 
Chapter 2.4
136
Respondents were instructed to answer to what extend their skin problem had affected their lives in the past 7 
days. A not relevant response (NRR) option was offered in eight out of ten items (as presented here; e.g. patient 
does not work or study), as well as categorical responses to allow respondents to grade the influence (e.g. the skin 
problem had affected work or study: very much, a lot, a little, not at all). 
Figure 3. Responses to Dermatology Life Quality Index (DLQI) items offering a not- 
relevant response in patients <65 years old (<65yo) and patients ≥65 years old (≥65yo).
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Treatment goals, preferences and satisfaction 
Treatment goals
To be free of pruritus and scaling, as well as visible lesions were most frequently reported 
as relevant in both groups (NRR in n=39 [4.1%], n=6 [0.6%] and n=9 [0.9%] respectively) and 
were also valued as important treatment goals (overall mean respectively 4.56, 4.37 and 
4.15). Pain and sleeping disturbances were marked not relevant by respectively 181 (19.1%) and 
371 (39.1%) patients. However, the remaining patients highly valued these treatment 
goals (overall respectively mean 4.44 and 4.35). Patients ≥65yo valued to be free of scaling, 
complete clearance of all skin lesions, and to be free of redness as significantly more important 
than patients <65yo (mean 4.43 in ≥65yo vs. 4.32 in <65yo, p=0.003, 4.16 in ≥65yo vs. 4.00 in 
<65yo, p=0.009 and 4.11 vs. 3.94, p=0.006). An overview of the treatment goals as scored by 
both patients groups is presented in Table 1.
Patient preferences 
Minimalization of adverse events associated with antipsoriatic therapies was valued as the most 
important patient preference in both age groups (overall mean 4.63). To have confidence in the 
therapy and to be able to apply or use therapies without help from others scored an overall 
mean of respectively 4.61 and 4.56. Minimizing the use of topical treatment, injections and pills 
or capsules were valued significantly more important by patients ≥65yo vs. patients <65yo, 
as can be seen in Table 1. Patients ≥65yo valued the minimalization of topical treatment and 
injections more important than not having to use pills or capsules (mean 4.13, 4.13 and 3.84, 
respectively). Moreover, the reduction of hospital visits was valued significantly more important 
by patients ≥65yo vs. patients <65yo.
Treatment satisfaction
Overall, patients in both groups were satisfied with their current treatment (overall mean 
3.73). However, 102 (11.5%) patients were dissatisfied or very dissatisfied (Likert-score<3). 
Patients ≥65yo using a combination of systemic therapies (e.g. methotrexate combined with 
adalimumab) were most satisfied (mean treatment satisfaction 4.47 vs. 3.98 [modern systemic 
therapies], vs. 4.14 [conventional systemic therapies] vs. 3.43 [topical treatment only], vs. 3.11 
[UV therapy], p<0.001). Patients ≥65yo reporting adverse events due to their therapies, scored 
the burden of the adverse events equally low as patients <65yo (mean adverse event burden 
was 2.56 in in ≥65yo vs. 2.51 in <65yo, p=0.806). 
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Table 1. An overview of treatment goals, treatment satisfaction and patient preferences in 









    To be free of pruritus (mean±SD) 4.52±0.7 4.61±0.6 39 (4.1) 0.059
    To be free of pain (mean±SD) 4.41±0.7 4.47±0.7 181 (19.1) 0.517
    To be free of scaling (mean±SD) 4.32±0.7 4.43±0.8 6 (0.6) 0.003
    To be free of sleep disturbances (mean±SD) 4.31±0.9 4.39±0.8 371 (39.1) 0.374
      To be free of negative impact on daily activities (mean±SD) 4.28±0.8 4.23±0.9 192 (20.2) 0.713
    To be free of visible lesions (mean±SD) 4.09±1.0 4.23±0.9 9 (0.9) 0.050
    Complete clearance of psoriasis lesions (mean±SD) 4.00±1.0 4.16±0.9 2 (0.2) 0.009
    To be free of redness (mean±SD) 3.94±0.9 4.11±0.9 19 (2.0) 0.006
Treatment satisfaction
    Ease of current treatment (mean±SD) 3.90±1.0 3.96±0.9 - 0.433
    Overall treatment satisfaction (mean±SD) 3.71±1.0 3.75±1.0 - 0.763
    Satisfaction regarding treatment frequency (mean±SD) 3.58±1.1 3.69±1.0 - 0.165
    Burden of side effects (mean±SD) 2.51±0.9 2.56±0.9 - 0.806
Patient preferences
    Minimize the adverse effects of therapy (mean±SD) 4.64±0.5 4.61±0.7 - 0.875
    To have confidence in therapy (mean±SD) 4.64±0.5 4.57±0.6 - 0.170
    To apply/use therapy without help from others (mean±SD) 4.56±0.7 4.56±0.7 - 0.891
    Minimize the use of topical treatment (mean±SD) 3.94±1.1 4.13±1.0 -  0.004
    No usage of injections/syringes/intravenous treatment 
    (mean±SD)
3.74±1.4 4.13±1.2 - <0.001
    Minimize the amount of hospital visits (mean±SD) 3.77±1.2 4.04±1.1 - <0.001
    No usage of pills/capsules (mean±SD) 3.40±1.4 3.84±1.3 - <0.001
    To apply/use therapy without laboratory assessment 
    (mean±SD)
2.89±1.4 3.34±1.4 - <0.001
Treatment goals and patient preferences were measured using a 5-point Likert scale, 5 indicating highly 
important, 1 indicating not important at all. Treatment satisfaction was measured using a 5-point Likert scale, 
5 indicating highly satisfied and 1 indicating least satisfied. The burden of side effects was measured using a 
5-point Likert scale, 5 indicating a high burden, 1 indicating no burden at all. 
* All results were calculated using a Mann-Whitney U test; means were presented to improve comprehensibility 
 of the outcomes.
NRR, not relevant response, SD, standard deviation. 
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Discussion
Psoriasis management in patients ≥65yo can be complex due to age- and frailty-related 
characteristics and the limited available data on treating this specific patient group.5 Since 
disease severity in patients ≥65yo with psoriasis is often mentioned to be comparable to 
patients <65yo,3,7,8,10 a difference in treatment choices might be due to differences in 
comorbidities and concomitant medication, or due to disease perception by geriatric 
patients.6,7,13 As the array of therapeutic options continues to expand, it is crucial to 
further specify the unmet needs of this frequently vulnerable population. This might help to 
understand existing treatment patterns and improve patient-centred care for older psoriasis 
patients. Therefore, the aim of this study was to gain insight in quality of life, treatment goals, 
preferences and satisfaction in geriatric psoriasis patients. 
    In this study, QoL impact measured by the DLQI-R did not significantly differ between 
patients ≥65yo and patients <65yo. However, the original DLQI score did show differences 
between the groups, due to varying rates of NRR between age groups. For patients ≥65yo, 
significantly more DLQI items were not relevant, and a significant higher increase between 
DLQI and DLQI-R was seen compared with patients <65yo. These results are in accordance 
with previous studies stating that DLQI responses are affected by age and that older patients 
more frequently mark NRRs.9 This suggests an underestimation of the actual quality of life 
impairment, as NRRs are currently scored as "0", equivalent to not at all. Moreover, previous 
studies have shown that patients using NRRs had more severe disease than patients using 
a not at all response.14,15 Thus, in line with previous research,13,15,16 this study emphasizes that 
using original DLQI scoring system in patients ≥65yo results in a disproportional 
underestimation of true QoL-impact.
  Several studies criticize the frequently used DLQI, as medical decision-making 
currently quite heavily relies on the DLQI score despite its psychometric shortcomings in 
heterogeneous populations.9,16-18 An insufficient reflection of QoL-impairment and 
undertreatment could be a consequence, since reimbursement criteria in several 
countries are based on a minimum DLQI score for certain treatment options.14,16 More-
over, in other QoL-instruments as the Short Form Survey (SF-36) and Skindex-29 no NRR 
option is offered at all. Moreover, neither of the tools assess symptoms related to psoriatic 
arthritis (PsA); which was most frequently mentioned by respondents of this study as currently 
lacking in the DLQI. Using the DLQI-R would not solve the lack of PsA assessment, but could 
possibly reflect QoL-impairment better than the already widely used original DLQI. 
Moreover, although patients ≥65yo more frequently marked NRRs than patients 
<65yo, significantly less patients ≥65yo reported to miss certain items in the DLQI. 
Therefore, the relevant items included in the DLQI might be adequate for a group of patients 
≥65yo, whereas using the original scoring system might not adequately represent the true 
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QoL-impact in many patients. Especially in case of clinical decisions depending on 
QoL-impact (e.g. reimbursement criteria for biologic therapies) or studies comparing QoL 
between age groups, calculation of the DLQI-R should be considered. Specific attention to PsA 
assessment and other personal bothersome aspects not captured by the DLQI-R, could further 
improve personalized psoriasis-care. 
   In line with previous research,19-21 this study showed that itch, scaling and visibility 
were reported as most bothersome aspects of psoriasis in both age groups and were 
consequently the top-cited treatment goals. Although small differences were seen in 
treatment goals and satisfaction, no clinically relevant differences were found between 
the age groups. Whereas visible lesions were less frequently experienced as bothersome 
by patients ≥65yo than those <65yo, it was still considered as one of the most 
bothersome aspects in both age groups. Moreover, visibility-related treatment 
goals as complete clearance and to be free of redness were valued as more important 
treatment goals by patients ≥65yo. Also, treatment goals related to pain and sleep 
disturbances were highly valued in those patients for whom applicable. These 
differences further accentuate the heterogeneity of the psoriasis population, pleading for an 
individualized patient-centred approach assessing relevant treatment goals, reaching 
further than age alone.
   Patient preferences regarding the reduction of different treatment modalities were 
valued significantly more important by patients ≥65yo when compared with patients 
<65yo. More specifically, patients ≥65yo valued a reduction of topical treatment and 
subcutaneous treatment as significantly more important compared with patients <65yo. 
Dependency on others could be an explanation for this outcome, since functional 
impairments in this patient group can cause difficulty in reaching those areas of the body 
affected by psoriasis.10 The treatment burden of topical therapies and subcutaneously 
administrated therapies can therefore be higher in patients ≥65yo. Moreover, 
patients ≥65yo use concomitant medication more often than patients <65yo,10 which is a 
well-known factor associated with the patient preference to reduce medication use 
altogether.22 Furthermore, patients ≥65yo valued the reduction of laboratory tests and 
hospital visits as more important than patients <65yo. This is consistent with previous 
research by Maul et al, and can be explained by the longer duration of the disease 
leading to subsequent higher number of hospital visits in the past.23 Dependency on 
others and the necessity of hospital visits for other health issues could attribute to this 
preference. The extent to which patients ≥65yo are burdened by these aspects, depends 
on many more factors (e.g. somatic, psychosocial and functional factors) which 
should be individually assessed.
     Naturally, certain limitations need to be addressed. Any survey is associated with factors 
as recall bias and a possibility of misinterpretation of the questions. However, a pilot study 
was performed in advance of the study to reduce these risks. Although this study gained 
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insight in important aspects of one of the largest geriatric psoriasis populations assessing 
disease burden so far, members of a patient association are frequently older and show 
higher disease severity, possibly resulting in selection bias.10 The results of this study might 
therefore not be generalizable to all psoriasis patients. Lastly, the results of this study 
shouldbe interpreted with caution since this study did not evaluate changes in outcome 
measures over time or changes due to therapies, which could limit representativity of the 
results in other circumstances. Future studies evaluating disease burden and management 
considerations in older adults are needed to evaluate temporal changes in disease course.
In conclusion, the use of the DLQI-R in patients ≥65yo should be preferred over DLQI 
assessment, since it appears NRRs frequently lead to an underestimation of the true 
QoL impact in patients ≥65yo. Overall treatment goals, bothersome disease aspects and 
treatment satisfaction were comparable between the age groups, although the heterogeneity 
in these outcomes accentuate the need of individualized management decisions and specific 
attention for individual patient goals and preferences. It should be taken into account that patient 
preferences in patients ≥65yo differ from those of patients <65yo (in particular the 
reduction of medication use and hospital visits), possibly depending on functional 
deterioration, dependency on others, comorbidities and comedication. 
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Incorporating patient-related factors associated with treatment outcomes could improve 
personalized care in older basal cell carcinoma (BCC) patients.  
Objective
To evaluate and identify predictors for treatment burden, treatment outcomes and overall 
survival in patients ≥70 years, surgically treated for BCC in the head-and-neck area. 
Methods
Data from the prospective multicenter BATOA (“BAsal cell carcinoma Treatment in Older 
Adults”) cohort study was extracted to evaluate experienced treatment burden (visual 
analog scale 0-10cm; lower scores indicating higher treatment burden), treatment outcomes and 
mortality.  
Results
539 patients were included (median age: 78 years). Patients experienced a low overall 
treatment burden (median 8.6) and good cosmetic result. Predictors for higher treatment 
burden were instrumental activities of daily living (iADL) dependency, female sex, 
complications, tumor diameter, and polypharmacy. Thirty-five (6.5%) patients died (none 
BCC-related) within follow-up, predictors for mortality were increasing comorbidity index 
and iADL dependency. No difference in these outcomes were seen between Mohs 
micrographic surgery and conventional excision after correction for covariates. Age was not 
significantly associated with any outcome.
Limitations
A selection bias may exist due to the observational design.
Conclusion
BCC management decisions based on chronological age alone should be avoided, whereas 
more attention is recommended for patient-related factors. Based on these data, early BCC 
intervention is beneficiary for robust and fit patients or those experiencing symptoms.
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Introduction
Basal cell carcinoma (BCC) is the most common type of skin cancer, frequently 
characterized as slowly growing, low-malignant and often initially asymptomatic.1 
However, BCCs can cause substantial long-term morbidity due to local tissue invasion and 
functional deterioration, especially in the head-and-neck area.2 Due to the rising 
incidence of BCCs and the fact that BCCs are most frequently seen at older age, 
older adults with BCC comprise a large and rapidly growing population.2 Optimal BCC 
management in older adults can be complex, balancing the risk of under- and 
overtreatment. It may be reasonable to forego treatment (and associated risks of 
discomfort, complications) when the remaining lifespan is expected to be shorter than the 
time to develop BCC-related symptoms (e.g. disfigurement, bleeding, infection).3 However, 
both expected treatment burden and limited life expectancy (LLE) can be difficult to 
determine in the heterogenous geriatric population. Therefore, undertreatment may 
occur when patients are suboptimally treated due to misjudged LLE or expected 
treatment burden. It could be helpful to include frailty-related patient characteristics 
(e.g. multimorbidity and/or functional status) in medical decision-making, as frailty has 
been associated with increased mortality and complications rates in several medical fields.4-6  
    To optimize individualized medical decision-making, this study aimed to evaluate the 
treatment burden in older adults who were surgically treated for BCC in the head-and-
neck area. Furthermore, treatment outcomes (complications, cosmetic outcome and 
recurrence risk), overall survival, and the identification of relevant predictors were studied. 
Study outcomes were compared between patients treated with Mohs micrographic surgery 
(MMS) and conventional surgical excision (CE).
Methods
Study Design and Participants 
The BATOA (BATOA: “BAsal cell carcinoma Treatment in Older Adults”) cohort is a 
prospective multicenter observational cohort study of older patients (aged ≥70 years) 
treated for BCC in the head-and-neck area. Although the BATOA cohort includes 
BCC patients treated with several treatment modalities, only patients who were 
surgically treated for a histologically proven BCC were included in the analyses 
described here. Patients who were treated for multiple tumors were enrolled only 
for the first tumor as described in the treatment plan. Patients unable to understand 
the study information (e.g. patients with dementia) were excluded. Patients were 
consecutively included in five medical centers (private practices, academic and 
general hospitals) in the Netherlands between November 2016 and February 2019 
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(Figure S1). Approval of the Medical Ethical Committee was obtained from each 
participating center and written informed consent was obtained from all participants. 
Outcome measures
The primary outcome was the experienced treatment burden, as indicated by patients 
on a visual analog scale (VAS; 0 to 10cm) 2-4 months after treatment; lower scores 
representing a higher treatment burden (Figure S2). Open questions were added to 
allow patients to elaborate on their experience. A pilot study was performed with 33 geriatric 
patients and 7 health care providers were consulted to improve comprehensibility and 
wording of the questions and explanation. The VAS is a widely accepted method to 
evaluate surgical treatment outcomes and is commonly used because it is user-friendly, 
easily applicable and well validated for many treatment outcomes.7,8 
   Secondary outcomes were: complications (defined according to the Dutch Society of 
Dermatology and Venereology classification),9 cosmetic results (VAS 0-10cm; higher 
scores representing a better cosmetic result), recurrences, overall survival and 
predictors for each outcome measure, and differences in outcome measures between 
patients treated with MMS and those treated with CE. 
Data collection 
Treatment decisions (e.g. treatment with MMS or CE) were made prior to inclusion and 
were based on clinical judgement and in accordance to clinical guidelines, regardless of 
participation in this study. The following (frailty-related) data were systematically collected 
using structured data forms: 
(i) patient-related characteristics including sex, age at time of surgery, history of keratinocyte 
cancer (KC) and subsequent therapies, Charlson comorbidity index (CCI; a weighted index 
with higher scores corresponding with poor survival, in particular at a score ≥3),10-13 
polypharmacy (defined as the chronic use of ≥5 medications with different ATC3 codes),14,15 
the Katz’s index of activities of daily living (ADL;16 patients were considered ADL dependent 
if they were unable to perform ≥1 activities independently),17 Lawton and Brody’s index of 
instrumental ADL (iADL;18 patients were considered iADL dependent if they were unable to 
perform ≥1 activities independently), and travel distance to treatment center;
(ii) tumor-related characteristics including primary or recurrent tumor, tumor location 
(categorized according to cosmetic subunits)19, histopathological subtype, tumor diameter; 
(iii) treatment-related characteristics including treatment center, number of stages (in 
case of MMS), defect size, wound closure technique, histopathological clearance, and 
the physician performing the surgical procedure(s).
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For all patients, a minimum follow-up period of 18 months was maintained. Follow-up 
data was extracted from medical patient charts, Personal Records Database 
(in Dutch: Basisregistratie Personen, BRP) and the Dutch nationwide network and 
registry of histopathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd 
Archief; PALGA).20
Statistical analyses
Data were analyzed using Statistical Package for Social Sciences (SPPS) Statistics for 
Windows, version 25.0 (IBM, Armonk, NY, U.S.A.) and R version 3.6.3 (The R Foundation 
for Statistical Computing, Vienna, Austria). Prior to inclusion, a minimum sample size 
of 227 patients per treatment modality was estimated to be able to detect a difference 
of 0.5 (5%) in treatment burden between the groups standard deviation 1.9, 
alpha=0.05 and beta=0.2). Continuous variables were reported as mean (±SD) or 
median (interquartile range; IQR), when appropriate. Categorical variables were reported 
as frequencies and percentages. Univariate analysis was performed using a 
Student’s t-test or Mann-Whitney U test, and the chi-square or Fisher’s exact test. 
Multivariable analysis using quantile regression was performed to correct for the 
effect of various potentially relevant patient-, tumor-, and treatment characteristics on 
the median treatment burden and cosmetic result. A step-down procedure with optimal 
Akaike information criterion (AIC) as stopping criterion was used to identify predictors 
for treatment burden and cosmetic result. Logistic regression was used to correct for 
possible confounders regarding complications and to calculate odds ratios (ORs) and 
95% confidence intervals (95%CI), using a step-down procedure with p<0.1 as stopping 
criterion. Kaplan-Meier curves were plotted to determine overall survival, and Cox 
regression was used to correct for confounding variables and to calculate hazard ratios 
(HRs) and 95%CIs for mortality prediction. Missing values were excluded. To ensure 
comparability between successive models, all model-based analyses were performed 
on cases that were complete regarding the covariates for the specific outcome. 
Results 
Study participants
A total of 539 patients were included with a median age of 78 years (IQR 74-83 years), 
296 (54.9%) were treated with MMS and 243 (45.1%) with CE. Most tumors (309; 57.3%) 
were ≥1 cm, 68 (12.6%) were ≥2 cm. Comorbidities were prevalent; 370 (70.6%) patients 
had a CCI ≥1, and in 166 (31.7%) patients a CCI ≥3 was seen. Baseline characteristics of the 
participants are summarized in Table 1. 
Chapter 3.1
152
Table 1. Patient-, tumor and treatment characteristics of older adults (aged ≥70 years) 
surgically treated for basal cell carcinoma in the head-and-neck area.
Overall study 
population MMS CE p-value
Patient characteristics
       Agea (years), 
          Median (IQR)








       Sex, n (%)
          Male








       History of KC, n (%)
          Previous KC, median (range)
          Previously treated with CE, n (%)    
          Previously treated with MMS, n (%)

















       CCIb, 
          Median (IQR)






2.2 ± 2.0 0.026
       Polypharmacyc, n (%) 264 (50.1) 144 (50.3) 120 (49.8) 0.899
       ADL dependentd, n (%)









       Travel distance (km), 
          Median (IQR) 11 (6-17) 11 (7-18) 9 (5-17) 0.023
Tumor characteristics
       Previous treatment, n (%)
          Primary tumor








       Tumor location, n (%)
          Forehead
          Peri-ocular
          Cheek
          Nose
          Peri-oral
          Chin
          Ear
          Neck





























       BCC subtype, n (%)
          Mixed
          Nodular
          Micronodular
          Infiltrative
          Superficial




















       Maximum tumor diameter in mm, 
          Median (IQR)
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Values may not add up due to missings and rounding. 
a  at time of treatment. The maximum age of the included patients was 95 years in both treatment groups. 
b  Charlson comorbidity index (CCI) is a weighted index, frequently used in geriatric medicine, with higher scores 
   corresponding with poor survival, in particular at a score ≥3)10-13
c  defined as the use of the chronic use of ≥5 medications with different ATC3 codes.14,15 
d  the Katz’s index of activities of daily living (ADL)16 comprise: bathing, dressing, transferring, toileting, continence 
  and eating. Patients were considered ADL dependent if they were unable to perform ≥1 activities 
  independently. Lawton and Brody’s index of instrumental ADL (iADL)18 comprise: telephone use, grocery 
   shopping, preparing meals, housekeeping, laundering, using transportation, taking medication, and managing 
   finances. Patients were considered iADL dependent if they were unable to perform ≥1 activities independently. 
   When analyzing iADL according to sex (i.e. excluding meal preparation, housekeeping and laundering in men 
   and excluding managing finances), 89 (30.7%) MMS patients were iADL dependent and 72 (30.1%) CE patients 
   were iADL dependent. 
e  in case of MMS
f  including both flaps and grafts.
ADL, Activities of Daily Living; BCC, basal cell carcinoma; CCI, Charlson Comorbidity Index; 
CE, conventional excision; iADL, instrumental activities of daily living; IQR, interquartile range; MMS, Mohs 
micrographic surgery; NA, not applicable; KC, keratinocyte cancer; RT, radiotherapy; SD, standard deviation. 
Overall study 
population MMS CE p-value
Treatment characteristics
       Maximum defect diameter in mme, 
       median (IQR) NA 15 (11-24) NA NA
       Number of stagese, median (IQR) NA 1 (1-2) NA NA
       Wound closure technique, n (%)
          Primary closure
          Through secondary intention











       Separate surgical procedure for wound closure 
         or re-excision due to positive margins, n (%)





Patients experienced a low overall treatment burden, with a median visual analogue 
scale (VAS)-score of 8.6 (IQR 7.3-9.4; higher values indicate a lower treatment burden). 
Overall, 420 (80.2%) patients experienced the treatment as expected, and valued the 
information given prior to surgery as sufficient. However, 72 (13.7%) patients 
experienced a longer duration of surgery than expected, and 55 (10.5%) patients 
experienced a more painful treatment than expected. As shown in Table 2, predictors 
for higher experienced treatment burden were iADL dependency (effect=-0.42; 95%CI 
-0.82…-0.21, p<0.001), female sex (effect=-0.52, -0.81…-0.19, p=0.002), complications (ef-
fect=-0.84, -2.23-…-0.15, p=0.018), tumor diameter (effect=-0.021, -0.043…-0.003, p=0.024), and 
polypharmacy (effect=-0.31, -0.63-…-0.01, p=0.042). As complications were the only 
covariate that could not be assessed preoperatively, a sensitivity analysis was performed 
without including complications; similar outcomes were seen. No association was found for age, 
CCI, and other covariates presented in Table 1. As presented in Figure S3, no significant 
difference was seen between treatment burden after MMS or CE using univariate analyses 
(medians were 8.6 and 8.7 respectively, p=0.093). Furthermore, no significant difference 




As shown in Table S1, complications were seen in 52 (9.6%) patients. Significant predic-
tors for complications were tumor diameter (OR 1.07; 1.03…1.11, p=0.001) and wound closure 
technique (OR 2.69 [healing through secondary intention vs. primary closure]; 1.19…6.10, p=0.017; 
and OR 4.98 [reconstructions vs. primary closure]; 2.49…9.98, p<0.001). The final 
multivariable model of the step-down procedure is presented in Table 3 and Table S2. 
After correction for these covariates, multivariable analysis showed no significant 
difference between complications after MMS vs. CE (OR 0.92; 0.46…1.81, p=0.800). 
Cosmetic result
Overall, patients reported a good cosmetic result (median 8.5; 6.7-9.5, Figure S4). Significant 
predictors for lesser cosmetic scores were female sex (effect=-0.74; -1.13…-0.30, p=0.001), 
method of closure (effect of healing through primary closure vs. secondary intention -0.56; 
-0.79…-0.15, p=0.007) and the occurrence of complications (effect=-0.91; -2.46…-0.17, p=0.016). 
No significant difference in cosmetic result was found between MMS and CE after correction for 
confounders identified by regression analyses (effect=0.15; -0.12…0.79; p=0.271).
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All patient-, tumor- and treatment characteristics reported in Table 1 were initially included in the full 
multivariable quantile regression model. Final predictors as shown in this table were selected using a 
step-down procedure with optimal Akaike information criterion (AIC) as stopping criterion. Treatment 
burden was measured on a visual analog scale (0-10cm, lower scores representing a higher treatment 
burden). A negative effect listed here therefore indicates increasing treatment burden compared to the 
references status. 
* Reference status.
a Reference status is “male”, for all other categorized variables “no” was the reference status. 
b defined as the chronic use of ≥5 medications with different ATC3 codes.14,15 
c ADL: bathing, dressing, transferring, toileting, continence and eating. iADL: telephone use, grocery shopping, 
 preparing meals, housekeeping, laundering, using transportation, taking medication, and managing finances. 
 When analyzing iADL according to sex (i.e. excluding meal preparation, housekeeping and laundering in men 
 and excluding managing finances), no differences in outcome measures were seen. 
d including both flaps and grafts.
95%CI, 95% confidence interval; ADL, Activities of Daily Living; iADL, instrumental activities of daily living; 
KC, keratinocyte cancer. 
Table 2. Results of the step-down procedure used in multivariable analyses (quantile 
regression) of covariates possibly associated with the experienced treatment burden in 




       Sexa -0.52 -0.81…-0.19   0.002
       History of KC -0.19 -0.46…0.15   0.274
       Polypharmacy -0.31 -0.63…0.01   0.042
       ADL dependentc







       Travel distance (km) 0.008 -0.004…0.023   0.180
Tumor characteristics
       Maximum tumor diameter (mm) -0.021 -0.043…-0.003   0.024
Treatment characteristics
       Wound closure technique
          Primary closure
          Through secondary intention








       Complications -0.84 -2.23…-0.15   0.018
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Table 3. Results of the step-down procedure used in multivariable analyses (logistic 
regression) of covariates possibly associated with postoperative complications in older 
adults (aged ≥70 years) surgically treated for basal cell carcinoma in the head-and-neck 
area.
The potentially clinically relevant patient-, tumor- and treatment characteristics initially included in the 
logistic regression model were: age, sex, Charlson comorbidity index, Diabetes Mellitus type 2, polypharmacy, 
(instrumental) activities of daily living dependency, primary/recurrent tumor, tumor location**, 
BCC subtype, tumor diameter, individual treatment center, treatment modality, wound closure technique, 
and closure on a second hospital visit. Final predictors as shown in this table were selected using a 
step-down procedure with p<0.1 as stopping criterion. The chi square value for the Hosmer-Lemeshow 
Test was 4.349 (p=0.824); indicating support for the model. The pseudo R squared value was 0.148. 
*   Reference status. 
** Tumor location was too detailed to include in the final multivariable analysis model, descriptives are shown in 
     Table S2. 
a    including both flaps and grafts.
OR, odds ratio; 95%CI, 95% confidence interval.
Tumor recurrence
The mean follow-up time for tumor recurrence was 23.0±6.4 months. Three (0.6%) patients 
developed a recurrent BCC, all initially treated with CE, with postoperative histologically 
confirmed clearance. The time to recurrence was 9, 13 and 15 months. 
Overall survival 
Of all included patients, 35 (6.5%) died during follow-up, with a mean time until death 
of 14.0±5.4 months. No deaths were BCC-related. For the remaining patients, the mean 
follow-up for survival was 23.3±1.4 months. Predictors for all-cause mortality were increasing 
CCI (HR 1.30; 1.12…1.51, p<0.001), and iADL dependency (HR 3.21; 1.48…6.98, p=0.003; 
Figure 1). No significant difference was seen between survival after MMS or CE 
after correction for confounders shown in Table S3 (HR 1.69; 0.83…3.45, p=0.149). 
Outcomes were similar when looking at 1-year (n=13, 2.4%) and 2-year survival only.
OR 95% CI p-value
Primary tumor 2.43 0.91…6.51   0.077
Tumor diameter (mm) 1.07 1.03…1.11   0.001
Wound closure technique
    Primary closure
    Through secondary intention
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Figure 1. Kaplan Meier-curve to indicate the survival estimates of the surgically treated 
patients in older adults (aged ≥70 years) surgically treated for basal cell carcinoma in the 
head-and-neck area.
Overall short-term survival with 95%CI for patients (aged ≥70 years) surgically treated for basal cell 
carcinoma in the head-and-neck area, plotted by Charlson comorbidity index ≥3 (A) and instrumental 
activities of daily living dependency (B). The Hazard ratios corrected for covariates are summarized in Table S3.
CCI, Charlson Comorbidity Index; depend, dependent; iADL, instrumental activities of daily living; 








































































It seems essential to include treatment burden and its predictors in BCC management 
to improve time-to-benefit estimation in older adults.21,22 Especially in frail older adults with 
a decreased functional reserve, hospital visits, surgical procedures and postoperative 
care can be overwhelming and cause substantial distress.6,23 Remarkably, older adults 
included in this study experienced a low overall treatment burden (median VAS-score of 
8.6; (IQR 7.3-9.4) and overall mortality (6.5%), and frailty-related patient characteristics were 
important predictors for higher treatment burden (iADL dependency and polypharmacy), 
and with overall mortality (comorbidities and iADL dependency). 
     Overall, the results of this study showed no reason to assume that surgical treatment of BCC 
in the head-and-neck area is too burdensome for patients with advanced age only. Moreover, 
despite the fact that MMS is more labor-intensive and time-consuming than CE,12 multivariable 
analyses showed no significant difference between treatment burden, nor in the incidence of 
complications after MMS vs. CE. Whereas the results on complications are comparable with 
previous studies,12,22,24,25 literature on BCC treatment burden is sparse.21 The results of this study 
appear consistent with available studies reporting that older adults frequently experience 
surgical BCC treatment as satisfactory.26-28 It should be noted that patient satisfaction 
is not entirely comparable with treatment burden; patients can be satisfied with overall 
clinical care and health care professionals, but still experience a high treatment burden due to 
the impact of treatment on their daily activities and social resources. Moreover, the impact of 
unsatisfactory cosmetic results should not be underestimated in older adults, as the patients 
included in this study regularly mentioned esthetic outcome as an important factor in overall 
treatment experience. Nonetheless, overall results of this study and previous studies 
indicate that older adults endure surgical BCC treatment well and chronological age should 
not lead to a priori rejection of certain treatment options. This too can be accentuated by 
the high overall survival seen in this study (93.5%) after a mean follow-up of 23.3 months. 
A possible explanation for this could be that patients treated for BCC can be presumed quite 
fit and generally high functioning (i.e. relatively few comorbidities and (i)ADL dependency) 
compared with the overall population.29 This is supported by a 16.6% lower 2-year 
mortality compared with Dutch citizens of the same age,30 although these numbers are not 
entirely comparable due to the distribution of the data. Moreover, the baseline demographics 
of the included patients further emphasize the heterogeneity of the geriatric population and 
encourage individualized medical decision-making.
   The predictors for higher treatment burden in this study consisted of iADL dependency, 
female sex, larger tumor diameter and polypharmacy. These findings could aid clinicians 
in advising those patients who may need extra measures to reduce the burden of therapy; 
for instance, extra postoperative care, home visits or help from medical caretakers, general 
practitioner or relatives. In line with several articles,3,13,29,31 comorbidities (increasing CCI) 
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and iADL dependency were significantly associated with increased overall (non-BCC- 
related) short-term mortality, although the study of Linos et al. indicated the CCI to be less 
accurate at estimating 5-year survival in a majority of the included patients.12 Therefore, 
it remains difficult to estimate life expectancy and more research is highly needed 
to provide consensus in this field. Nonetheless, as both comorbidities and iADL 
dependency are frailty-related, frailty screening could aid in estimating patients’ life 
expectancy in a more holistic approach,23 although current experience in dermatology 
daily care is limited.21,32 However, as chronological age was not identified as a significant 
predictor for treatment burden, complications, cosmetic result, or overall survival, 
physicians should refrain from making treatment decisions based solely on age, and preferably 
prioritize the consideration of frailty-related patient characteristics that could lead to adverse 
health outcomes.
    The combination of overall low treatment burden and high overall survival leads us to 
believe that the surgical treatment choices have been adequate in this part of the BATOA 
cohort. As tumor growth was associated with higher treatment burden and 
complications, early BCC intervention is beneficiary for robust and fit patients or those 
experiencing symptoms. However, as currently much is still unknown concerning the 
natural course of BCCs, it remains difficult to estimate the time-to-benefit. Naturally, 
treatment choices should align with individual patient values, treatment goals and 
preferences, especially when the life expectancy and time-to-benefit are roughly equal. 
Watchful waiting could be a suitable alternative for surgical BCC treatment in certain 
patients with LLE and higher odds of a high treatment burden, and if the burden of the tumor 
itself is low (e.g. no BCC-related burdensome symptoms). Currently, little data is available 
in guiding clinicians in which situations watchful waiting is an appropriate management 
option and more research clarifying this dilemma is essential.21,22
   Certain limitations need to be addressed; a selection bias may exist due to the 
observational design of the study. However, the results presented here probably adequately 
represent daily clinical care, and correction for baseline differences was applied to reduce bias as 
much as possible. Of note, treatment burden was evaluated at one time point, whereas patient 
experiences might fluctuate over time. At the start of this study, no validated tools were 
available to evaluate surgical treatment burden, therefore a VAS scale was used after a 
pilot study to ensure comprehensibility. Also, future studies with adequate power and longer 
follow-up are needed to provide more information on recurrences and survival, as these 
results are probably influenced by the relatively short follow-up.33 Moreover, any study using 
real world data is subject to a preselection of patients, as only patients who appear fit enough 
to undergo surgery were included in this study. Apparently, the preselection of patients as 
included in this cohort has been adequate, with overall adequate results on treatment burden, 




In conclusion, BCC management decisions merely on the basis of age as sole patient- 
related factor should be avoided, as chronological age showed no significant association with 
treatment burden, complications, cosmetic results and overall mortality. Moreover, using 
advanced age as an exclusion criterium could lead to a delay in adequate medical 
interference, leading to larger tumors and a subsequent higher chance of tumor- 
related complaints, complications and treatment burden. This study has identified 
important patient-related aspects which could aid in medical decision making: in patients 
with higher CCI, iADL dependency and polypharmacy, the risks of treatment, 
including the treatment burden, might outweigh the benefits in individual 
cases. As it remains difficult to properly predict life expectancy, more research 
in this field is highly needed and determining which patients are too frail for 
surgery should not only include these frailty-related aspects, but also the treating 
physician’s estimation of life expectancy, a discussion with patients about their goals of care, 
risks of treatment, and the common sequelae of BCC non-treatment with the estimated 
timeframe within which these sequelae may occur.
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Supplementary Materials
Figure S1. Flow-chart of the inclusion of older adults (aged ≥70 years), surgically treated 
for basal cell carcinoma in the head-and-neck area.
Treatment decisions were made prior to inclusion, based on clinical judgement of the treating physicion, in 
accordance with Dutch clinical guidelines and regardless of this study. Private practices included MohsA 
Clinic Eindhoven, the Netherlands and MohsA Clinic Venray, the Netherlands. General hospitals included Rijnstate 
Hospital Arnhem/Velp, the Netherlands and Queen Beatrix Hospital Winterwijk, the Netherlands. The academic 
hospital was the Radboudumc Nijmegen, the Netherlands.
*  2-4 months after the treatment, patients were asked to score treatment burden and cosmetic result. 
    The occurrence of complications was extracted from electronic patient files. 
** No patients were loss to follow-up, as survival and recurrence data were extracted from medical patient 
      charts, Personal Records Database (in Dutch: Basisregistratie Personen, BRP) and the Dutch nationwide network 
     and registry of histopathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief; PALGA).20
Inclusion criteria:
- ≥70 years of age
- BCC in head-and-neck area
- Treatment with MMS or CE
Exclusion criteria:
- Unable to understand study 
    information (e.g. dementia)















Did not reach time point: n=0




Did not reach time point: n=122





Figure S2. The questionnaire used to evaluate treatment burden and cosmetic result in 
older adults (aged ≥70 years), surgically treated for basal cell carcinoma in the head-and-
neck area.
Questionnaire after surgical treatment for basal cell carcinoma
We would like to ask you some questions about the surgical treatment which you have had a few months ago 
because of a basal cell carcinoma. In some of these questions, a scale is used. On the presented line you can 
answer the question by drawing a vertical line, as presented in the example below:
EXAMPLE:                   Very unsatisfied                                                   Very satisfied
1. What was your overall experience with the treatment?
Worse than expected                                                                       Better than expected
2. Can you elaborate on this? (multiple answers allowed)
    A.  The treatment was fine, exactly as was explained/discussed beforehand.
    B.  The treatment duration took longer than I expected.
    C.  The treatment was more painful than I expected. 
    D. Other: 
 …...………………..........……………………………………………………………………………………………………………………
3. What is your opinion on the scar/result?
          Very ugly                                                                                           Very pretty
4. Do you have additional remarks?
...………...…………………………………………………………………………………………………...…………............................................…
 
THANK YOU VERY MUCH FOR FILLING IN THIS FORM!
The questionnaire as presented above was filled in by patients 2-4 months after surgical treatment for basal cell 
carcinoma in the head-and-neck area. The questionnaire was tested in a pilot study including 33 patients from 
the target population to improve comprehensibility, and to base power calculations on. Moreover, seven health 
care professionals (4 dermatologists/Mohs surgeons and 3 experienced surgical assistants) were consulted in two 
rounds to develop and improve the VAS scale.
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Figure S3. Treatment burden in older adults (aged ≥70 years) surgically treated for basal 
cell carcinoma in the head-and-neck area.
Univariate analyses as presented here were calculated using a Mann-Whitney U test. Results of multivariate 
analyses using quantile regression are summarized in Table 2.
* Treatment burden was measured on a visual analog scale (0-10cm, higher scores indicating a lower treatment 
   burden. 
CE, conventional excision; MMS, Mohs micrographic surgery; ns, not significant.
Figure S4. Cosmetic results as rated by older adults (aged ≥70 years) surgically treated for 
basal cell carcinoma in the head-and-neck area.
* Cosmetic result was measured using a visual analog scale (0-10cm, higher scores indicating a better cosmetic 
result. Univariate analyses as presented here were calculated using a Mann-Whitney U test. 
CE, conventional excision; MMS, Mohs micrographic surgery; ns, not significant.










Table S1. Specifications of complications in older adults (aged ≥70 years) surgically treated 








    Bleeding
    Infection
    Sensory changes
















Values may not add up due to missings and rounding, and two patients treated with CE experiencing two 
complications.
 
a Other complications included ectropion (n=4 at MMS vs. 1 at CE), delirium (MMS n=0 vs. CE n=1), reconstruction
 failure (MMS n=2 vs. CE n=3). 
CE, conventional excision; MMS, Mohs micrographic surgery. 
Table S2. Complications per tumor location in older adults (aged ≥70 years) surgically 
































































As tumor location was too detailed to include in the final multivariable analysis model presented in Table 3, 
descriptives are shown here. 







Tumor location, n (%)
    Forehead
    Peri-ocular
    Cheek
    Nose
    Peri-oral
    Chin
    Ear
    Neck
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Table S3. Results of the step-down procedure used in multivariable analyses (Cox regres-
sion) of covariates possibly associated with short-term survival in older adults (aged ≥70 
years) surgically treated for basal cell carcinoma in the head-and-neck area.
iADL dependent 3.21 1.48…6.98 0.003
CCI 1.30 1.12…1.51 <0.001
HR 95% CI p-value
The relevant patient-, tumor- and treatment characteristics initially included in the Cox regression model were: 
age, sex, Charlson comorbidity index, polypharmacy, (instrumental) activities of daily living dependency, and 
treatment modality. Final predictors as shown in this table were selected using a step-down procedure with 
p<0.1 as stopping criterion, reference status of iADL dependency was iADL independency. Similar outcomes were 
found when 1-year and 2-year survival were calculated.
95%CI, 95% confidence interval; CCI, Charlson Comorbidity Index; HR, hazard ratio; iADL, instrumental 
activities of daily living. 
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Frailty screening in dermato-oncology practice: 
a modified Delphi study 
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Appropriate management and prevention of both under- and overtreatment in older skin 
cancer patients can be challenging. It could be helpful to incorporate frailty screening in 
dermato-oncology care, since frailty is associated with adverse health outcomes.
Objectives 
This study aimed to identify and prioritize the requirements a frailty screening tool (FST) should 
fulfil in dermato-oncology practice and to select the best existing FST(s) for this purpose.
Methods 
A modified two-round Delphi procedure was performed among 50 Italian and Dutch special-
ists and patients to review and prioritize a list of potential FST requirements, using a 5-point 
Likert scale. Consensus was defined as a mean score of ≥4.0. A systematic literature search was 
performed to identify existing multidomain FSTs, which were then assessed on the 
requirements resulting from the modified Delphi procedure.
Results 
Consensus was achieved on evaluation of comorbidities (4.3±0.7), polypharmacy (4.0±0.9) 
and cognition (4.1±0.8). The FST should have appropriate measurement properties (4.0±1.0), 
be quickly executed (4.2±0.7), clinically relevant (4.3±0.7), and both easily understandable 
(4.1±1.2) and interpretable (4.3±0.7). Of the 26 identified FSTs, four evaluated the content- 
related domains: the Geriatric-8 (G8), the modified Geriatric-8 (mG8), the Groningen Frailty 
Indicator (GFI) and the Senior Adult Oncology Program 2 (SAOP2) screening tool. Of these, the 
G8 was the most extensively studied FST, with the best psychometric properties and execution 
within 5 min.
Conclusions 
The G8 appears the most suitable FST for assessing frailty in older adults with skin cancer, 
although clinical studies assessing its use in a dermato-oncology population are needed to 
further assess whether or not frailty in this particular patient group is associated with relevant 
outcomes (e.g. complications and mortality), as seen in previous studies in other medical fields.
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Introduction
Physicians are increasingly confronted with older adult patients with skin cancer. The majority 
of skin cancers are characterized by a relatively low-malignant potential, but can cause 
significant morbidity in the long term. Therefore, appropriate management and prevention 
of both under- and overtreatment in this population can be challenging. In current clinical 
guidelines, treatment choices are mainly based on tumour-related characteristics, while 
patient-related characteristics seem relatively underrepresented.1,2 However, factors as life 
expectancy and expected patient burden of both the tumour and the treatment are of vital 
importance to determine to what extent a patient will benefit from a certain therapy, although 
not always easily predicted.2
     Frailty is a clinical syndrome, defined as a state in which depletion of physiological reserves 
leads to adverse health outcomes and low tolerability of stress.3,4 In several medical oncology 
fields, frailty has been demonstrated to be associated with increased disability, functional 
dependence, institutionalization and the risk of mortality. To detect frailty, a comprehensive 
geriatric assessment ([C]GA) can be performed, evaluating somatic, psychosocial and functional 
domains.3–7 However, these assessments are time-consuming and therefore may not be feasible 
for the many older adult patients seen in dermatologic practice.8–13
    Multidimensional frailty screening tools (FSTs) can be used as brief evaluations to detect 
which patients are in need of or most likely to benefit from a more extensive evaluation by a 
geriatric assessment.4 There is a wide variety of available FSTs used in oncology patients. Data 
on selecting a suitable FST in dermatologic oncology patients are currently lacking, although 
multiple studies conclude that more guidance on medical decision-making in frail skin cancer 
patients is needed to improve personalized medical decision-making and the prevention of 
both under- and overtreatment.1,14
This study aimed to identify and prioritize the most important requirements a multidimensional 
FST should fulfil in dermato-oncology care for older adults and to select the best existing FST(s) 
for this purpose from a systematic review of the available literature.
 
Methods
A mixed-methods approach was used combining a modified Delphi procedure and a systematic 
literature review.
Modified Delphi procedure
Between April 2018 and March 2019, an international modified 2-phase Delphi procedure 
was performed to achieve a consensus on the requirements a FST should fulfil for the target 
population of older adults with skin cancer.15 The study was facilitated by an online 
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survey methodology (SurveyMonkey Inc., San Mateo, CA, USA). The survey included items 
related to content, quality and clinical applicability of the FST, based on previous research 
and experiences of interdisciplinary experts.
    In the first round, 22 items were presented followed by a short list of demographic 
questions. Respondents were encouraged to comment on the relevance of items; missing 
items could be added, and statements could be rephrased or removed. Suggestions from 
participants were used to adjust the statements for the second round, in which participants 
were asked to grade the importance of each FST requirement using a 5-point Likert scale, a 
higher score indicating an item was considered more important. Consensus was defined as a 
group mean score of ≥4.0. Descriptive statistics were performed on demographic variables. 
Continuous variables were summarized using the mean and standard deviation and 
categorical variables were expressed as frequencies and percentages. All data were 
collected using SurveyMonkey and analyzed using SPSS Statistics for Windows, version 25.0 
(IBM, Armonk, NY, USA). This study was conducted according to the Standards for Reporting 
Qualitative Research (SRQR).16
Participants of the Delphi procedure
A multidisciplinary working group of Dutch and Italian experts and patients was formed. 
To represent all specialties involved in skin cancer care, the expert group consisted of 
dermatologists, plastic surgeons, otorhinolaryngologists, oral and maxillofacial surgeons, 
radiotherapists and geriatricians, who all had extensive clinical experience in skin cancer and/
or geriatric care. Age, gender, healthcare setting and years of experience were taken into 
account to optimize a well-balanced working group. National guideline committees in the 
field of dermato-oncology or frailty were represented by one or multiple members. Seven skin 
cancer patients from outpatient clinics in both Italy and the Netherlands participated as well; 
the majority aged 70 years or older.
     Potential respondents were approached by the investigators, who explained the study 
and requested participation. Agreeing to participate was construed as informed consent. 
Participants who did not fill out the survey were sent two reminders by e-mail, after 
which all participants were contacted personally or by phone. Interrespondent anonymity 
was maintained to ensure no respondents were influenced by the identities of other 
participants.
Systematic literature search
A systematic literature search was conducted to identify available multidimensional FSTs 
combining the search terms ‘frailty’, ‘screening’ and ‘cancer’. PubMed, EMBASE, Cochrane 
Library, SUMSearch and Trip Database were searched up to 16 May 2019, as well as websites 
of relevant organizations, and guidelines on FSTs (Tables S1 and S2). Manual review of the 
abstracts as well as a full-text evaluation was independently performed by two reviewers. 
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In case of disagreement, consensus was achieved by discussion. Articles were excluded 
if written in any language other than English, Dutch, German, French, Spanish or Italian. 
FSTs assessing a single domain or FSTs including physical, laboratory or imaging 
techniques were also excluded, as well as conference abstracts or articles of which full-text 
remained unavailable after contacting the authors. This review was conducted in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA).17
Assessment of identified FSTs
All identified FSTs were assessed on the presence of the content- related items as 
presented in round 2 of the modified Delphi procedure. FSTs assessing all of the content-related 
domains that met consensus were further assessed on psychometric properties with the 
aid of the Consensus-based Standards for the selection of health Measurement 
Instruments (COSMIN) checklist.18 All related articles on the selected FSTs were evaluated on 
relevant characteristics.In case of missing data, the FST developers were contacted and if 
necessary additional measurements were performed by the research team.
Results
Multidisciplinary working group characteristics
Of the 53 working group members who agreed to participate in the study, 50 (94.3%) 
consented and completed the first round. Only respondents who completed round 1 were 
invited for the second round, in which a response rate of 92.0% (n=46) was achieved. The working 
group characteristics are summarized in Table 1.
Composition and prioritization of the list of items
In round 1, both patients and experts were requested to express their thoughts on the initial 
set of 22 statements presented as possible requirements for a FST. Consequently, 12 items were 
rephrased, five were deleted, and two were added. In the second round, the final 19-item list 
(Table S3) was prioritized by the respondents with an overall mean score of 3.7±0.5.
  Consensus was met concerning the evaluation of comorbidities (mean 4.3±0.7), 
polypharmacy (4.0±0.9) and cognition (4.1±0.8). Other FST characteristics for which consensus 
was met were appropriate measurement properties (4.0±1.0), easy interpretation of the 
outcome (4.3±0.7), suitability for low-literate and low-educated patients (4.1±1.2), quick 
completion of the FST (4.2±0.7) and a clinically relevant outcome (4.3±0.7). No consensus 
was reached on the other potential FST requirements, including whether the screening tool 
should be filled in by patients or medical workers. A complete overview of the results is 
provided in Figure 1. Outcomes were consistent when only responses of dermatologists were 
analyzed (data not shown).
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Working group characteristics Value
Age (years), mean ±SD
    Specialists 47.3±8.3
    Patients 73.1±17.2
Gender, n (%)
    Male 25 (50.0)
    Female 25 (50.0)
Specialists, n (%) 43 (86.0)
    Dermatologist 23 (46.0)
    Radiation therapist 4 (8.0)
    (Facial) surgeonsa 11 (22.0)
    Geriatrician or elderly care physician 5 (10.0)
    Years of experienceb, mean ±SD 15.8±8.9
Patients, n (%) 7 (14.0)
Healthcare setting, nc (%)
    General hospital 14 (27.5)
    Academic hospital 30 (58.8)
    Private practice 5 (9.8)
    Other 2 (3.9)
Table 1. Multidisciplinary working group characteristics of this modified Delphi study on 
requirements a multidimensional frailty screening tool (FST) should fulfil in dermato- 
oncology care
a   (Facial) surgeons included plastic surgeons, otorhinolaryngologists, or oral and maxillofacial surgeons.
b   Years of experience in skin cancer care.
c   Including multiple specialists working in more than one treatment facility.
Systematic literature search and FST selection
An initial search for FSTs generated 1354 publications. A total of 439 duplicates were removed. 
Of the remaining 915 publications, titles and abstracts were screened for eligibility, after which 
54 articles remained for full-text screening. A total of 26 unique FSTs were identified after 
full-text evaluation.19–47 A flow chart on the literature search and reasons for exclusion can be 
found in the Figure S1.
175
Frailty screening in dermato-oncology practice
3.2
Each statement started with ‘The screening tool should...’. Green bars represent those in which consensus 
was achieved; consensus was defined as a mean score ≥4.0. Orange bars represent items that did not reach 
consensus, e.g. a mean score of <4.0. *Complete statements can be found in Table S3.
...have appropriate measurement
properties*
...be available in multiple languages
...include items related to comorbidities
...include items related to
medication use or polypharmacy
...include items related to mobility and falls
...include items related to
(instrumental) activities of daily living
...include items related to
neurosensory deficits
...include items related to cognitive function*
...include items related to
mood, anxiety and/or depression
...include items related to nutritional status 
...include items related to social support system* 
...include items related to the
ethnic or cultural background 
...be filled in by a physician/physician
assistant/nurse (practitioner) 
...be filled in by a patient or relative/friend 
...be easy to understand for
a low-educated and/or low-literature population* 
...be quickly performed in
daily dermatology practice 
...be easy to interpret 
...have a relevant impact in daily dermato-
oncology practice (clinical relevance)
...have a predictive value
concerning life expectancy





















Figure 1. Results of the multidisciplinary modified Delphi study on requirements a multi-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     Subsequently, FSTs were assessed for the inclusion of the domains which met consensus 
in the final Delphi round. Eighteen tools (69.2%) contained items related to comorbidity or 
self-reported health assessment, 8 (30.8%) on the evaluation of polypharmacy and 16 (61.5%) 
on the evaluation of cognitive function. Table 2 lists the domains included in each of the 
identified FSTs.
    In four FSTs, the assessment of comorbidities/self-reported health, polypharmacy and 
cognitive function was included: the Geriatric-8 (G8), the modified Geriatric-8 (mG8), 
the Groningen Frailty Indicator (GFI) and the Senior Adult Oncology Program 2 (SAOP2) 
screening tool.19–22,45 The G8 and mG8 can be performed within 5 min; the GFI and SAOP2 can 
be completed in 10 min.4,6,10,48,49 All four FSTs have clear cut-off points to identify frail patients in 
need of more extensive geriatric evaluation. No studies were available on the suitability of the 
(m)G8, GFI and SAOP2 for low-literate or low-educated patients, nor on the clinical relevance 
and impact of the outcomes in daily dermato-oncology practice. 
   Table 3 summarizes general and psychometric characteristics of the selected FSTs, 
including sensitivity and specificity on predicting frailty with a (C)GA as a reference test. 
The screening methods included in the reference (C)GA differed among the included studies 
and the cut-off point determining frailty varied between ≥1 and ≥2 deficiencies (Table S4). 
The included studies assessing the G8 and GFI showed the least risk of bias according to the 
modified COSMIN standards (Table 3).
Discussion
Management of skin cancer in older patients can be challenging due to various patient- 
related factors influencing treatment decisions and outcomes, such as limited life expectancy 
and frailty. Frailty screening tools (FSTs) are available to identify patients in need for more 
extensive geriatric assessment, but are currently rarely used in older patients with cutaneous 
malignancies. The aim of this study was to identify and prioritize the requirements for a FST in 
dermato-oncology daily practice and to select the best-fitting existing FST(s). A FST could assist 
dermatologists in selecting those patients in need for a more extensive geriatric assessment, 
establishing personalized treatment options or include additional preparations to minimize the 
risk of adverse health outcomes.
     According to this modified Delphi study, a FST suitable for dermato-oncology patients 
should minimally include evaluation of comorbidities, polypharmacy and cognition. A quick 
execution of the FST is necessary, and the FST should be suitable for a low-literate population. 
Four of the 26 FSTs that were identified by the literature review included the required do-
mains: The Geriatric-8 (G8), the modified Geriatric-8 (mG8), the Groningen Frailty Indicator (GFI) 
and the Senior Adult Oncology Program 2 (SAOP2) screening tool.19–22,45 The G8 is the most 
extensively studied tool with appropriate measurement properties when compared to a full 
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GA.10–13,19,48,50–65 In the few articles studying the recently developed mG8, sensitivity (89–92%) 
and specificity (36–79%) for geriatric impairments detected by GA appear higher than the 
original G8.20,61 However, the mG8 is currently only available in a limited number of 
languages. The GFI, although frequently used, has a relatively low sensitivity 
(39–76%), which is an important shortcoming for a well-functioning FST.13,49,59,62,66–68 
Only two articles could be identified studying the SAOP2 screening tool, which showed a 
high sensitivity (94–100%) and a low specificity (40–50%).12,21 The SAOP2 is the most time- 
intensive tool when compared to the (m)G8 and GFI. None of the articles studying the 
(m)G8, GFI or SAOP2 provided information on the education level of the patients, nor 
reviewed whether low-literate patients understood all questions. Based on the results of 
this study,the G8 appears the most suitable FST for assessing frailty in older adults with skin 
cancer,but relevant clinical studies assessing its use in a dermato-oncology population are 
currently lacking.
  Several studies address the need for implementation of frailty screening in 
dermatology–oncology care.1,14,69 Rogers et al.14 concluded that comorbidity indices and 
chronological age alone did not adequately explain survival rate differences in non- 
melanoma skin cancer patients. Bras et al.,70 assessed frailty in 90 patients with head-and-
neck malignancies, including 45 skin cancer patients in need of major surgery, mostly 
under general anaesthesia. Frailty was associated with a non-significant lower overall 
survival rate and no significant differences in complication rates between frail patients and 
robust patients were seen in this relatively small population with heterogeneous underlying 
diseases.70 Valdatta et al.,71 however, did find a higher complication and mortality rate in 
frail patients undergoing reconstructive surgery after non-melanoma skin cancer surgery. 
These studies used various instruments to detect frailty, frequently based on 
those frailty-related aspects that were fortuitously available from retrospectively 
extracted clinical data, which highly limits comparison and generalizability. Many 
studies have been conducted in other medical fields, including various oncology 
populations, indicating a strong association between frailty and adverse health outcomes 
after treatment.48,56,72 However, the association of frailty with complications and mortality 
seen in previous studies might not be applicable to dermato-oncology. Therefore, more 
research on the consequences of frailty for dermatological oncology patients is needed.
     It should be noted that the items that reached consensus in this modified Delphi study 
might reflect domains that are already currently considered as important factors in 
skin cancer care. Domains as malnutrition and mobility were valued as less important, although 
these have been proven to be vital domains in frailty screening as well as in 
geriatric oncology.3,7,8,72 The use of a FST could assist physicians in assessing these 
domains in addition to other clinically relevant domains as comorbidity, medication 
and cognitive function. More awareness should be raised for these and other frailty- 
related aspects in dermatology, as suggested by previous research.1 The (m)G8 does 
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not only assess self-reported health, polypharmacy and dementia, but also reviews 
additional factors associated with treatment-related outcomes in several other 
oncology fields.
    In this study, only FSTs that did not require physical or laboratory tests were included. 
Since dermatologic consultations are often short, it was estimated that a FST would not be 
used in daily dermatology practice if extensive assessments were required. However, a FST is 
not meant to replace clinical judgement, nor to include all possible domains that could 
influence therapy choices. Personalized medical decision-making should be strived at in 
every patient, including tumour-related aspects, patient preferences and patient-related 
aspects,of which frailty could be an important factor in prediction of adverse health outcomes.
     Frailty screening tools have been developed to identify those patients in need for a more 
extensive assessment.4 A full GA was therefore considered as the gold standard for the 
identification of frailty.5 However, no consensus exists on the components of a (C)GA nor on 
the cut-off point defining frailty,5,7,73 which led to heterogeneity among the included studies 
and outcomes (Table S4). Questionable is whether or not the presented psychometric 
properties of the FSTs are applicable to a dermato-oncology setting, since these patients 
might be in better health in comparison with the populations previously studied.14 
More research is needed to assess the clinical relevance and feasibility of frailty 
screening in dermato-oncology and the consequences of frailty on risks associated 
with dermato-oncology therapies. Application of frailty screening and geriatric 
assessments in the busy dermato-oncology practice may prove challenging, 
due to the broad spectrum of morbidity associated with skin cancer in older 
patients and the heterogeneity of clinical settings (outpatient vs. inpatient vs. specialized 
skin cancer clinics) across different European countries. Nonetheless, a personalized 
and frailty-based clinical management in combination with a shared, rational clinimetric 
framework may support a more patient-based clinical decision-making process, especially in 
the presence of expanding therapeutic options for skin cancer.
Conclusion
More attention for frailty screening in dermato-oncology is generally desired, but clinical 
studies are currently limited. Based on this study, the assessment of comorbidities, 
polypharmacy and cognition should at least be covered by a FST. The FST should have 
appropriate measurement properties, be quickly executed, clinically relevant, and both easily 
understandable and interpretable. The G8, mG8, GFI and SAOP2 are possible suitable FSTs, of 
which the G8 seems the most appropriate existing FST for dermato-oncology practice. More 
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Table S1. Systematic literature search to identify frailty screening tools
Database searched: PubMed, Embase (Excerpta Medica Database), Cochrane Library, SUMsearch, PsycINFO 
and Trip Database
Period of time searched: Articles published up to 16-5-2019
Limit(s): none.
Search details (search strategy shown for PubMed, similar search terms were used for other databases):
("frailty"[MeSH Terms] OR "frailty"[All Fields]) AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR 
"screening"[All Fields] OR "mass screening"[MeSH Terms] OR ("mass"[All Fields] AND "screening"[All Fields]) 
OR "mass screening"[All Fields] OR"screening"[All Fields] OR "early detection of cancer"[MeSH Terms] OR 
("early"[All Fields] AND "detection"[All Fields] AND "cancer"[All Fields]) OR "early detection of cancer"[All Fields]) 
AND ("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields])
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Table S2. List of relevant websites and organisations included in the systematic search to 




International society of geriatric oncology 





World Health Organisation (WHO) Worldwide http://www.who.int/cancer/en 
http://www.who.int/ageing/en
European Organisation for Research and 
Treatment of Cancer (EORTC)
Europe www.eortc.org
Organisation of European Cancer 
Institutes (OECI)
Europe http://oeci.eu/AboutOeci.aspx
European CanCer Organisation (ECCO) Europe http://www.ecco-org.eu
European Society of Medical Oncology 
(ESMO)
Europe http://www.esmo.org






European Union (EU), including 
European Commission (EC) and the Europe-
an Innovation Partnership on Active Health 










American Cancer Society (ACS) United States https://www.cancer.org





American Geriatrics Society (AGS) United States https://www.americangeriatrics.org
Netherlands Comprehensive Cancer Organ-





Dutch Cancer Society (KWF) The Nether-
lands
https://www.kwf.nl
Dutch Geriatrics Society (Nederlandse 








British Geriatrics Society Great Britain http://www.bgs.org.uk
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Table S3. Statements as presented in round 2 of the modified Delphi procedure on the 
requirements a frailty screening tool should fulfil in older dermato-oncology patients
The screening tool should have appropriate measurement properties*
*following the COSMIN checklist, which included: internal consistency, reliability, measurement error, 
content validity, structural validity, hypothesis testing, cross-cultural validity, criterion validity, responsiveness, and 
interpretability
The screening tool should be available in multiple languages
The screening tool should include items related to comorbidities
The screening tool should include items related to medication use or polypharmacy
The screening tool should include items related to mobility and falls
The screening tool should include items related to (instrumental) activities of daily living
The screening tool should include items related to neurosensory deficits
The screening tool should include items related to cognitive function (e.g. dementia and/or delirium risk)
The screening tool should include items related to mood, anxiety and/or depression
The screening tool should include items related to nutritional status
The screening tool should include items related to social support system (i.e. relatives/friends) or health care 
related support system (community nursing)
The screening tool should include items related to the ethnic or cultural background
The screening tool should be filled in by a physician/physician assistant/nurse (practitioner)
The screening tool should be filled in by a patient or relative/friend
The screening tool items should be easy to understand for the person filling in the screening tool; e.g. also 
suitable for use in a low-educated and/or low-literature population
The screening tool should be quickly performed in daily dermatologic practice
The outcome of the screening tool should be easy to interpret
The outcome of the screening tool should have a relevant impact in daily dermato-oncologic practice (clinical 
relevance)
The outcome of the screening tool should have a predictive value concerning life expectancy
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Figure S1. Flow-chart of the systematic search to identify frailty screening tools
Screening tools included in this 
systematic review (n=26)
 Records identified through database search* 
(n=1354)
Duplicates removed (n=439)
Records screened by title/abstract
(n=915)
Records excluded after title/abstract 
screening (n=861)
Records assessed for eligibility in 
full-text (n=54)
Full-text articles excluded (n=28):
Irrelevant (n= 13)
Tools already included (n=11) 
Physical or laboratory tests needed (n=4)
Unique screening tools identified (n=26)
Screening tools identified by 
website screening (n=12) Duplicates removed (n=12)














































Bellera, 201218 364 85 65 ≥1 ADL, IADL, MMSE, GDS-15, MNA, CIRS-G, 
and GUG
Bellera, 201218 364 92  45 ≥2 ADL, IADL, MMSE, GDS-15, MNA, CIRS-G, 
and GUG
Luce, 201259 211 65 3 ≥1 ADL, IADL, MMSE, GDS, MNA, CCI, social  
evaluation, biochemical lab, Mob-T,  
WHOQOL, pain, polypharmacy
Pottel, 201272 51 86 75 ≥2 ADL, IADL, MMSE, GDS, MNA, CIRS-G and  
Tinetti balance and gait
Baitar, 201312 170 92 52 ≥1 ADL, IADL, MMSE, GDS-30, MNA, CIRS-G, 
TUG, and MOS-SSS
Hamaker, 201449 108 69 79 ≥2 ADL (Barthel), IADL, MMSE, GDS-30, TUG,
polypharmacy, BMI/weight loss, and F-Sozu
Holmes, 201451 50 70 71 ≥2 ADL, IADL, CLOX 1, CLOX 2, TMTA, TMTB, 
HADS-anxiety and depression, MNA, HCT-
CI, polypharmacy, SPPB, and MOS
Kenis, 20148 937 87 59 ≥2 ADL, IADL, MMSE, GDS-15, MNA-short form, 
and CCI
Liuu, 201471 518 87 60 ≥2 ADL, IADL, MMSE, mini-GDS, MNA, CIRS-G, 
and GUG
Soubeyran, 20149 1597 77 64 ≥1* ADL, IADL, MMSE, GDS-15, MNA, CIRS-G, 
and TUG
Velghe, 201456 50 89 100 ≥1 ADL, IADL, MMSE, GDS-4, MNA, and any 
falls in the previous year
Smets, 201458 398 78 68 ≥1 ADL (Barthel), IADL, MMSE, GDS-15, food  
intake, weight loss, medication
Dubruille, 201510 90 80 56 ≥2 ADL, IADL, MMSE, GDS-4, MNA, CCI, TUG, 
Mob-t, HADS, and polypharmacy




729 87 58 ≥2 ADL, IADL, MMSE, Mini-GDS, MNA, CIRS-G, 
and TUG
Hentschel, 201650 84 38 63 ≥2 IADL, cognition, NCCN Distress Thermo- 
















































de Thezy, 201770 49 100 73 ≥1 ADL, IADL, MMSE, GDA, TUG, and mal-
nutrition
Osborne, 201754 178 44 84 ≥1 ADL, IADL, MNA, BMI, CCI, polypharmacy, 




269 90 35 ≥1 ADL, simplified IADL, MMSE, mini-GDS, 
BMI, albumin, and SPPB
Pamoukdjian, 
201760
269 93 29 ≥2 ADL, simplified IADL, MMSE, mini-GDS, 
BMI, albumin, and SPPB
van Loon, 201761 123 92 26 ≥2 ADL, IADL, MMSE, GDS, MNA, CIRS-G, 
TUG, ECR, CDT,and fluency
Russo, 201811 282 89 50 ≥3 ADL (Barthel), IADL, MMSE, GDS-15, MNA, 
CIRS-G, TUG, CDT, Tinetti Scale, Gijon 
Scale and risk of falls
Yokom, 201857 28 73 80 ≥2 IADL, cognition, mood, nutrition, CCI, so-










269 89 65 ≥1 ADL, simplified IADL, MMSE, mini-GDS, 
BMI, albumin, and SPPB
Pamoukdjian, 
201760
269 92 36 ≥2 ADL, simplified IADL, MMSE, mini-GDS, 
BMI, albumin, and SPPB
Kellen, 201048 113 39 86 ≥2 ADL (Barthel), IADL, MMSE, and GDS
Baitar, 201312 170 66 87 ≥1 ADL, IADL, MMSE, GDS-30, MNA, CIRS-G, 
TUG, and MOS-SSS
Smets, 201458 398 76 73 ≥1 ADL (Barthel), IADL, MMSE, GDS-15, food 
intake, weight loss, and medication
Hamaker, 201464 73 69 76 ≥1 IADL, MMSE, GDS-15, BMI, CCI, and poly-
pharmacy
Kenig, 201553 135 64 86 ≥2 ADL, IADL,BOMC, GDS, MNA, CCI, TUG, 
and CDT
van Loon, 201761 123 74 52 ≥2 ADL, IADL, MMSE, GDS, MNA, CIRS-G, 
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* ≥1 missing was also scored as abnormal CGA
ADL, Activities of Daily Living; BMI, Body Mass Index; BOMC, Blessed Orientation-Memory-Concentration; CCI, 
Charlson Comorbidity Index; CDT, Clock Drawing Test; CES-D, Center for Epidemiologic Studies Depression Scale; 
CGA, comprehensive geriatric assessment; CIRS-G, Cumulative Illness Rating Scale for Geriatrics; CLOX, Clock 
Draw Test; ECOG PS, Eastern Cooperative Oncology Group Performance Scale; ECR, Enhanced Cued Recall; 
F-Sozu, Fragebogen zur Erfassung der sozialen Unterstützung; G8, Geriatric-8; GDS, Geriatric Depression Scale 
(followed by the number of items); GFI, Groningen Frailty Index; GUG, Get Up and Go; HADS, Hospital Anxi-
ety and Depression Scale; HCT-CI, Hematopoietic and Cellular Therapy-Comorbidity Index; IADL, Instrumental 
Activities of Daily Living; mG8, modified Geriatric-8; Mini-GDS, Mini Geriatric Depression Scale; MMSE, Mini-Mental 
Status Exam; MNA, Mini Nutritional Assessment; Mob-T, Mobility-tiredness scale; MOS, Medical Outcomes 
Survey; MOS-SSS, Medical Outcomes Study Social Support Scale; NCCN, National Comprehensive Cancer Net-
work; NR, not reported; SAOP2, Senior Adult Oncology Program 2; SPPB, Short Physical Performance Battery; 
TUG, Timed Up and Go test; TMTA, Trail Making Test A; TMTB, Trail Making Test B; WHOQOL, World Health 













































31 100 40 NR ADL, IADL, MMS, GDS, CES-D, MNA, 
CIRS-G, self-rated health, ECOG PS
Russo, 201811 282 94 50 ≥3 ADL (Barthel), IADL, MMSE, GDS-15, MNA, 
CIRS-G, TUG, CDT, Tinetti Scale, Gijon 
Scale and risk of falls
SAOP2
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Chapter 3.3
Dear editor, Properly balancing the risk for both under- and overtreatment in older adults 
with basal cell carcinoma (BCC) frequently proves challenging.1,2 As BCCs are slowly growing 
tumors and initially asymptomatic, frail older adults with limited life expectancy (LLE) might 
frequently be overtreated,2 leading to an unnecessary and avoidable treatment burden,3 while 
little or no improvement in quality of life is achieved. To improve patient-centered care for 
older BCC patients, it was hypothesized that a more holistic approach, with specific attention 
for patient-related factors and treatment goals, might lead to different BCC management 
choices better aligning with patient preferences and an improved under- and overtreatment 
balance. 
    A prospective pilot study was conducted in the Radboud University Medical Center, 
evaluating BCC management in a specialized outpatient clinic for (frail) older adults. 
General practitioners and dermatologists were stimulated to refer older adults in case of 
dilemmas regarding optimal BCC management (e.g. frail patients with LLE). Longer timeslots 
were available per patient to provide more time for evaluation of patient-related factors 
as frailty (including the Geriatric-8 (G8) frailty screening tool),4,5 treatment goals, and a 
multidisciplinary approach (e.g. with radiotherapists, plastic surgeons, primary care 
physicians or nursing home specialists). A standardized shared decision-making (SDM) 
model was used,6 in which physicians and patients shared their views on both medical and 
personal preferences. All possible BCC management options were discussed, including the 
risks (e.g. complications, recurrence risk, treatment burden)3 and benefits (e.g. prevention 
of progression, symptom relief). Both active BCC therapies (including adapted management 
regimes deviating from current guidelines) and watchful waiting (WW; no active BCC 
treatment) were discussed.2 BCC management decisions were made by patients and 
proxies after careful consideration of potential risks and benefits. Follow-up after BCC 
management was carried out at least once, if feasible for patients and peers. The outcomes 
were compared with the expected regular practice management (ERPM) for each BCC, 
according to current guideline recommendations. Statistical analyses were performed to 
compare groups using Mann-Whitney U-tests or Chi-square tests. Missing values were 
excluded from analyses.
     Between January 2018 and December 2018, 85 patients with (the suspicion of) one or 
more BCCs were seen with a mean age of 86.4±5.8 years. After initial consultation, 59 (69.4%) 
patients, 26 (44.1%) men and 33 (55.9%) women, were diagnosed with 125 BCCs in total (116 
histologically confirmed). Twenty-three (41.8%) patients had asymptomatic BCCs. 
Forty-eight  (87.3%) patients were classified as (potentially) frail (G8≤14). Treatment goals 
other than curation were mentioned by 37 (62.7%) patients. In 24 (40.7%) patients with 58 
(46.4%) BCCs, BCC management differed from ERPM (e.g. WW instead of surgery); in 21 
(43.8%) frail patients and 2 (28.6%) robust patients (p=0.686); 1 missing. During a median 
follow-up of 29.5 months (interquartile range 11-33.5), the ERPM was initiated after all 
for 16 (27.6%) BCCs (Figure 1). Overall, in 19 (32.2%) patients with 37 (29.6%) BCCs it was 
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estimated that less hospital visits were needed than after ERPM. Most commonly, this 
was due to treatment during the initial consultation, a shortened treatment schedule, and 
multidisciplinary consultations during one hospital visit. In 8 (13.6%) patients with 29 (23.2%) 
BCCs it was estimated that more hospital visits were needed than after ERPM. During 
follow-up, 21 (35.6%) patients died (after 14.1±9.2 months, none BCC-related), 10 (47.6%) 
after BCC management different from ERPM.
 These experiences indicate that adapted management regimes after 
thorough SDM, can be less burdensome and more appropriate care for a substantial 
proportion of frail BCC patients. Our experiences are in line with those seen in 
other medical fields, where geriatric assessments led to changes in treatment 
(e.g. less intensive) in more than a third of geriatric patients.7 As individual treatment goals 
other than curation were highly relevant among frail older adults, considering all 
management options is advised, which might include deviation from clinical guidelines. 
A decision aid can be considered to ensure feasibility in daily care.8 Incorporation of 
integrated, holistic care is not always easy in busy daily practice; although the use of 
predictive instruments (e.g. the G8 or other frailty screening tools)5 might assist in 
identifying patients in need of multidisciplinary approaches and/or more extensive 
counseling before, during and/or after BCC management. As the population described 
here is relatively small, more research on these tools and the clinical consequences (e.g. 
mortality or complications) is needed. In case of higher mortality rates, the time-to- 
benefit from BCC treatment might exceed life expectancy, and frail patients might 
consequently benefit more from WW or symptomatic treatment. However, medical 
decision-making based solely on age should be avoided, as the heterogeneity in functional 
status, resilience, and frailty underscores the need for an individualized approach.
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Few studies have examined watchful waiting (WW) in patients with basal cell carcinoma (BCC), 
although this approach might be suitable in patients who might not live long enough to benefit 
from treatment.
Objective 
To evaluate reasons for WW, the natural course of basal cell carcinoma in patients who chose 
WW, and reasons to initiate treatment in a later stadium (if applicable).
Methods
A prospective observational cohort study was carried out between January 2018 and Novem-
ber 2020 studying patients with ≥1 untreated BCC for ≥3 months. WW was chosen by patients 
and proxies regardless of this study. The reasons for WW and treatment were extracted from 
patient files and were categorized for analyses. Linear mixed models were used to estimate 
tumor growth and identify covariates associated with tumor growth. 
Results
WW was chosen for 280 BCCs in 89 patients, with a median follow-up of 9 (4-15) months. 
The median age of the included patients was 83 (IQR 73-88) years. Most commonly, WW 
was chosen because of patient-related factors or preferences (74; 37.2%, i.e. prioritizations of 
comorbidities, severe frailty or limited life expectancy), or tumor-related factors (n=49; 
24.6%). Treatment-related and circumstantial reasons accounted for 15.6% and 20.6% of re-
ported reasons, respectively. The minority of tumors increased in size (46.8%). Tumor 
growth was associated with BCC subtype (OR 3.35; 95%CI 1.47…7.96, p=0.005), but not 
with initial tumor size and location. The estimated tumor diameter increase was 4.46mm 
(80% prediction-interval 1.42…7.46mm) in one year for BCCs containing at least an infiltrative/ 
micronodular component and 1.06mm (-1.79…4.28mm) for the remaining BCCs (only 
nodular/superficial component/clinical diagnosis). Most common reasons to initiate 
treatment (n=107 BCCs; 38.2%) were (potential) tumor burden (40.6%), resolved- 
(circumstantial) reason(s) for WW (23.8%), followed by re-evaluation of patient-related factors 
(18.8%).
Conclusions and Relevance
WW might be an appropriate (temporary) approach in some patients with BCC, especially those 
with asymptomatic nodular/superficial BCCs and a limited life expectancy. However, patients 
should be followed-up regularly to determine whether a WW approach is still suitable, whether 
patients still prefer WW and to reconsider consequences of (refraining from) treatment.
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Introduction
Basal cell carcinoma (BCC) is the most common type of skin cancer, and is generally 
characterized by a relatively indolent nature.1 Although BCCs are often initially 
asymptomatic, long-term morbidity can be substantial because of local tissue invasion 
and destruction.2 Preventing both under- and overtreatment can be a clinical challenge, 
especially in patients with a limited life expectancy (LLE). Since patients with LLE might not 
live long enough to develop bothersome symptoms from a BCC, the lag time until benefit from 
BCC treatment is achieved (time-to-benefit) might exceed life expectancy.3 
    Therefore, patients with LLE and asymptomatic BCCs might benefit more from a watchful 
waiting approach than active treatment. Watchful waiting (WW) entails the monitoring of the 
natural course of a disease without actively treating it. The main short-term advantage of WW 
is the avoidance of treatment-related risks and treatment burden. However, the risk of WW 
is further growth of the tumor, which could cause (more) tumor-related complaints and/or 
complicate treatment options (e.g. more invasive therapies needed). In several other 
medical fields, WW and active surveillance (AS; watchful waiting accompanied with more 
invasive manners of follow-up, such as additional biopsies) have been accepted treatment 
options in patients with LLE with nonlethal and asymptomatic conditions.4-7
     However, since limited data is available on the natural course of BCCs and the consequences 
of refraining from BCC treatment,2,8,9 it is difficult to properly inform patients on the expected 
tumor growth, progression and the chance of developing symptoms during a WW approach. 
Therefore, this study endeavors to provide more insight in the reasoning and clinical outcomes 
of a WW approach.
Methods
Study design and participants
A monocentric observational cohort study was conducted at the outpatient department of 
Dermatology, Radboud University Medical Centre between January 2018 and November 2020. 
All physicians and physician assistants were requested to prospectively enroll patients with 
BCC who chose a watchful waiting (WW) approach after thorough consideration, regardless of 
localization or subtype. Patients were also included in case a WW approach was carried out 
before the start of the study, in which case a chart review was performed to collect additional 
data retrospectively. BCCs that were incompletely excised, for which WW was chosen directly 
after excision, were excluded. WW was defined as no active BCC treatment for at least three 
months after initial presentation, including patients who refused treatment although it was 
advised by treating physicians. The decision for WW was made after a regular (multidis-
ciplinary) shared decision-making process between the treating physicians, patients and 
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proxies, and the decision was made regardless of this study. All patients and proxies were 
informed on the possible tumor progression and therapeutic implications as a consequence of a 
WW approach. Patients who chose WW, were advised to remain under observation every 3-6 
months. At each visit the shared decision-making process was repeated, with explanation of 
diagnosis, prognosis and therapeutic options, with (potential) tumor and symptom pro-
gression taken into consideration. The Medical Ethical Committee of the Radboud 
University Medical Center waived the need for written informed consent according to 
Dutch legislation. All patients in the included pictures (or legal representatives) provided 
written informed consent. This study was reported according to the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) criteria.10
Outcome measures
The main study outcome were patients’ reasons for WW (as reported in patient 
files) and the proportion and reasons to initiate treatment later on (if applicable). 
Reasons were categorized into the following categories: patient-related factors or 
preferences(e.g. prioritizations of comorbidities, severe frailty or LLE), tumor- 
related factors (e.g. asymptomatic tumors), treatment-related factors (e.g. the expected treatment 
burden), and circumstantial reasons. Secondary objectives were to evaluate the 
natural course of BCCs, including tumor growth and tumor symptoms, and whether 
or not treatment was initiated at a later time point. Interrater agreement (intraclass 
correlation; ICC) on tumor measurements was evaluated in a separate pilot study 
including 40 BCCs assessed by two different observers; the agreement and corresponding 
95% confidence intervals (95%CI) were computed using a two-way randomeffect model with 
consistency.
Data collection
Electronic patient charts were reviewed retrospectively to systematically obtain patient and 
tumor characteristics (e.g. tumor diameter per visit, tumor complaints and other variables 
mentioned in Table 1). All follow-up variables were collected in regular daily practice. Reasons 
for WW and the reasons for treatment initiation after a period of WW (if applicable) were 
extracted from electronic patient charts and/or verified by the treating physician.
Statistical analyses
Statistical analysis was conducted using Statistical Package for Social Sciences (SPPS) Statistics 
for Windows (version 25.0; IBM, Armonk, NY, U.S.A.) and R (version 3.6.3). Continuous data were 
presented as mean ±SD or median (interquartile range, IQR), for normally or non-normally 
distributed data, respectively. Frequencies and percentages were used to summarize 
categorical data. Tumors were defined as “growing” when the difference in tumor size 
between initial tumor diameter and final tumor diameter (≥3 months later) was at least 1mm. 
205
Watchful waiting in patients with basal cell carcinoma
3.4
A sensitivity analysis was performed with tumor growth defined as >2mm and assessed 
the effects on outcome measures. Missing values were excluded from analyses. Univariate 
analysis were performed using the chi-square or Fisher’s exact test. Mixed-model logistic 
regression analyses were used to determine odds ratios (ORs) and 95%CI for covariates 
regarding occurrence of tumor growth. Linear mixed models were used to determine 
tumor growth (in mm), accounting for potential correlations with tumor subtype, initial tumor 
diameter and tumor location. These models were used to calculate 80% prediction intervals for 
tumor growth, which is the range for the growth of a certain type of tumor in which 80% of the 
cases will be.
Results
After extensive consultation, including explanation of the potential consequences of a pos-
sible WW approach, WW was chosen for a cumulative number of 280 BCCs in 89 patients 
(Table 1). In 47 (52.8%) patients, a WW approach was chosen for more than one BCC and in 19 
(21.3%) patients for more than three BCCs. The median age of the included patients was 83 
(IQR 73-88) years and 47 (52.8%) were male. One patient with Gorlin syndrome was included. 
Of all BCCs, 234 (83.6%) were histologically confirmed BCCs, and 144 (51.4%) were located in 
the head-and-neck area. The median follow-up duration of all tumors was 9 months, with a 
maximum of 78 months. A flow-chart of the study design is shown in Figure S1. 
An ICC of 0.975 (0.953-0.987, p<0.001) was seen in the pilot study on tumor measurements, 
indicating high inter-observer agreement. 
Patients’ reasons for watchful waiting
Overall, WW was mainly chosen because of patient-related factors or preferences (n=74; 
37.2%), for example prioritizations of comorbidities, severe frailty or LLE (Figure 1). 
Tumor-related factors, such as absence of symptoms and the indolent nature of BCCs, 
accounted for 24.6% (n=49) of the reasons mentioned. Treatment-related factors, such 
as the expected treatment burden, accounted for 15.6% (n=31), and circumstantial 
reasons (e.g. planning or transportation difficulties) for 20.6% (n=41). Lastly, insufficient 
understanding or processing of the information on BCC accounted for 2.0% (n=4) of the reasons 
mentioned. Of the 28 patients who chose WW because of LLE, 8 (28.6%) patients died of non-
BCC related causes, compared with 9 (14.8%) patients with other reasons than LLE (p=0.124). 
In 59 (66.3%) patients, multiple reasons for WW were noted in electronic patient charts 
(e.g. LLE and asymptomatic).
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Values might not add up due to rounding and multiple reasons mentioned by one patient; in 59 (66.3%) patients, 
multiple reasons for WW (e.g. both LLE and asymptomatic), were noted in electronic patient charts; all reasons 
that were mentioned are included in this donut graph. 
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Table 1. Patient-, tumor and follow-up characteristics of the included patients and basal 
cell carcinomas for which a watchful waiting approach was chosen.
Patient characteristics
    Age# (years), 
       Median (IQR)
       Mean ± SD
83 (73-88)
79.5 ± 12.3
    Sex, n (%)
       Male
       Female
47 (52.8)
42 (47.2)
    History of KC, n (%)
       Number of previous KC, median (IQR)
       Previously treated with CE
       Previously treated with MMS






    CCIa, median (IQR) 2 (0-4)
    Polypharmacyb, n (%) 49 (55.1)
    Mentally competent, n (%) 78 (87.6)
    Travel distance (km),
       Median (IQR) 8 (4.5-17.5)
Tumor characteristics
    Number of BCCs for which WW approach was initiated per patient,
       Median (IQR)
       Mean ± SD
2 (1-3)
3.17 ± 4.0
    Previous treatment, n (%)
       Primary tumor
       Recurrent/residual tumor
267 (95.4)
11 (3.9)
    Tumor location, n (%)
    Head-and-neck area
       Forehead
       Peri-ocular
       Cheek
       Nose
       Peri-oral
       Chin
       Ear
       Neck
       Scalp
    Trunk
    Upper extremities














    Biopsy-proven BCCs, n (%)
       Low-risk (nodular and/or superficial subtype)c










    Follow-up duration (months), 
       Median (IQR) 9 (4-15)
    Number of observations per BCC,
       Median (IQR) 2 (1-3)
    Died within follow-up time, n (%) 17 (19.1) 
NB numbers might not add up due to missings. 
# At time of diagnosis
a The CCI is a weighted comorbidity index associated with mortality.3,8,26,27
b Polypharmacy is a frailty-related aspect frequently associated with decreased life expectancy. Polypharmacy 
   entails the chronic use of ≥5 medications.28,29
c
  Containing nodular and/or superficial component only. 
d  Containing at least a micronodular or infiltrative component.
BCC, basal cell carcinoma; CCI, Charlson Comorbidity Index; CE, conventional excision; MMS, Mohs micrographic 
surgery; IQR, interquartile range; KC, keratinocyte cancer; RT, radiotherapy; SD, standard deviation; WW, watchful 
waiting. 
Natural course of BCCs
Tumor growth
During follow-up, 317 (65.8%) measurements were done by two observers per visit and 
142 (29.5%) by one observer. In 7 BCCs, no residual tumor was seen after initial diagnostic 
punch biopsy was taken. As is shown in Table S1, most of these tumors were 5mm or smaller, 
although also one micronodular BCC of 25mm located on the lower back regressed after 
biopsy. Examples of the natural course are shown in Figure 2.
   In 124 (68.8%) BCCs at least two tumor diameter measurements were suitable for 
analyses. Whereas 58 (46.8%) BCCs showed tumor size increase, 66 (53.2%) BCCs did not 
show tumor growth over time (including 2 and 8 clinically diagnosed BCCs without histologic 
confirmation, respectively). Of the latter, 21 (31.8%) even showed a decrease in tumor diameter 
(including 3 clinically diagnosed BCCs). Significantly more low-risk BCCs (nodular/superficial/
clinical BCCs) showed a stable or decreasing tumor diameter compared with high-risk BCCs 
(infiltrative/micronodular) in univariate analyses (61.9% vs. 35.0%, p=0.006). Moreover, 78.6% of 
low-risk BCCs showed a maximum tumor growth of 2mm, vs. 45.0% of high-risk BCCs (p<0.001). 
Furthermore, a significant association was seen between tumor growth (>1mm) and 
high-risk BCC subtype in multivariable analysis (OR 3.35; 1.47…7.96, p=0.005). Results were 
robust when sensitivity analysis was performed defining tumor growth as >2mm (n=40), 
whereas the predictive capability of the model increased (Table S2). Tumor size and tumor 
location were not associated with tumor growth (Table 2).
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   In the 58 (46.8%) BCCs that showed tumor growth >1mm, only BCC subtype affected 
tumor growth. The estimated tumor diameter growth was 4.46mm (80% prediction- 
interval 1.42…7.46) in one year for high-risk BCCs and 1.06mm (80% prediction interval 
-1.79…4.28) for low-risk BCCs.
BCC-related symptoms
As expected, the majority of BCCs (81; 60.9%) were reported to be asymptoma- 
tic at initial presentation, although the absence or presence of symptoms was frequently 
underreported. The most frequently reported complaints from the remaining 
tumors were bleeding (n=19; 23.8%), itch (n=13; 16.3%) and/or crustae (n=12; 23.1%). 
For 11 (8.0%) BCCs, patients developed (additional) symptoms (e.g. bleeding) during 
a median follow-up time of 18 (9-25) months. It should be noted that not all 
patients were bothered by these symptoms (e.g. experiencing bleeding without being bothered 
by it).
Treatment after watchful waiting
After an initial WW approach, 107 (38.2%) BCCs in 54 (62.8%) patients were treated 
later on. Three (3.4%) patients were loss to follow-up. The median time until treatment was 
7 months (5-11 months) and conventional excision was most frequently initiated 
(n=81, 73.6%; Figure S1). Most common reasons to initiate treatment after WW were 
(potential) tumor burden (n=65; 40.6%), resolved (circumstantial) reason(s) for WW 
(n=38; 23.8%), followed by re-evaluation of patient-related factors (n=30; 18.8%) and 
expected treatment burden in case of tumor growth (n=27; 16.9%). In three (2.8%) 
BCCs a more invasive intervention (e.g. reconstructive surgery instead of expected primary 
closure) was needed than the estimated intervention at initial presentation. In total, 
eight surgically treated tumors initially classified as low-risk histologic subtypes 
were discordant with the initial biopsy histology (e.g. mixed nodular/infiltrative subtype 
instead of nodular subtype only). In two tumors subsequent histopathology turned 
out to be squamous cell carcinoma instead of basal cell carcinoma (Figure 2).
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Figure 2. Examples of natural basal cell carcinoma behavior over time
Time frame as indicated in the pictures represents the total time elapsed since the initial diagnosis in months. 
a. 31 months follow-up of a biopsy-proven nodular basaalcelcarcinoom (BCC) on the nose; a more evident clinical 
 picture is seen over time.
b.21 month follow-up of a biopsy-proven nodular and superficial BCC in the neck; a more evident clinical picture 
 is seen over time.
c. 11 months follow-up of a biopsy-proven infiltrative BCC of the upper lip, rapidly progressing. Additional 
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d.40 months follow-up of a biopsy-proven nodular BCC retro-auricular. Histopathology after radical resection 
 of the tumor showed both nodular and infiltrative BCC. 
e. 13 months follow-up of a biopsy-proven nodular BCC of the scalp (frontotemporal), rapidly progressing. 










Table 2. Results of mixed-model logistic regression analyses of the potentially relevant 
covariates associated with basal cell carcinoma (BCC) growth (>1mm) vs. stable/ 
decreasing BCC diameter (≤1mm).
OR 95%CI p-value
Tumor location
    Head-and-neck areaa 0.93 0.42…2.13
0.862
BCC subtype
   Infiltrative/micronodularb 3.35 1.47…7.96
0.005
Initial tumor diameterc 0.96 0.89…1.03 0.255
Tumors that regressed after biopsy was taken are not included in these analyses and are described in Table S1. 
Tumor growth was defined as an increase in tumor diameter of >1mm (n=58). In this analysis, BCCs that showed 
1mm increase in tumor diameter were considered stable, as this difference could be due to measurement errors.
 
a Reference status: tumor located outside of the head-and-neck area 
b Tumor subtype consisting of at least micronodular and/or infiltrative subtype. References status: nodular and/or 
  superficial subtype only, or clinical BCC diagnosis (histologic subtype not determined). 
c
 Continuous variable, in mm. When tumor diameter was categorized (<10mm and ≥10mm), no meaningful 
   difference in the model were seen.
OR, odds ratio; 95%CI, 95% confidence interval.
Discussion
Although considerable research has been performed in dermato-oncology, it remains difficult 
to estimate the time-to-benefit from BCC treatment.11 Active treatment of BCCs is indicated 
in case the time-to-benefit is estimated to be shorter than the residual life expectancy 
(Figure S2), whereas (temporarily) refraining from treatment could be in the best interest of 
patients with a limited life expectancy (LLE) or specific reasons outweighing the benefit of 
early treatment.2 In this study, patient-related factors and/or preferences were most 
commonly reported as reasons for WW. In case treatment was performed later on (38.2%), 
more invasive treatment (e.g. reconstruction instead of expected primary closure when treated 
at first presentation or MMS instead of CE) was needed in only 2.8%. 
     Whereas LLE, frailty and patient preferences were considered important factors for patients 
choosing WW, in line with a previous study,12 integration of these items in clinical guidelines 
remains limited.2,13 These aspects can be difficult to estimate in daily dermatology practice, 
which is underscored by the substantial proportion of treatment initiation after re-evaluation 
of patient-related characteristics. It could be useful to learn from geriatric care and geriatric 
assessments to evaluate LLE and frailty. Frailty is defined as a state of vulnerability and physical 
deterioration, leading to disproportionally decreased ability to cope with stressors.14 In several 
medical fields, frailty has been associated with increased mortality.15 Although research on 
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frailty and frailty-related patient characteristics in dermatology is sparse, results appear to be in 
accordance with those found in other medical fields (e.g. associated with LLE).3,8,11,17-19 However, 
the definition of LLE and the natural tumor behavior naturally influence the time-to-benefit. 
For instance, if the time to develop BCC-related complaints in an individual patient is 
hypothetically 2 years, this patient probably still benefits from treatment if his life expectancy 
is estimated at 5 years. Therefore, future studies are highly needed to define relevant LLE and 
patient characteristics predictive of LLE in dermato-oncology.16,20,21 As it currently remains 
challenging to predict life expectancy in individual patients, a multidisciplinary 
approach involving other specialists or the general practitioner could aid in decision- 
making. In patients with a LLE and asymptomatic low-risk tumors, the time-to-benefit from 
treatment might exceed life expectancy and WW should be discussed as a potentially appropriate 
approach (Figure 3).
   Moreover, in case of personal preferences or circumstances, a WW approach can 
(temporarily) be initiated, as long as follow-up (e.g. every 3-6 months) and observation is 
maintained. At each follow-up visit management options should be reconsidered, 
including whether or not WW remains medically justified or the risk-to-benefit ratio has 
changed over time. Naturally, the frequency of hospital visits should be adjusted to what is 
feasible for individual patients (i.e. should not be more burdensome than the treatment 
burden associated with active treatment). The rationale for follow-up is to gain insight on the 
tumor behavior in every individual patient, either strengthening previously made decisions, 
or strengthening the advice for initiating curative BCC treatment. Remarkably, this study 
showed that a majority of tumors (53.2%) remained stable in diameter over time or even 
decreased in size. The results should be interpreted with caution; contraction of the tumor 
may have occurred after initial biopsy, and tumor behavior, patient characteristics, 
follow-up duration/frequency varied widely among the included patients. However, the 
results are comparable with those found by Wehner et al., who described that only 
48.7% of 39 clinical BCCs showed tumor growth during a mean follow-up of 15.8 months.22 
In our study, 46.8% of BCCs increased in size, estimated at 4.46mm in one year for 
infiltrative/micronodular and 1.06mm for remaining BCCs. The broad prediction intervals 
found in our study accentuate the heterogeneity regarding natural tumor behavior and 
the need for follow-up visits to evaluate tumor progression. Nonetheless, these results 
raise the question of whether or not nodular and superficial BCCs might be overtreated 
in current clinical care, as the vast majority (61.9% and 78.6%) of these tumors did not 
increase more than 1mm or 2mm, respectively.
     Naturally, we do not advocate a WW approach in each individual patient; the decision 
 for WW should be considered very carefully. It should be noted that several of the 
included patients have been advised not to proceed with WW, but refused treatment. 
This might be an explanation for the relatively high proportion of patients with BCCs 
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significant association between tumor growth with known risk factors as tumor 
location and tumor size, although this could be due to a lack of power. Therefore, 
more research is highly needed to provide evidence-based guidance on the 
expected natural tumor behavior, prognostic factors on both tumor growth and 
patient prognosis, and to aid in identification of those tumors that might show (rapid) 
tumor growth and lead to substantial patient burden. Expected treatment burden was 
mentioned as a reasons for WW in a substantial part of the included patients, although 
previous studies have shown that older adults mostly tolerate BCC treatment well.11 
Physicians should therefore be aware of information framing; the fact that patients heavily 
rely on the way information is formulated.23 However, the option of WW should be discussed 
and considered, as the relatively large population included in this observational study 
accentuates that not all patients prefer to be actively treated (at first). The use of decision 
aids might lead to more personalized medical care without sacrificing feasibility in daily 
clinical care.24,25
     A cautious approach should be maintained in tumors developing unexpectedly. In line 
with previous research,1 this study showed a discrepancy between initial biopsy histology and 
eventual histology after excision in several tumors. Mostly, another histological subtype of BCC 
was found (e.g. mixed nodular/infiltrative subtype after excision vs. nodular subtype only at 
biopsy), but also two squamous cell carcinomas (SCC) were seen. It is unclear whether or 
not the discrepancies found in this study can be attributed to biopsy sampling errors (e.g. 
basosquamous component not seen in the small biopsy sample) or development of more 
aggressive types of skin cancers (e.g. SCC arising in long-existing ulcers). Re-evaluation of 
the tumor behavior should occur at each follow-up visit to determine whether the original 
diagnosis appears correct or additional biopsies are in place; in case of unusual clinical behavior.
   Certain limitations should be addressed. A selection bias might exist due to the 
preselection of patients who visit a university hospital and patients generally fit enough to be 
referred by general practitioners. Furthermore, the limitations of a clinical observation should 
be taken into consideration; although the pilot study on tumor measurements showed excellent 
interobserver agreement, individual tumor measurements can vary (e.g. when tumors were 
poorly defined), and only tumor diameter was included in analyses (i.e. degree of infiltration 
was not included in analyses). Also, in this study real-world data was evaluated, leading to 
relatively limited follow-up duration, and reasons for WW, treatment and tumor-related symp-
toms were extracted from patient files retrospectively, which might have been underreported. 
Nonetheless, this is one of the first studies to evaluate a WW approach in a large number of 




This study showed that WW might be an appropriate (temporary) approach in patients with 
BCC, especially in case of a limited life expectancy and asymptomatic nodular/superficial BCCs. 
However, all patients should be followed-up regularly to determine whether a WW approach 
is still suited, if patients still prefer WW and to reconsider the consequences of (refraining 
from) treatment. Patient preferences, treatment goals and the option for proceeding with a 
WW approach should be discussed as part of personalized shared decision-making. As data 
on WW and the natural course of BCCs is extremely sparse, additional prospective studies and 
real-world evidence are needed to further develop evidence-based guidance in this growing 
patient group. 
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Figure S1. Flow-chart of medical decision-making in the 280 included basal cell carcinoma 
for which watchful waiting was chosen.
All numbers represent the BCCs (unless stated otherwise) for which WW was still maintained at the time point 
mentioned on the left side.
 
a One patient had 10 BCCs for which WW was chosen, he died before 2 tumors could reach 6 months of WW, and 
  before 8 tumors could reach 12 month WW follow-up, and is therefore mentioned twice. Three other patients 
  died after being treated.
* For these patients, WW was continued but patients did not yet reach the next time point during the study period 
  (until November 2020).
BCC, basal cell carcinoma; CE, conventional excision, LFU: lost to follow-up, e.g. in case 
patients refrained from follow-up visits, or were followed-up in another treatment center; MMS, Mohs 

































diagnosis (mm) Tumor subtype
FU time 
(months)
1 85 M Abdomen 5 Nodular 26
2 84 F Forehead 4 Nodular 63
3 79 M Cheek 5 Nodular 78
4 83 F Nose 3 Nodular 11
5 88 M Back 25 Micronodular 22
6 91 F Neck missing Superficial 33
7 85 M Nose 5 Micronodular 73
FU, follow-up
Table S2. Sensitivity analysis using mixed-model logistic regression analyses of the poten-
tially relevant covariates associated with basal cell carcinoma (BCC) growth (defined as an 
increase >2mm) vs. stable/decreasing BCC diameter (increase ≤2mm).
OR 95%CI        p-value
Tumor location
   Head-and-neck areaa 0.65 0.25…1.63  0.357
BCC subtype  
   Infiltrative/micronodularb 5.91 2.40…16.74 <0.001
Initial tumor diameterc 0.95 0.87…1.02  0.178
Tumors that regressed after biopsy was taken are not included in these analyses and are described in Table S1. 
Tumor growth was defined as an increase in tumor diameter of >2mm (n=40). BCCs that showed a maximum of 
2mm increase in tumor diameter were considered stable, as this difference could be due to measurement errors. 
a Reference status: tumor located outside of the head-and-neck area 
b Tumor subtype consisting of at least micronodular and/or infiltrative subtype. References status: nodular and/or 
 superficial subtype only, or clinical BCC diagnosis (histologic subtype not determined)
c Continuous variable, in mm.
OR, odds ratio; 95%CI, 95% confidence interval.
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Time-to-benefit can be defined as the period between an intervention (e.g. surgical excision) and the moment 
when a significant improvement in health outcome(s) becomes evident (e.g. curing symptoms). In the example 
illustrated here basal cell carcinoma patients with a residual life expectancy that exceeds the green dashed line 
are likely to benefit from treatment (treatment will most likely do more good than harm), those with a residual 
life expectancy less than the green dashed line will benefit more from watchful waiting, since treatment burden 
remains higher than tumor burden with its own natural course. 
*Naturally, in individual patients the intervention-curve and tumor-curve could be more close to each other, or on 
 different time points. 















(Potential) advantages, e.g.: 
- Cure, improve or prevent symptoms 
- Improve quality of life 
 
(Potential) disadvantages, e.g.: 
- Complications  
- Treatment burden  
Time to benefit*
treatment burden = tumor burden
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Summary, Discussion and Future Perspectives
The rapidly growing population of older adults requires specific attention in daily healthcare, as 
this population is highly heterogeneous with regard to patient-related characteristics as frailty, 
comorbidities, ageing-related organ impairment and functional capabilities.1 This thesis aimed 
to provide guidance for patient-centered geriatric dermatology care and to improve shared 
decision-making by striving for optimal risk-to-benefit ratio. Two common disease entities 
were studied; the common inflammatory disease psoriasis, and the most common type of skin 
cancer, basal cell carcinoma.
4.1 Psoriasis management in older adults
4.1.1 Summary on geriatric psoriasis management
In chapter 2.1, we present a systematic review on the representation of older adults in ran-
domized controlled trials (RCTs) studying systemic antipsoriatic therapies. Many older adults 
were excluded from RCTs, whereas these studies frequently provide the primary source of data 
for clinical guidelines. Not only were older adults excluded based on age alone in 33.3% of the 
162 RCTs studied, but an additional 90.6% of the remaining RCTs maintained exclusion criteria 
indirectly affecting the geriatric population, e.g. by excluding patients who had concurrent 
medical illnesses. It is therefore questionable to what extent the data from RCTs are applicable 
to older adults in daily clinical care.2,3
        Due to a disproportional exclusion of various patient populations in clinical trials, real-world 
data gained increasing importance in medical care. The available evidence on effectiveness 
and safety of systemic antipsoriatic therapies is described in a review in chapter 2.2. Overall, 
limited data were available. The effectiveness of most systemic antipsoriatic therapies appeared 
not to be influenced by age. On the other hand, advanced age was associated with an increased 
adverse event rate in cyclosporin users; renal function impairment in particular. Infections were 
common among older biologic users, although no association with advanced age was found. 
Based on this systematic review, age as a chronological number should not be considered as 
a limiting factor in psoriasis management. Naturally, certain comorbidities can be a contra- 
indication to the use of systemic antipsoriatic therapies and awareness of comorbidities and 
possible interactions with concomitant medication use is highly important. However, the 
reluctance to prescribe systemic therapies to older psoriasis patients based on age alone 
cannot be justified by the evidence found in this thesis, and can possibly even lead to 
undertreatment and a subsequent diminished quality of life in this population.
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       It should be noted that most adverse events described in chapter 2.2 were reversible upon 
cessation of the antipsoriatic agent. Remarkably, in the nationwide survey study described in 
chapter 2.3, 414 older adults (≥65 years) reported less side-effects from their antipsoriatic 
treatment than the 536 patients <65 years. However, a limitation of this self-assessment 
survey is that patients probably did not report laboratory abnormalities, and reasons for 
ceasing previous therapies were not evaluated. Therefore, additional research is 
recommended to systematically observe adverse events in large populations of older adults 
using antipsoriatic therapies. In this study, significantly more comorbidities, comedication 
use and functional dependency on both medical caretakers or family members were reported 
by patients ≥65yo. Still, no significant differences were seen between the age groups 
regarding the use of several systemic antipsoriatic systemic therapies (38.3% in ≥65 years 
vs. 42.3% in <65 years; p=0.219). Moreover, as disease characteristics and severity were 
comparable between patients ≥65 and patients <65yo, the indication for systemic therapy 
regularly existed in the older adults included in this study.
     As the array of therapeutic options is rapidly expanding, it is crucial to identify unmet needs 
in the frequently vulnerable population of older adults. The second part of the survey study 
conducted among all members of the Dutch psoriasis association is presented in chapter 2.4. 
Older adults mentioned different treatment preferences than patients <65 years. Most 
importantly, older adults valued the reduction of medication use and hospital visits as 
significantly more important than patients <65 years old, but overall treatment goals (e.g. to be 
free of pruritus, scaling and visible lesions) were highly comparable between older adults and 
younger patients. Moreover, treatment satisfaction and disease burden were highly comparable 
between the age groups, although heterogeneous outcomes were seen among individual 
respondents. This too, accentuates the need for individualized evaluation of treatment goals, 
patient preferences and disease and treatment burden.
   The use of the DLQI-R, an alternative scoring system for the validated and frequently 
used quality of life assessment DLQI (Dermatology Life Quality Index) tool, can further aid in 
individualized medical care, as this scoring system more accurately reflected the true 
QoL-impact in older adults compared to the original DLQI scoring system. At least one not 
relevant response was reported by 238 (60.7%) patients aged ≥65 years vs. 161 (31.3%) patients 
aged <65 years (p<0.001), responses that are scored as "0" in the original DLQI, equivalent to 
not at all. This led to a lower overall DLQI score in patients aged ≥65 years vs. patients aged 
<65 years, although the DLQI-R score did not significantly differ between the groups. To reduce 
the chance of suboptimal QoL-assessment, it is therefore recommended to use the DLQI-R 




4.1.2 Discussion and Future Perspectives on Geriatric Psoriasis Management
Overall, the studies described in this thesis have shown that the geriatric psoriasis population 
(≥65 years) is distinct from patients <65 years by means of comorbidities, comedication, 
functional dependency, but also regarding treatment preferences (chapter 2.3 and 2.4). 
Shared decision-making is the key in achieving optimal individualized patient-care; 
treatment goals and preferences are highly personal and should be thoroughly discussed before 
treatment choices can be made. Consideration of patients’ preferences should hereby 
be of utmost importance. The treating physicians should keep these goals in mind when 
advising patients; if disease control is achieved at a level that is acceptable for that individual 
patient, it is not necessary to proceed with more aggressive and possibly more burdensome 
treatment to reach the medically highest achievable disease control. Therefore, it would be 
interesting to prospectively evaluate to what extent treatment goals and patient preferences are 
currently achieved in the geriatric population with psoriasis.
      Currently, clinical guidelines focus on PASI and DLQI scores, whereas personalized guidance 
is remains underrepresented. Although the World Health Organization defines QoL as “an 
individual’s perception of their position in life in the context of the culture and value systems 
in which they live and in relation to their goals, expectations, standards, and concerns”,9 
it appears not all physicians currently act accordingly.10,11 Therefore, guidelines should include 
attention for individual treatment goals and achieving the greatest benefit for the individual 
patient, with the lowest possible risks. Individualizing psoriasis care has gained increasing 
attention over the past years; for instance in practical tools that can aid in clinical care. 
The Patient Benefit Index (PBI), the Beliefs about Medicine Questionnaire (BMQ) or the 
Treatment Satisfaction Questionnaire for Medication (TSQM) might aid in structural 
treatment evaluation and improve treatment adherence.12-14 Moreover, in the geriatric 
population in particular, practicality of therapies should be kept in mind; homecare should 
be considered in case physical deterioration limits independent treatment application, 
cognitive impairment may lead to insufficient understanding of medication schedules 
(e.g. MTX weekly dosing),15 and the burden of timely therapies should not be 
underestimated as patients’ reduced ability to cope with complicated schedules for 
topical treatment might cause them a tremendous amount of energy and distress. 
Also, more extensive assessment in the frail geriatric population (e.g. more frequent 
laboratory assessment or extra [phone] consultations) is recommended to evaluate 
whether or not individual patients are at risk for the development of adverse 
events. In case of doubt, multidisciplinary approaches might be considered, to discuss 
treatment options with a geriatrician, general practitioner or nursing home physician, striving 
for an optimal risk-to-benefit ratio. 
Chapter 4
228
The many similarities that were seen in both age groups (patients <65 years and those ≥65 
years) should not be overseen either; disease characteristics, severity and treatment goals were 
highly comparable between the two age groups (chapter 2.3 and 2.4). Moreover, whereas the 
burden of visible psoriasis plaques and the cosmetic effect of psoriasis is sometimes assumed 
to be lower in older adults, the patients included in chapter 2.4 still mentioned these aspects 
as one of the most bothersome aspects of the disease. This too, is highly individual, but should 
not be underestimated based on chronological age alone.
       To achieve optimal targeted care, it is necessary to adequately understand the impact of 
the disease on one’s daily life. Using an instrument that includes non-relevant items, could lead 
to underestimation of the true QoL-impact and possibly subsequent undertreatment, especially 
if those non-relevant items are interpreted as equivalent to no QoL-impact.17,18 Moreover, in 
several countries, reimbursement criteria for biological criteria are based on the DLQI,4,5 which 
could mean older adults are not considered eligible for certain treatment options because of 
a suboptimal QoL-assessment tool.6 As the DLQI is already widely used,7 using the DLQI-R can 
be easily implemented in daily clinical care and is highly recommended based on the results of 
this thesis.
    As the effectiveness of several antipsoriatic therapies appears comparable between 
younger and older patients as well (chapter 2.2), and most therapies were not associated 
with a higher chance of safety issues, advanced age as a number should not lead to a priori 
exclusion of certain therapies or scientific studies (chapter 2.1). Naturally, in case of danger for 
the patients or study participants  (e.g. in case of drug interactions) excluding certain therapies 
might be necessary and justifiable, but to lower the chance of confounding influences 
(e.g. to ensure that the effects seen in the study are attributable to the study protocol, not 
to the effects of confounding comorbidities), stratification might serve as a solution. 
However, excluding patients with comorbidities or advanced age whatsoever leads to lower 
generalizability of the study results, and to outcomes of RCTs that possibly do not reflect the 
true effectiveness. Therefore, we encourage studying the effects of antipsoriatic therapies 
in older adults in both real-world studies and RCTs, with stratification on comorbidities 
and other relevant frailty-related factors to improve generalizability and the scarcity of useful 




4.1.3 Guidance for patient-centered geriatric psoriasis management 
For patient-oriented management in older psoriasis patients, the following recommendations 
can be given:
   1. Advanced age alone should not be a reason to exclude certain antipsoriatic therapies. 
   2. Treatment goals and preferences are highly personal and should be thoroughly discussed 
 before treatment choices can be made.
  3. The cosmetic impact of psoriasis should not be underestimated, as for many older adults 
 this remains one of the most burdensome aspects of the disease. 
  4. The use of the DLQI-R should be preferred over the original DLQI scoring system, as the 
    not relevant responses lead to an underestimation of the true QoL impact, especially in 
 patients ≥65yo.
   5. Frailty-related aspects should be considered when choosing antipsoriatic treatment (e.g. 
 cognitive impairment, comorbidities, concomitant medication, altered pharmacokinetics 
 and -dynamics, functional dependency, mobility, and social resources). 
   6.The feasibility of practical therapies and the burden of treatment should be considered 
 for each individual geriatric patient; in case of frail patients, certain therapies might serve 
 as a disproportional stressor. 
      7. Multidisciplinary approaches should be considered in case of doubt (e.g. with a 
 geriatrician, general practitioner or nursing home physician).  
   8. Cyclosporin should only be prescribed with caution, as its use in the geriatric population 
 is associated with adverse events. 
   9. Additional follow-up assessments (geriatric assessments, laboratory assessments and/or 




4.2 Skin cancer management in older adults
4.2.1 Summary on skin cancer management in the geriatric population
Skin cancer care can be challenging in the geriatric population, as patients with a limited 
life expectancy (LLE) might not live long enough to benefit from skin cancer treatment. To 
determine the time-to-benefit, studies on patient-, tumor-, and treatment-related aspects 
affecting life expectancy, tumor and treatment burden are highly needed. 
     To evaluate regular daily practice, chapter 3.1 reports on a prospective multicenter 
cohort study assessing the effects of frailty-related patient characteristics on BCC treatment 
burden, survival and treatment outcomes. Overall, 539 geriatric patients were included, most 
of whom experienced a low surgical treatment burden (in case of both MMS and CE), and 
an overall high survival (93.5%) was seen. As expected, no BCC-related deaths occurred. 
However, multiple frailty-related patient characteristics were associated with survival and 
treatment outcomes; Charlson comorbidity index and dependency on others regarding 
(instrumental) activities of daily living (iADL; e.g. telephone use and transportation) were 
significant predictors for mortality. Moreover, polypharmacy, iADL dependency, and 
complications were significant predictors for the treatment burden experienced by older 
adults after surgical treatment for BCC. This leads us to believe that for fit and robust patients, 
early intervention is the most appropriate treatment for BCC in the head-and-neck area. 
However, more attention in daily practice is recommended for patient-related factors associated 
with frailty, as for individual cases, the risks of BCC treatment might outweigh the benefits. 
   To further study the role of frailty assessment in dermato-oncology, chapter 3.2 
describes a modified Delphi procedure carried out to identify what frailty-related aspects were 
deemed important for both physicians involved in skin cancer treatment and patients with 
(a history of) skin cancer. Evaluation of comorbidities, cognitive impairment and 
polypharmacy were highly valued by the working group. A frailty screening tool (FST) 
could assist dermatologists in identifying those patients who might benefit from 
multidisciplinary approaches (e.g. additional consultations with geriatricians, the general 
practitioner and/or homecare) and/or more extensive additional (geriatric) assessments. 
Of all 26 multidomain frailty screening tools identified from a systematic literature search, 
the Geriatric-8 (G8) appeared the most appropriate FST for dermato-oncology care based on 
the results of this study.
     A first evaluation of the G8 and its effects on medical decision making in dermato- 
oncology was reported in chapter 3.3, where a prospective pilot study is described 
concerning a specialized outpatient clinic for older adults. A large proportion of the included 
patients were classified as frail (87.3%) and of those, 43.8% chose BCC treatment different 
from expected regular practice management (ERPM) (e.g. a shortened radiotherapy schedule 
or watchful waiting instead of surgery) after careful consideration of treatment goals, patient 




All in all, ERPM led to a reduction of hospital visits in 19 (32.2%) patients, whereas in 13.6% of 
patients an increase in hospital visits was seen; in case curative treatment was needed after 
all (median follow-up 29.5 months). This study shows that personalizing geriatric dermato- 
oncology care frequently leads to different BCC management decisions than ERPM 
(e.g. watchful waiting or less extensive and/or burdensome therapies while accepting a higher 
recurrence rate). In this study, these therapies appeared more in line with individual treatment 
goals. Therefore, curative treatment is not always necessarily in the best interest of the patient 
if patients do not live long enough to benefit from this treatment; in other words, when the 
time-to-benefit from curative BCC treatment exceeds life expectancy.
     In order to gain more knowledge on the time-to-benefit for BCC treatment, it is highly 
necessary to obtain more information on the natural course of BCCs when they remain 
untreated. Therefore, we studied watchful waiting (chapter 3.4) in a daily practice cohort of 
89 patients with 280 BCCs. In only three patients with three corresponding BCCs, more 
extensive treatment was needed after a period of WW (e.g. reconstruction was required 
instead of primary closure). Patients frequently chose WW because of comorbidities, frailty or 
LLE. Therefore, WW can be a suitable option in frail patients with asymptomatic tumors and 
the expectation of a low tumor burden on the short-term, if adequately aligning with patient 
preferences. Of note, the findings in this study emphasize the importance for appropriate 
follow-up, with periodical re-evaluation of management options. This too, is accentuated by 
the fact that the majority of BCCs (53.2%) did not show tumor growth during follow-up time. 
The estimated growth highly differed between BCC subtypes; for infiltrative/micronodular 
BCCs the estimated tumor growth was 4.46mm in one year, whereas only 1.06mm was 
estimated for nodular/superficial/clinical BCCs. Broad prediction intervals were seen, indicating 
that the included tumors behaved highly heterogeneously, further emphasizing the need for 
individual follow-up and reconsideration of the time-to-benefit at each visit.
4.2.2 Discussion and Future Perspectives on skin cancer management in the geriatric 
population
Appropriately managing nonfatal conditions in patients with LLE, while weighing the risk of 
over- and undertreatment, is a frequent struggle in daily clinical care. Undertreatment may 
occur when a suboptimal therapy is chosen or patients are not treated at all due to misjudged 
LLE or misjudged expected treatment burden, after which the patient endures avoidable 
tumor burden. For instance, although MMS is proven to be a highly effective BCC treatment, 
it is sometimes presumed too burdensome for older adults due to the labor-intensive and 
time-consuming aspects of this therapy.20-22 As not all older adults are necessarily frail, age as 
a chronological number should not be considered a valid reason to refrain from certain types 
of skin cancer treatment. The results of chapter 3.1 indicate that most older adults experi-
enced a low overall BCC treatment burden, with no statistical significant difference between 
MMS and CE, low complications and high overall survival. In line with previous research,23,24 
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BCC patients showed a higher survival than the overall Dutch population. Therefore, in robust 
patients without LLE, BCC treatment is probably the best preservation of QoL, as treating BCCs 
may prevent severe morbidity caused by long-existing untreated BCCs. In other words, for fit 
and robust patients without LLE, early BCC treatment is recommended in most cases; as for 
these patients the time-to-benefit is probably shorter than the overall life expectancy.
      On the other hand, overtreatment regularly occurs in patients whose remaining lifespan is 
shorter than the time to ever develop BCC-related symptoms. In other words, overtreatment 
occurs when the remaining lifespan appears too short to benefit from treatment (time-to- 
benefit),19 whereas the risks of treatment (e.g. avoidable treatment-related complications or 
overall treatment burden) might be more burdensome in these individual cases. To estimate 
the time-to-benefit for skin cancer care, incorporating frailty- and patient-related factors in 
medical decision-making is highly needed; in this thesis, frailty-related patient characteristics 
were associated with treatment burden and mortality (chapter 3.1), and were important 
factors for patients to choose a WW approach (chapter 3.4). Moreover, in chapter 3.3 
a large proportion of frail older adults chose BCC treatment different from regular clinical 
care (e.g. treatment with higher chances of recurrence in case this treatment is less 
burdensome), as it better aligned with their treatment goals and preferences. Therefore, 
in frail patients with iADL dependency, polypharmacy and/or multiple comorbidities, 
WW or symptomatic therapies might be better management approaches than 
therapies with the highest cure rates, especially in the case of asymptomatic nodular or 
superficial BCCs. Therefore, incorporating frailty-related patient characteristics and 
treatment goals in daily clinical care and clinical guidelines might improve geriatric skin cancer 
care.
     With the eye on feasibility in daily dermatology care and limited health care resources, 
implementing time-consuming geriatric assessments is not desirable, especially as it is probably 
not beneficial for every older adult. Therefore, we suggest to implement frailty screening 
tools (chapter 3.2) in regular dermato-oncology care, especially in case of advanced tumors 
or when extensive therapies are required. In several medical fields, frailty has been associ-
ated with LLE and adverse health outcomes.25-28 However, BCC patients might be in better 
overall health than the (oncology) populations in which FSTs and associated life expectancy 
algorithms are tested. Previous research has shown that frailty screening in patients 
with a relatively good health and prognosis can be less accurate than in general oncology 
populations due to a lower a priori mortality chance.29 Therefore, FSTs might not perform 
as well in dermatology populations when compared to general oncology populations. 
Additional prospective research is needed to evaluate whether frailty in dermato-oncology 
is associated with complications and short-term mortality, and whether or not frailty and FST 




      As frailty is a dynamic process and the overall situation of individual patients can change 
rapidly, frailty screening should be repeated over time. Naturally, frailty evaluation immediate-
ly after a complicated time in one’s life might lead to overdiagnosis of frailty, whereas these 
patients could recover within a few months. As shown in chapter 3.4, a wide variety of reasons 
for refraining or postponing therapy was mentioned by older adults, and part of those reasons 
resolved over time. Environmental and social factors (e.g. prioritizing the medical situation of 
a spouse or moving to a new apartment) can cause temporary stressors that do not allow the 
patient to focus on other, less urgent health problems. This could lead to undertreatment, 
especially when patients are discharged from further follow-up, or the decision for WW is not 
re-evaluated after a few months. Therefore, it is important to recognize the difference between 
WW and refraining from follow-up consultations altogether. While WW allows therapeutic 
interventions in the earliest stage a tumor causes medical, functional or symptomatic problem 
s, refraining from follow-up could easily lead to tumor neglect. Thus, periodical re-evaluation 
(e.g. 3-6 months) of the tumor growth, the overall condition of the patient and of patient 
preferences, treatment goals and risk-to-benefit ratio is advised to avoid undertreatment after 
patients have chosen WW.
     To discriminate between robust older adults and frail older adults with associated LLE, 
chronological age might serve as a signal to evaluate age-associated factors (e.g. comorbidities, 
concomitant medication, functional deterioration and frailty) that could contribute to disease 
or treatment burden more extensively. Whereas advanced age is not necessarily synonymous 
to LLE,28,30,31 learning from geriatric and palliative care can help in improving dermatologic care 
for older adults. In several medical fields, refraining from treatment is widely accepted in certain 
nonfatal, indolent conditions.32-34 However, daily dermatology practice is to treat most BCCs; 
a frequently asymptomatic, slowly-growing tumor.35 Changing this mindset can be quite a 
challenge as refraining from treatment remains controversial; physicians are taught not to deny 
patients possibly helpful care and consequently risking tumor progression and decreased QoL. 
Moreover, physicians regularly remember patients who, years after the initial presentation, 
present at the outpatient clinic with large inoperable tumors, whereas untreated patients 
who died before they would potentially benefit from treatment might not even be brought to 
attention.
     Additionally, the current health care system with the corresponding financial incentives 
might influence treatment choices; refraining from treatment can be less attractive for 
health-care providers/organizations from a financial point of view in case of treatment-based 
incentives. Fortunately, a development towards a more value-based health care approach is 
gaining more and more attention over the past years.36 As value-based health care is aimed 
at achieving optimal value for individual patients, it is highly in line with our recommendations 
towards personalized dermatologic care, in which treatment goals and patient preferences are 
prioritized in shared decision-making. As shared decision-making can be challenging in case 
of older adults with cognitive impairment, the criteria to evaluate whether or not older adults 
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are capable of medical decision-making are illustrated in Figure 1. In case patients are not 
capable of decision-making, the risks and benefits of curative or palliative BCC management 
options should be discussed with legal representatives and a multidisciplinary approach should 
be considered. 
   The need for WW and symptomatic BCC therapies is accentuated by the large number of 
patients that chose to deviate from regular skin cancer care in two cohorts described in this 
thesis (chapter 3.3 and 3.4). In these studies, thorough discussion of all treatment options, 
including those with lowest cure rates, were discussed after thorough and structured shared 
decision-making. This accentuates the importance of information framing; patients heavily rely 
on the wording used by their physician.37 Many patients will choose curative treatment if this 
is advised by physicians, whereas these patients might have considered different management 
options if they were even discussed. Currently, it remains difficult to appropriately discuss the 
risks of WW, as studies on WW are scarce.38 Possibly, future research, confirming the results 
described in chapter 3.4, will lead to more reluctance to treat every BCC in patients with LLE. 
To further provide guidance in this controversial finding, specific skin cancer research is needed 
to obtain information on appropriate measures to estimate life expectancy; to evaluate FSTs 
(chapter 3.2) and other life expectancy tools,39 and their predictive function on mortality. 
Moreover, more prospective (randomized) studies are needed to evaluate the natural course 
of BCCs (e.g. tumor growth and the time until symptoms arise) in a WW approach. This way, 
the time-to-benefit and consequent relevant life expectancy in BCC patients can be defined 
more clearly (e.g. estimate 2-year survival in case burdensome tumor-related symptoms are 
expected after 2 years). The results of these studies combined might provide more clear 
cutoffs to determine when the chance on treatment burden exceeds the chance of tumor 
burden. Physicians should be educated on this risk, and additional time might be needed 
in order to achieve a holistic approach for the geriatric dermatology patient. Discussion of 
non-curative management options should be incorporated in daily clinical care, possibly 




Figure 1. Relevant criteria for the decision-making capacity of older adults with skin 
diseases, adapted from Soto-Perez-de-Celis et al.42
It is apparent that in older adults patient- and frailty-related aspects have to be considered in addition to the 
disease-specific aspects. A host of factors are relevant to be considered before a decision is taken. In this respect 
the voice of the patient has to be reconciled with the medical possibilities. The model as depicted in this figure 
is a practical aid.
• Acknowledges medical condition
• Understands the likely outcomes
• Is able to rationally compare 
 and contrast options
• Clearly indicates preferences












• Grasps the meaning of the 
 information provided




4.2.3 Guidance for patient-centered skin cancer management in older adults
For the management of skin cancer in frail elderly the following recommendations can be given: 
     1. Advanced age alone should not be a reason to exclude surgical BCC therapies. 
     2. Advanced age may serve as a signal to more thoroughly evaluate ageing-related factors 
     (e.g. frailty) that could contribute to disease and/or treatment burden. Therefore, the 
          implementation of  frailty screening tools (e.g. the G8) is recommended, especially in case 
         of advanced tumors or when extensive therapies are required.
     3. As frailty is a dynamic process and the overall situation of individual patients can change 
         rapidly, frailty screening should be repeated over time (e.g. every 6 months). 
     4. Treatment goals and patient preferences are highly personal and should be thoroughly 
         discussed before treatment choices can be made.
     5. Evaluate whether or not the patient is capable of medical decision-making (Figure 1). 
     In case patients are not capable of decision-making, the risks and benefits of BCC 
         management options should be discussed with legal representatives and, if necessary, in 
         a multidisciplinary approach. 
     6. Try to estimate the time-to-benefit by considering both patient- and frailty-related 
      factors (e.g. functional dependency and cognitive impairment) as well as tumor- and 
         treatment characteristics (e.g. tumor subtype and expected treatment burden).
     7. Be aware of information framing; patients heavily rely on the wording used by their 
         physician. The use of a decision aid might be considered to objectively present treatment 
         options, including symptomatic therapies or those with low cure rates. 
     8. For fit and robust patients without LLE, early treatment of BCCs, especially high-risk BCC 
         in the head and neck area, is recommended in most cases. 
     9. In frail patients with iADL dependency, polypharmacy and/or multiple comorbidities, 
 WW or symptomatic therapies might be better management approaches than 
      therapies with the highest cure rates, especially in the case of asymptomatic nodular or 
         superficial BCCs.
       10. Multidisciplinary approaches should be considered in case of doubt (e.g. with a 
         geriatrician, general practitioner or nursing home physician).  
     11. Follow-up (e.g. 3-6 months) should be strived at in any patient choosing BCC 
        management other than regular care (e.g. WW). At these visits re-evaluation should take 
         place of the tumor growth, the overall condition of the patient and of patient preferences, 






In this thesis several aspects of the management of psoriasis and skin cancer have been high-
lighted in the geriatric population. In both entirely different diseases it is apparent that in older 
adults patient- and frailty-related aspects have to be considered in addition to the disease- 
specific aspects. Based on the results of this thesis, chronological age alone should not be a 
reason to refrain from certain therapies in both psoriasis as well as skin cancer care. 
Advanced age might serve as a signal to further evaluate frailty, the need for multidisciplinary 
approaches, additional (phone) consultations and/or assessments. Shared decision- 
making should be strived at in any patient. Essential in this conversation is the discussion 
of the time-to-benefit principle, patient preferences and treatment goals. Especially in frail 
older adults with nodular/superficial BCCs, the risks of treatment may outweigh the benefits. 
Weighing the risks and benefits of psoriasis treatment in older adults is a different, but a partly 
comparable dilemma. Whereas psoriasis can affect QoL severely, treatment-associated burden 
can also highly impact QoL, especially for patients who experience a relatively low disease 
burden. Therefore, to improve patient-oriented dermatology care, factors that contribute to 
the burden of both the diseases as well as the burden of the treatment should be taken into 
consideration. In individual cases it could be in the best interest of the patient to deviate from 
medical guidelines or regular care, as QoL in frail patients with LLE might possibly be more 
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De snel groeiende groep ouderen vraagt om specifieke aandacht in de dagelijkse gezond- 
heidszorg, aangezien deze patiënten regelmatig extra zorg nodig hebben wat betreft patiënt- 
gerelateerde kenmerken als kwetsbaarheid, verouderings-gerelateerde orgaanstoornissen, 
andere medische aandoeningen en functionele afhankelijkheid. Het doel van dit proefschrift 
was om meer begeleiding te bieden bij patiëntgerichte geriatrische dermatologische zorg 
en het verbeteren van gezamenlijke besluitvorming (Engels: shared decision-making) door 
te streven naar een optimale verhouding tussen voor- en nadelen van de verschillende 
behandelopties. Twee ziekte-entiteiten werden bestudeerd; de veel voorkomende inflam- 
matoire huidaandoening psoriasis en het meest voorkomende type huidkanker, basaalcel- 
carcinoom (BCC).
5.1 Behandeling van psoriasis bij ouderen
In hoofdstuk 2.1 wordt een systematisch literatuuronderzoek gepresenteerd naar de 
vertegenwoordiging van ouderen in gerandomiseerde gecontroleerde studies (Engels: 
Randomized Controlled Trials; RCT's) waarin systemische antipsoriasis behandelingen 
werden onderzocht. Veel ouderen werden uitgesloten van deelname aan deze RCT's, terwijl 
deze onderzoeken vaak de primaire bron van gegevens vormen voor klinische richtlijnen. 
Niet alleen werden ouderen geëxcludeerd op basis van leeftijd in 33,3% van de 162 onder-
zochte RCT's, maar in nog eens 90,6% van de overige RCT’s werden geriatrische patiënten 
ge-excludeerd op een indirecte manier (bijvoorbeeld door patiënten uit te sluiten die 
bepaalde medische aandoeningen hadden). Het is daarom de vraag in hoeverre de gegevens 
uit RCT's van toepassing zijn op ouderen in de dagelijkse praktijk.
 Door een disproportionele exclusie van verschillende patiëntengroepen in klinische 
onderzoeken, worden ervaringen uit de dagelijkse praktijk (Engels: real-world evidence) steeds 
belangrijker in de gezondheidszorg. De beschikbare gegevens over effectiviteit en veiligheid 
van systemische antipsoriasis behandelingen worden beschreven in een literatuuroverzicht 
in hoofdstuk 2.2. Over het algemeen waren er beperkte gegevens beschikbaar. De 
effectiviteit van de meeste systemische antipsoriasis behandelingen bleek niet te worden 
beïnvloed door leeftijd. Daarentegen werd bij patiënten die behandeld werden met ciclospo-
rine wel een associatie gezien tussen hogere leeftijd en bijwerkingen; nierfunctiestoornissen in 
het bijzonder. Infecties kwamen vaak voor bij patiënten die behandeld werden met biologicals, 
hoewel er geen verband met hogere leeftijd werd gevonden. Op basis van dit systematische 
literatuuronderzoek mag leeftijd als getal niet worden beschouwd als een beperkende factor 
bij de behandeling van psoriasis. Uiteraard kunnen bepaalde medische aandoeningen 
een contra-indicatie vormen voor het gebruik van (bepaalde) systemische antipsoriasis 
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behandelingen en is het belangrijk om behandelbeslissingen te maken met het in acht 
nemen van de medische voorgeschiedenis van een patiënt en de mogelijke interacties met 
gelijktijdig medicatiegebruik. Echter, de terughoudendheid om systemische medicatie 
voor te schrijven aan oudere psoriasispatiënten op basis van kalenderleeftijd alleen, 
kan niet worden gerechtvaardigd door het bewijs gevonden in dit proefschrift. Dit kan 
mogelijk zelfs leiden tot onderbehandeling en een daaropvolgende verminderde kwaliteit van 
leven in deze populatie.
 Het is belangrijk om te realiseren dat de meeste bijwerkingen beschreven in hoofdstuk 2.2
reversibel waren na stopzetting van het medicijn. Opmerkelijk is, dat in de landelijke 
survey-studie beschreven in hoofdstuk 2.3, 414 oudere volwassenen (≥65 jaar) minder 
bijwerkingen van hun antipsoriasis medicatie rapporteerden dan de 536 patiënten <65 jaar. 
Een belangrijke beperking van dit onderzoek is dat patiënten de antwoorden zelf invulden 
en waarschijnlijk geen laboratoriumafwijkingen hebben gemeld. Bovendien waren de 
redenen om met eerdere therapieën te stoppen, niet geëvalueerd. Daarom wordt aanvullend 
onderzoek aanbevolen om systematisch bijwerkingen te observeren bij grote populaties 
oudere volwassenen die antipsoriasis medicijnen gebruiken. In deze studie (hoofdstuk 2.3) 
werden significant meer medische aandoeningen, comedicatiegebruik en functionele 
afhankelijkheid (van zowel medische zorgverleners als familieleden) gerapporteerd door 
patiënten ≥65 jaar. Toch werden er geen significante verschillen tussen de leeftijdsgroepen 
gezien met betrekking tot het gebruik van diverse systemische antipsoriasis medicatie (38,3% 
in patiënten ≥65 jaar tegenover 42,3% in patiënten <65 jaar; p=0,219). Bovendien, aangezien 
ziektekenmerken en -ernst vergelijkbaar waren tussen patiënten ≥65 en patiënten <65 jaar, 
bestond de indicatie voor systemische therapie regelmatig bij de ouderen die aan deze studie 
deelnamen.
 Aangezien het scala aan therapeutische opties snel groeit, is het van cruciaal belang om 
onvervulde behoeften te identificeren bij de vaak kwetsbare ouderenpopulatie. Het tweede 
deel van het survey-onderzoek onder leden van de Nederlandse psoriasisvereniging wordt 
gepresenteerd in hoofdstuk 2.4. Ouderen rapporteerden andere behandelvoorkeuren 
dan patiënten <65 jaar. Het belangrijkste verschil was dat ouderen de vermindering van 
medicatiegebruik en ziekenhuisbezoeken als significant belangrijker waardeerden dan 
patiënten <65 jaar oud, maar de algemene behandeldoelen (bijv. vrij zijn van jeuk, schilfering 
en zichtbare plekken) waren zeer vergelijkbaar tussen ouderen en jongere patiënten. 
Bovendien waren de behandel-tevredenheid en de ziektelast zeer vergelijkbaar tussen de 
leeftijdsgroepen, hoewel heterogene uitkomsten werden gezien bij individuele 
respondenten. Ook dit benadrukt de behoefte aan geïndividualiseerde evaluatie van 
behandeldoelen, patiëntvoorkeuren en ziekte- en behandelingslast.
 Het gebruik van de DLQI-R, een alternatief scoresysteem voor de DLQI (Dermatology 
Life Quality Index), een gevalideerd en veelgebruikt meetinstrument voor kwaliteit van leven, 





keuriger de ware impact op kwaliteit van leven weergaf, vergeleken met het oorspronkelijke 
DLQI-scoresysteem. Er werd ten minste één niet-relevant respons (Engels: not relevant 
response; NRR) gemeld door 238 (60,7%) patiënten van ≥65 jaar versus 161 (31,3%) patiënten 
van <65 jaar (p<0,001). Terwijl een hogere DLQI/DLQI-R score gelijk staat aan een heviger 
impact op kwaliteit van leven, wordt een NRR gescoord als "0" in de oorspronkelijke DLQI, 
gelijk aan helemaal niet. Dit leidde tot een lagere algehele DLQI-score bij patiënten van 
≥65 jaar versus patiënten van <65 jaar, hoewel de DLQI-R-score niet significant verschilde 
tussen de groepen. Om de kans op suboptimale QoL-beoordeling te verkleinen, wordt daarom 
aanbevolen om de DLQI-R te gebruiken in plaats van de DLQI.
5.2 Behandeling van huidkanker bij ouderen
Huidkankerzorg kan een uitdaging zijn in de geriatrische populatie, aangezien patiënten 
met een beperkte levensverwachting (Engels: limited life expectancy) mogelijk niet lang 
genoeg leven om baat te hebben bij de behandeling van huidkanker. Om in kaart te brengen 
wat de tijd tot gezondheidsvoordeel (Engels: time-to-benefit) is, zijn er meer onderzoeken 
nodig naar patiënt-, tumor- en behandelgerelateerde aspecten die de levensverwachting, 
tumor-en behandelingslast beïnvloeden.
 Om de dagelijkse praktijk te evalueren, wordt in hoofdstuk 3.1 geschreven over 
een prospectieve multicenter cohortstudie waarin beoordeeld wordt wat de effecten zijn 
van kwetsbaarheidsgerelateerde (Engels: frailty) patiëntkenmerken op de ervaren BCC- 
behandelbelasting, overleving en behandelresultaten. In totaal werden 539 geriatrische 
patiënten geïncludeerd; de meeste patienten gaven aan een lage  chirurgische behandel- 
belasting te hebben ervaren  (zowel in het geval van Mohs micrografische chirurgie als conven-
tionele excisie), en een hoge algehele overleving (93,5%) werd gezien (gemiddelde follow-up: 
23.3 maanden). Zoals verwacht waren er geen BCC-gerelateerde sterfgevallen. Echter, meerdere 
kwetsbaarheidsgerelateerde patiëntkenmerken waren geassocieerd met overleving en 
behandeluitkomsten; de Charlson comorbiditeitenindex en afhankelijkheid van anderen met 
betrekking tot instrumentele activiteiten in het dagelijks leven (Engels: instrumental activities 
of daily living, iADL; bijv. telefoongebruik en vervoer) waren significante voorspellers voor 
mortaliteit. Bovendien waren polyfarmacie (het chronische gebruik van 5 of meer 
medicamenten), iADL-afhankelijkheid en complicaties significante voorspellers voor de 
behandelbelasting ervaren door ouderen na chirurgische BCC behandeling. Zodoende 
lijkt, voor fitte en niet-kwetsbare patiënten, vroege BCC behandeling de meest geschikte 
strategie voor BCC in het hoofdhalsgebied te zijn. Echter, in de dagelijkse praktijk is het 
belangrijk om meer aandacht te besteden aan patiëntgerelateerde factoren die 
samenhangen met kwetsbaarheid, aangezien in individuele gevallen de nadelen van 
BCC-behandeling groter kunnen zijn dan de voordelen.
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 Om de rol van kwetsbaarheidsscreening in dermato-oncologie verder te bestuderen, 
werd in hoofdstuk 3.2 een aangepaste Delphi-procedure beschreven, die is uitgevoerd om 
vast te stellen welke kwetsbaarheidsgerelateerde aspecten belangrijk werden geacht voor 
zowel artsen die betrokken zijn bij de behandeling van huidkanker, als patiënten met (een 
voorgeschiedenis van) huidkanker. Evaluatie van medische voorgeschiedenis, cognitieve 
stoornissen en polyfarmacie werden hoog gewaardeerd door de werkgroep. Een 
kwetsbaarheids-screeningsinstrument (Engels: frailty screening tool; FST) zou dermato- 
logen kunnen helpen bij het identificeren van de patiënten die mogelijk baat hebben bij 
multidisciplinaire benaderingen (bijv. aanvullend overleg met een geriater, de huisarts 
en/of thuiszorg) en/of uitgebreidere, aanvullende (geriatrische) onderzoeken. Van alle 26 
multi domein screeningsinstrumenten die werden geïdentificeerd uit een systematisch 
literatuuronderzoek, bleek de G8 (Geriatric-8) de meest geschikte FST voor dermato- 
oncologische zorg.
 Een eerste evaluatie van de G8 en de effecten ervan op medische besluitvorming in 
de dermato-oncologie werd gerapporteerd in hoofdstuk 3.3, waar een prospectieve 
pilotstudie wordt beschreven over gespecialiseerde poliklinische zorg voor (kwetsbare) 
ouderen met (de verdenking op) basaalcelcarcinoom, met extra aandacht voor het gedeelde 
besluitvormingsproces. Een groot deel van de geïncludeerde patiënten werd geclassificeerd 
als kwetsbaar (87,3%) en daarvan koos 43,8% na zorgvuldige afweging voor een 
BCC-behandeling die verschilde van het verwachte reguliere beleid (expected regular practice 
management; ERPM); bijvoorbeeld een verkort radiotherapie schema. De behandel- 
beslissingen werden genomen na zorgvuldige overweging van behandeldoelen, patiënt- 
kenmerken en patiëntvoorkeuren op een gestandaardiseerde manier van gedeelde 
besluitvorming. Afwijken van ERPM leidde tot een vermindering van ziekenhuis 
bezoeken bij 19 (32,2%) patiënten, terwijl bij 13,6% van de patiënten een toename van 
ziekenhuisbezoeken werd gezien; indien curatieve behandeling alsnog nodig was 
(gemiddelde follow-up 20,0±12,0 maanden). Deze studie laat zien dat het personaliseren van 
geriatrische dermato-oncologische zorg vaak leidt tot andere beleidsbeslissingen dan ERPM 
(bijv. waakzaam wachten of minder uitgebreide en/of belastende therapieën terwijl een 
hoger recidief-percentage wordt geaccepteerd). In deze studie leek beleid anders dan ERPM 
meer in lijn met de individuele behandeldoelen. Curatieve behandeling is niet altijd in het 
belang van de patiënt wanneer patiënten niet lang genoeg leven om baat te hebben bij 
invasieve behandeling; met andere woorden: wanneer de tijd tot gezondheidsvoordeel van 
curatieve BCC-behandeling de levensverwachting overschrijdt.
 Om beter in kaart te brengen wanneer een patiënt voordelen gaat ervaren van BCC- 
behandeling, is het noodzakelijk om meer informatie te verkrijgen over het natuurlijke beloop 
van BCC's wanneer ze onbehandeld blijven. Daarom hebben we waakzaam wachten 
(Engels: watchful waiting, WW) bestudeerd (hoofdstuk 3.4) in een cohort van 89 patiënten 





een beperkte levensverwachting. Bij slechts drie patiënten met drie BCC's was een 
uitgebreidere behandeling nodig na een periode van WW (bijvoorbeeld wanneer 
reconstructies nodig waren in plaats van primaire sluiting). Zodoende zou WW een geschikte 
optie kunnen zijn voor kwetsbare patiënten met asymptomatische tumoren (en te verwachte 
lage tumorlast op korte termijn), mits goed afgestemd op de voorkeuren van de patiënt. De 
bevindingen in deze studie benadrukken het belang van een passende follow-up, met een 
periodieke herevaluatie van de (behandel)mogelijkheden. Dit wordt ook bevestigd door het 
feit dat de meerderheid van de BCC's (53,2%) geen tumorgroei liet zien tijdens de follow-up. 
De geschatte groei verschilde sterk tussen de verschillende BCC-subtypes; voor infiltratieve/
micronodulaire BCC's was de geschatte tumorgroei 4,46 mm in één jaar, terwijl slechts 1,06 mm 
werd geschat voor nodulaire/oppervlakkige/klinische BCC's. Er werden brede voorspellings- 
intervallen gezien, wat aangeeft dat de geïncludeerde tumoren zich zeer heterogeen 
gedroegen, en wat de noodzaak van individuele follow-up en heroverweging van de tijd tot 
gezondheidsvoordeel bij elk bezoek verder benadrukt. 
Conclusie
In dit proefschrift worden verschillende aspecten van de behandeling van psoriasis en 
huidkanker belicht in de geriatrische populatie. Bij beide ziektebeelden blijkt dat bij oudere 
volwassenen, naast de ziektespecifieke aspecten, ook rekening moet worden gehouden 
met patiënt- en kwetsbaarheidsaspecten. Op basis van de resultaten van dit proefschrift zou 
de kalenderleeftijd alleen geen reden moeten zijn om bepaalde therapieën bij psoriasis of 
huidkankerzorg op voorhand af te schrijven. Gevorderde leeftijd kan een signaal zijn om 
kwetsbaarheid, de behoefte aan multidisciplinaire benaderingen, aanvullende (telefonische) 
consulten en/of verdere onderzoeken te evalueren. Gezamenlijke besluitvorming moet 
bij elke patiënt worden nagestreefd, waarbij het essentieel is om in dit gesprek de 
tijd tot gezondheidsvoordeel te bespreken, alsmede patiëntvoorkeuren en behandeldoelen. 
Vooral bij kwetsbare ouderen met nodulaire of oppervlakkige BCC's kunnen de risico's van 
behandeling groter zijn dan de voordelen. Het afwegen van de risico's en voordelen van 
psoriasisbehandeling bij oudere volwassenen is een ander, maar deels vergelijkbaar 
dilemma. Terwijl psoriasis de kwaliteit van leven ernstig kan beïnvloeden, kan de 
behandelbelasting ook een grote invloed hebben op de kwaliteit van leven, vooral voor 
patiënten die een relatief lage ziektelast ervaren. Om persoonsgerichte dermatologische 
zorg te verbeteren, moet daarom rekening worden gehouden met factoren die bijdragen aan 
zowel de belasting door de aandoening als de behandeling. In individuele gevallen kan het 
in het belang van de patiënt zijn om af te wijken van medische richtlijnen of reguliere zorg, 
omdat de kwaliteit van leven bij kwetsbare patiënten met een beperkte levensverwachting 
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de journal club), maar ik hoop dat de samenwerking tussen het lab en de klinische dermagroep 
nog lang blijft zoals hij is!
Ook de chocoladefestijnen en kletskwartiertjes in het archief mogen zeker niet vergeten 
worden! Superfijn om met jullie samen te werken, heel erg bedankt voor al jullie inclusies, de 
onderzoekersoverleggen en jullie meeleven bij zowel de leuke als de minder leuke nieuwtjes!
Lieve klega’s van de bieb/Lowlanders/bieb chickies 2.0/beliebers/OIO’s, wat een feest om met 
jullie te werken, borrelen, festivallen, dermatolo-skieën, co-promOIO bistro-en, hardlopen, 
sinterklazen, christmas paradisen, roadtrippen met het feestje, naar congressen te gaan met 
goddelijke Spaanse dinertjes, fluister broodjes kroket (ik hoop nog steeds dat maandag- 
kroketdag een ding gaat worden), sushi/pizza-avondjes, (vierdaagse) feesten, wifey- 
poseersessies, piep-in-je-oor-cursussen met stemoefeningen, Michelangelo "ping"-momentjes 
etc. etc. En natuurlijk in het bijzonder is hier dan eindelijk tóch het moment dat Quinn ook een 
podium krijgt in de acknowledgements, als jongste data-management-assistent ever! 
Freunden, waaronder natuurlijk mijn waarde paranimfen, jullie maken elke gelegenheid 
in mijn leven fantastisch en ik ben superblij met jullie allemaal! Dank voor alle avondjes/ 
weekendjes/weekjes vol met slechte grappen en bulderende lachsalvo’s, verkleedpartijtjes 
en toneelstukken, borrelplanken en biertjes/wijntjes/theetjes/capu’s/Jägermeisters, waarbij het 
leven buiten promotie 100% gevierd werd! Ik hoop dat we het festijn van deze dag kunnen 






Lieve schoonfamilie, ik heb me vanaf het begin welkom gevoeld in jullie lieve familie en die band 
is alleen maar sterker geworden de afgelopen jaren! Bedankt voor al jullie oprechte interesse! 
Vandaag proosten we op nog vele mooie toekomstige jaren!
Lieve parenti, jullie inspireren me zoveel méér dan jullie je realiseren! Niet alleen in jullie werk-
gerelateerde keuzes waar ik ontzettend veel bewondering voor heb, maar ook juist daarbuiten. 
Jullie staan altijd voor iedereen klaar, niets is onmogelijk, te gek of te veel, en dat heeft al heel 
veel geluk en een hoop pret opgeleverd! Door het heerlijke warme nest dat jullie geboden 
hebben, heb ik me kunnen ontwikkelen tot wie ik ben en wilde zijn, daar kan geen dankwoord 
aan tippen! Lieve Mutti, jij moet natuurlijk even persoonlijk superduperbedankt worden voor 
alle tijd en moeite die je in de vormgeving van m’n boekje hebt gestopt, het is echt fantastisch 
prachtig mooi geworden! 
Swaatje, de belletjes naar Australië tijdens de ochtendritjes naar werk mis ik wel nu je weer op 
de Hollandse bodem bent (zie je wel!), maar superfijn dat we weer volop live kunnen grappen 
en grollen nu we er weer meer tijd voor hebben! 
Lieve, lieve Wubbe, wat ben ik blij met jou! Jij steunt me in alles wat ik verzin (en zegt het als ik 
te ver ga, haha), denkt met me mee waar mogelijk, duimt met me mee waar nodig, feest met 
me mee bij elk vier-waardig momentje, en zorgt er ook nog eens voor dat we bijna dagelijks in 
een deuk liggen door onze gezamenlijke suffe humor ;) Nu hebben we eindelijk weer tijd voor al 






aCGA   Abbreviated Comprehensive Geriatric Assessment
ADA  adalimumab
AE  adverse event
ADL   activities of daily living 
AIC  Akaike information criterion 
AS  active surveillance 
ATC  Anatomical Therapeutic Chemical 
AV  atrioventricular
BATOA   BAsal cell carcinoma Treatment in Older Adults
BCC  basal cell carcinoma 
BMI  body mass index
BMQ  Beliefs about Medicine Questionnaire 
BOMC  Blessed Orientation-Memory-Concentration
BRP  Basisregistratie Personen
CDT  Clock Drawing Test
CES-D  Center for Epidemiologic Studies Depression Scale
CIRS-G  Cumulative Illness Rating Scale for Geriatrics
CLOX  Clock Draw Test
C-SGA  Cancer-specific geriatric assessment
CCI  Charlson comorbidity index 
CE  conventional excisision
CENTRAL  Cochrane Central Register of Controlled Trials
(C)GA  (comprehensive) geriatric assessment 
CI  confidence inderval
CONSORT  Consolidated Standards of Reporting Trials 
COSMIN  Consensus-based Standards for the selection of health Measurement 
  Instruments
COVID-19 coronavirus disease of 2019
CVD  Cardiovascular disease
DLQI  Dermatology Life Quality Index
DLQI-R  DLQI-Relevant
ECOG PS  Eastern Cooperative Oncology Group Performance Scale
ECR  Enhanced Cued Recall
EOW   every other week 
ERPM  expected regular practice management 
ETA  etanercept





F-Sozu  Fragebogen zur Erfassung der sozialen Unterstützung
FRAIL scale Fatigue, Resistance, Ambulation, Illnesses and Loss of weight scale
FST  frailty screening tool 
FU  follow-up
G8  Geriatric-8
GCP  Good Clinical Practice 
GDS  Geriatric Depression Scale
GFI  Groningen Frailty Indicator
GUG  Get Up and Go
HADS   Hospital Anxiety and Depression Scale
HBO  hoger beroepsonderwijs
HCT-CI  Hematopoietic and Cellular Therapy-Comorbidity Index
HIV  human immunodeficiency virus
HR  hazard ratio
iADL  instrumental activities of daily living 
ICC  intraclass correlation
ID  initiation dose
IFX  infliximab
IL  Interleukin
IMWG  International Myeloma Working Group 
IQR  interquartile range
ISAR   Identification of Seniors at Risk
ISAR-HP  Identification of Seniors At Risk Hospitalized Patients
ISAR-PC  Identification of Seniors At Risk Primary Care
ITT  intention-to-treat analysis
IV  intravenously
KC  Keratinocyte cancer
KCL  Kihon checklist
KG-7  Korean Cancer Study Group Geriatric Score
LFU  lost to follow-up
LLE  limited life expectancy
LOCF   last observation carried forward
M  male
mG8  modified Geriatric-8
Mini-GDS Mini Geriatric Depression Scale
MMS  Mohs micrographic surgery 
MMSE  Mini-Mental Status Exam
MNA  Mini Nutritional Assessment
Mob-T  Mobility-tiredness scale
264
Chapter 6
MOS   Medical Outcomes Survey
MOS-SSS Medical Outcomes Study Social Support Scale
MTX  methotrexate
NA  not applicable
NCCN  National Comprehensive Cancer Network
NR  not reported
NRI  nonresponder imputation
NRR  not relevant response
ns  not significant
OR  odds ratio
OW  once weekly
PALGA  Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief
PASI   Psoriasis Area and Severity Index 
PASI50  50% reduction in PASI compared with baseline
PASI75  75% reduction in PASI compared with baseline
PASI90  90% reduction in PASI compared with baseline
PASI100  100% reduction in PASI compared with baseline
PBI  Patient Benefit Index 
PHA   post hoc analysis
PRISMA   Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
PRISMA-7 Program of Research to Integrate Services for the Maintenance of Autonomy 
  Screening Instrument
PS  propensity score
PsA  psoriatic arthritis 
PTCH1  Protein patched homolog 1
QoL  quality of life
RAI  Risk analysis index
RCT  Randomized Controlled Trial
RoB  risk of bias
RT  radiotherapy
SAE   serious adverse event 
SAOP2  Senior Adult Oncology Program 2 
SAPASI  Self-Administered Psoriasis Area Severity Index
SCC  squamous cell carcinoma
SD  standard deviation
SDM  shared decision-making
Smo  Smoothened





SPPB  Short Physical Performance Battery
SPSS  Statistical Package for Social Sciences
STROBE  Strengthening the Reporting of Observational Studies in Epidemiology 
TFI   Tilburg Frailty Indicator
TMTA  Trail Making Test A
TMTB  Trail Making Test B
TNF  tumor necrosis factor
TOPICS-FI38 The Older Persons and Informal Caregivers Survey Frailty Index
TRST   Triage Risk Screening Tool
TSQM  Treatment Satisfaction Questionnaire for Medication
TUG  Timed Up and Go test
TW   twice weekly
UST  ustekinumab
UV  ultraviolet
VAS  visual analog scale
VES13  Vulnerable Elders Survey-13 
yo  years old
WHOQOL World Health Organization Quality of Life Questionnaire







Marieke van Winden werd geboren op 21 juni 1989 in Delft. Na het afronden van het Gymnasium 
aan het Sint Stanislascollege te Delft begon zij in 2007 aan haar bachelor studie Libaral Arts and 
Sciences aan de University College Roosevelt (voorheen: Roosevelt Academy), waar zij 
met veel plezier het pre-medical program volgde. In juni 2010 behaalde ze haar bachelor 
diploma, waarna ze werd toegelaten tot de dubbele master opleiding Arts-Klinisch 
Onderzoeker (A-KO) aan de Universiteit Maastricht. Naast deze studie werkte zij in een 
dermatologisch zelfstandig behandelcentrum, alwaar de interesse voor het vak 
Dermatologie werd gewekt. Haar afstudeerproject, een combinatie van zowel een 
wetenschappelijk als een (poli-)klinische afstudeerstage, vond plaats bij de Dermatologie 
in het Maastricht Universitair Medisch Centrum. In augustus 2014 behaalde Marieke haar A-KO 
diploma met een thesis over complicaties en cosmetiek na oncologische dermato-chirurgie. 
Nadien startte Marieke als ANIOS (arts-assistent niet in opleiding tot specialist) bij de 
Chirurgie in het Elisabeth-TweeSteden Ziekenhuis te Tilburg. Na twee jaar alhier te hebben 
gewerkt, verbreedde ze haar kennis als ANIOS bij de Interne Geneeskunde in het 
Amphia Ziekenhuis te Breda. Na 6 maanden kreeg Marieke de mogelijkheid om begin 2017 te 
starten als ANIOS-onderzoeksarts bij de Dermatologie in het Bravis Ziekenhuis, Roosendaal 
en Bergen op Zoom. Hier hield zij zich bezig met het includeren en opvolgen van patiënten 
voor klinische trials, afgewisseld door patiëntenzorg en poliklinische operatieve ingrepen. 
In januari 2018 begon zij als promovendus bij de Dermatologie in het Radboud Universitair 
Medisch Centrum te Nijmegen. Zij combineerde dit met een gespecialiseerd geriatrisch- 
dermatologisch spreekuur en dermatologische consulten in verschillende verpleeghuizen. 
In januari 2020 won Marieke de prijs voor beste posterpresentatie bij het jaarlijkse congres 
van de Nederlandse Vereniging voor Experimentele Dermatologie (“Treatment burden in older 
adults with high-risk basal cell carcinoma”). De resultaten van deze en verschillende andere 
klinische studies zijn gepresenteerd in dit proefschrift.
Na kortdurend als ANIOS op de Dermatologie- en COVID-afdeling in het Radboudumc te 
hebben gewerkt, is Marieke in april 2021 begonnen aan de specialistenopleiding tot derma-
toloog in het Radboudumc.
